U.S. SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549


FORM 10-K


[X]ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2016
[_]TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the fiscal year ended December 31, 2023

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _________to _________


Commission File Number 000-55114


Canfield Medical Supply, Inc.
001-40471

SPLASH BEVERAGE GROUP, INC.

(Exact name of registrant as specified in its charter)


ColoradoNevada 34-1720075
(State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.)

4120 Boardman-Canfield Road, Canfield, Ohio44406
(Address of principal executive offices)(Zip Code)

Registrant's Telephone Number,

1314 E Las Olas Blvd. Suite 221

Fort Lauderdale, FL33301

 (Address of principal executive offices) (Zip code)

(954) 745-5815

(Registrant’s telephone number, including area code: (330) 533-1914


Securities Registeredcode)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:None


Title of each classTrading SymbolName of each exchange on which registered
Common Stock, $0.001 par value per shareSBEVNYSE American LLC
Warrants to purchase shares of Common Stock, $0.001 par value per shareSBEV-WTNYSE American LLC

Securities Registeredregistered pursuant to Section 12(g) of the Act: Common Stock, No Par ValueNone


Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes No


Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes No


Indicate by check mark whether the registrant (i) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes Yes No


Indicate by checkmark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes Yes No


Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company, or an emerging growth company. See the definitions of "large“large accelerated filer," "accelerated filer"” “accelerated filer,” “smaller reporting company,” and "smaller reporting company"“emerging growth company,” in Rule 12b-2 of the Exchange Act.


Large accelerated filer
Accelerated filer
Non-accelerated filerSmaller reporting company
 
Accelerated filer  
Non-accelerated filer   
Emerging growth company
Smaller reporting company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).

Indicate by check mark whether the registrant is a shell company (as defined in rule 12b-2 of the Act). Yes No



State the

The aggregate market value of the voting and non-votingRegistrant’s common equity held by non-affiliates computed by reference to the price at which the common equity was last sold or the average bid and asked price of such common equity, as of the last business day of the registrant'sRegistrant’s most recently completed second fiscal quarter:  $228,720quarter was $40,216,244.


Indicate the number of shares outstanding of each of the registrant's classes of common stock, as of the latest practicable date. As of

On March 27, 2017, the registrant had 11,277,20029, 2024, there were 45,129,687 shares of common stockCommon Stock issued and outstanding.


DOCUMENTS INCORPORATED BY REFERENCE

None.



CANFIELD MEDICAL SUPPLY,

SPLASH BEVERAGE GROUP, INC.


FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2016


2023

TABLE OF CONTENTS

[NEED TO UPDATE]

PART I
  Page
PART I 1
   
Item 1.Business21
Item 1A.Risk Factors147
Item 1B.Unresolved Staff Comments1421
Item 2.Properties1422
Item 3.Legal Proceedings1422
Item 4.Mine Safety Disclosures1422
   
PART II 22
   
Item 5.Market for Registrant'sRegistrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities1522
Item 6.Selected Financial Data1522
Item 7.Management'sManagement’s Discussion and Analysis of Financial Condition and Results of Operations1623
Item 7A.Quantitative and Qualitative Disclosures about Market Risk1725
Item 8.Financial Statements and Supplementary Data17F-1
Item 9.Changes in and Disagreements Withwith Accountants on Accounting and Financial Disclosure1926
Item 9A.Controls and Procedures1926
Item 9B.Other Information1926
Item 9C.Disclosure Regarding Foreign Jurisdictions that Prevent Inspections 26
   
PART III27
   
Item 10.Directors, Executive Officers and Corporate Governance2027
Item 11.Executive Compensation2132
Item 12.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters2134
Item 13.Certain Relationships and Related Transactions and Director Independence2236
Item 14.Principal Accounting Fees and Services2236
   
PART IV 37
   
Item 15.Exhibits and Financial Statement Schedules2337
 Signatures2438

i

1




PART I


Except as otherwise indicated, references to “we”, “us”, “our”, “Splash”, “SBG” and the “Company” refer to Splash Beverage Group, Inc. and its wholly owned subsidiaries.

This Annual Report on Form 10-K (this “Annual Report”) contains “forward-looking statements” Forward-looking statements reflect our current view about future events. When used in this Report, the words “anticipate,” “believe,” “estimate,” “expect,” “future,” “intend,” “plan,” or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements include, but are not limited to, statements contained in this Report relating to our business strategy, our future operating results and liquidity and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward–looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors (including the risks contained in the section of this Annual Report entitled “Risk Factors”) relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended or planned.

Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance or achievements. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Except as otherwise indicated, references to “we”, “us”, “our”, “Splash”, “SBG” and the “Company” refer to Splash Beverage Group, Inc. and its wholly owned subsidiaries.

Item 1. Business.


General Information

Canfield Medical Supply,

Company Overview

Splash is a portfolio company managing multiple brands across several growth segments within the consumer beverage industry. Splash has built organizational capabilities and an infrastructure enabling it to incubate and/or acquire brands with the intention of efficiently accelerating them to higher volume and sales revenue. The management team has proven capabilities in building consumer franchises and marketing and distributing multiple brands of beverages within the non-alcoholic and alcoholic segments. Manufacturing is typically outsourced to third party co-packers and distillers, or in select cases for a brand such as Copa DI Vino® wines, performed within our own facility in Oregon.

We believe the distribution landscape in the beverage industry is changing rapidly as tech-enabled e-commerce business models are thriving. Direct to consumer, office or home solutions are projected to continue to gain traction in the future. Recognizing this opportunity Splash continues to shape its operating model to be vertically integrated with our e-commerce platform, Qplash, which purchases local and regional brands for developing a direct line of sales to boutique retail stores and consumers.

Splash’s wholly owned subsidiary, Splash Beverage Group II, Inc. ("the Company," "it," "we," "us," or "our") was originally incorporated in the State of OhioNevada under the name TapouT Beverages, Inc. for the purpose of acquiring the rights under a license agreement with TapouT, LLC (Authentic Brands Group). Splash has license rights to the TapouT Performance brand in North America (Including US Territories and Military Bases), United Kingdom, Brazil, South Africa, Scandinavia, Peru, Colombia, Chile and Guatemala.


In December 2020, Splash Beverage Group Inc. purchased the key assets of the Copa DI Vino® single serve wine company. The operations and IP for Copa DI Vino® are wholly owned by Splash and incorporated in the state of Nevada under the name Copa DI Vino® Wine Group Inc.

In addition, Splash has a joint venture with SALT Naturally Flavored Tequila and Pulpoloco sangria that comes in a biodegradable can.

The Company’s leadership understands the importance of infusing beverage brands with strong popular culture and lifestyle elements that drive trial, belief and, most importantly, repeat purchases.

Our management team led by Robert Nistico has over 28 years of experience in all levels of the three-tier distribution system used in the beverage industry working with brands such as Red Bull and companies such as Gallo Winery and Republic National Distributing Company (RNDC Texas). Our President & CMO, Bill Meissner, has led major beverage brands including Sparkling Ice, Fuze, Sweet Leaf Tea and Jones Soda. Our CFO, Stacy McLaughlin, has over 15 years of experience in public company accounting and finance, with an emphasis on Septemberreporting, fundraising and mergers and acquisitions. Our Senior Vice President of Sales, James Allred, has over 25 years’ experience in the beverage industry, predominately with Anheuser-Busch.

Our Strategy

Our strategy is to combine the traditional approach of manufacturing, distributing, and marketing of beverages, with early-stage brands that have a reasonable level of pre-existing brand awareness and market presence, or have attributes that we believe to be purely innovative. We believe this allows us to break through the clutter of numerous brand introductions and dilute risk. We apply this philosophy regardless of whether the brand is 100% owned or a joint venture.

For acquisition or joint venture consideration, we prefer to work with brands that already have one or more of the following in place:

Some level of preexisting brand awareness.

Regional presence that can be expanded.

Licensing an existing brand name (TapouT for example).

Add to an underdeveloped and/or growing category capitalizing on consumer trends.
Innovation to an existing attractive category (such as flavored tequila).
A near term clear path to profitability.

We believe this platform model provides us with two paths to success: one, developing our wholly owned core brands and two, the ability to tap into high growth, early-stage brands ready to scale. This platform allows us to limit risk, and significantly reduce development expenses while simultaneously increasing efficiencies for all brands in our portfolio.

Our management team has over 120 years of combined experience in the beverage industry, including decades of successful brand introductions by our management team (Gallo, Red Bull, Bacardi, Diageo, Sparkling Ice, Coca-Cola, FUZE Beverage, NOS Energy, PepsiCo, SoBe Beverages, AB InBev, Muscle Milk, Marley Beverages), we believe our ability to break through the distribution and retail bottlenecks makes us an attractive joint venture partner to many new brand owners.

Splash has the ability to fully own a brand or be flexible to engage in business ventures structured with a revenue split, or an equity position.

The benefit to Splash in these shared brand ownerships is the ability to avoid the development costs for new products. This model spreads our risk over several brands, contributes to our economies of scale, improves our relationship with distributors and reduces the overall cost of infrastructure.


The Company also believes the distribution landscape in the beverage category is changing rapidly. Tech-enabled business models are thriving and direct to consumer, office and home solutions are projected to continue to gain traction as beverage alcohol regulations evolve. A core strategy for us is to optimize the early success we’re seeing with the Qplash online platform, our consumer-packaged goods retail division and our first entry point into the growing e-commerce channel.

Products

We currently produce, distribute and market SALT Naturally Flavored Tequila (“SALT”), a 100% agave 80 proof line of flavored tequilas, “TapouT Performance,” a line of performance beverages that complete in the hydration and energy categories, Copa DI Vino® single serve wine by the glass, and also import Pulpoloco Sangria in 3 1992.flavors.

The following is a description of these products.

SALT Flavored Tequila

 

We oversee production, distribute, and market the following flavors under the brand name SALT Naturally Flavored Tequila:

Citrus flavor

Berry flavor

Chocolate flavor

Vodka, rum, and brown spirits have experienced significant growth when flavors are introduced, and we expect this growth of flavors to continue, as the tequila category continues to rapidly expand.

SALT is currently being distributed by various Anheuser-Busch & Miller-Coors distributorships, and other distributors in multiple U.S. states. Additionally, SALT is for sale in Mexico. SALT has also launched in Guatemala and Japan and efforts continue to grow the brand’s international presence.

SALT is a business venture between the Company and SALT USA, LLC. All aspects of manufacturing, logistics, distribution and marketing are our responsibility.


TapouT Performance Isotonic Sports Drinks

 

We produce, market, sell and distribute the following sports beverages under the brand name TapouT:

TapouT Performance

TapouT Energy

TapouT Performance Beverages are a line of unique advanced performance beverages containing ingredients known for various functional benefits including, focus, cognition, energy, recuperative and cell regeneration which promotes better absorption of nutrients, increase hydration and cellular recovery. They are exclusively formulated with GRAS (FDA Designation “Generally Regarded as Safe”) ingredients versus controversial ingredients often used in many competitive products. TapouT Performance Beverages are all natural with highly innovative proprietary blends designed to enhance physical and or mental performance.

TapouT, formally associated with the UFC and mixed martial arts has been producing branded clothing and light exercise equipment for over 23 years and has a high level of aided and unaided brand awareness.

TapouT License Agreement

We have the rights under a License Agreement with ABG TapouT (the “License Agreement”) to produce, market, sell and distribute TapouT sports beverages in North America (including US Territories and Military Bases), United Kingdom, Brazil, South Africa, Australia, Scandinavia, Peru, Colombia, Chile and Guatemala. The beverages covered by the License Agreement include sports drinks, energy drinks, energy shots, electrolyte chews, energy bars, water, protein, and teas.

We pay a 6% royalty of net sales or a guaranteed minimum annual royalty of $660,000, whichever is greater. The License Agreement will expire on December 31, 2025, with a renewal option through December 31, 2028 at which time it will be reviewed and renegotiated if necessary.

We have the right to use the TapouT brand to market, advertise and promote for sale our TapouT beverages and branded products. As part of the alliance, Splash commits to investing 2% of sales in marketing to the TapouT Performance Brand. TapouT provides marketing collateral for advertising and promotion and has influential relationships with select celebrities and athletic talent. TapouT agrees to use reasonable efforts to request its retained celebrities and/or athletes be present at autograph signings, tradeshows and other similar events.

Copa DI Vino® Wine Group, Inc. (CdV) and Related Financing

 On April 18, 2012 it changedDecember 24, 2020, the Company entered into an Asset Purchase Agreement with CdV, pursuant to which the Company purchased certain assets and assumed certain liabilities that comprise the CdV business for a total purchase price of $5,980,000, payable in the combination of $2,000,000 in cash, a $2,000,000 convertible promissory note to CdV and a variable number of shares of the Company’s common stock based on an attainment of revenue hurdles.

In conjunction with the acquisition, the Company also entered into a Revenue Loan and Security Agreement (the “Loan and Security Agreement”) by and among the Company, Robert Nistico, additional guarantor and each of the subsidiary guarantors from time-to-time party thereto (each a “Guarantor”, and, collectively, the “Guarantors”), and Decathlon Alpha IV, L.P. (the “Lender”). The Loan and Security Agreement provided for a revenue-based credit facility of $1,578,237 (the “Gross Amount”) with the Lender (the “Credit Facility”).

Copa DI Vino® Wine Group, Inc.

Copa DI Vino® is the leading producer of premium wine by the glass in the United States. The Copa DI Vino® product line is highly innovative as a ready to drink wine glass capable of going anywhere without the need for a bottle, corkscrew or glass. The company also has a growing keg wine business for on-premises restaurants and bars.

Through our acquisition of Copa DI Vino® Corporation, we are now able to offer nine varietals of wine: Pinot Grigio, Riesling, Merlot, Chardonnay, White Zinfandel, Moscato, Red Blend, Sauvignon Blanc and Cabernet Sauvignon. In addition to its domicilewine varietals, Copa DI Vino® also procures Pulpoloco, a sangria which is encased in an eco-friendly fiber based can from Spain. The rights to utilize this packaging for multiple categories were conveyed to SBG in conjunction with the distribution rights.


E-commerce

“Qplash” is a wholly owned division of Splash. It is our first entry point into the growing e-commerce channel. The division sells beverages online through www.qplash.com, and third-party storefronts such as Amazon.com. Inside of the division, there are two primary customer groups: business to business retailers, which in turn offer the products to their customers, and business to consumer, selling direct to end users. The business-to-business program allows businesses to control inventory, order with payment terms, and offer the convenience of delivery directly to each store.

 Currently Qplash offers over 1,500 listings and has warehouses that ship from both California and Pennsylvania.

Our Competitive Strengths

We believe the following competitive strengths contribute to the Company’s success and differentiate us from our competitors:

An established distribution network through global sales channels;

A hybrid distribution model that leverages multiple routes to market, including national chains, independent local markets, regional chains, and specialty food and C-Stores

Long-term relationships with retailers and the establishment of chains;

Premium customer service;

Dynamic and sustainable product offerings of natural quality and freshness with health benefits;

A highly experienced management team;

Strategically selected, dedicated sales professionals;

Qplash, our e-commerce platform, which provides us an integrated distribution platform for our non-alcoholic brands;

Ability to execute and distribute across many geographies on behalf of our licensed brand portfolio;
Strong brand awareness through partnerships and acquisitions of brands with pre-existing brand awareness, or viewed as truly innovative; and
Celebrity and professional athlete endorsement of our brands.

Manufacturing and Co-packing

We are responsible for the manufacturing of Copa DI Vino®, TapouT Performance and SALT. The Copa DI Vino® product line is bottled at our manufacturing facility in The Dalles, Oregon. Pulpoloco is imported from Spain as a finished product.

Although we are responsible for manufacturing TapouT Performance and SALT, we do not directly manufacture these products, but instead outsource such manufacturing to third party bottlers and contract packers and distillers.

Our TapouT Performance and SALT products are manufactured in the United States and Mexico, respectively under separate arrangements with each party. Our co-packaging arrangements are terminable upon request and do not obligate us to produce any minimum quantities of products within specified periods.


We purchase concentrates, flavors, dietary ingredients, cans, bottles, caps, labels, and other components and ingredients for our beverage products from our suppliers, which are delivered to our manufacturing operations and various third-party bottlers and co-packers. In some cases, certain common supplies may be purchased by our various third-party bottlers and co-packers. Depending on the product, the third-party bottlers or packers add filtered water and/or other ingredients (including dietary ingredients) for the manufacture and packaging of the finished products into our approved containers in accordance with our formulas.

Distribution

For our beverage-alcohol products, we operate within what is referred to as a “Three Tier Distribution System” where manufacturers are not permitted to sell directly to retailers, but instead contract for local and regional distribution with independent distributors. These distributors typically have geographic rights to distribute major beverage brands and call on every store in a given area such as major cities or regions. Our management team has extensive experience working within this channel and believes that we will be successful in building a strong network of these distributors.

In addition to working with these independent distributors, we also have distribution arrangements with national retail accounts to distribute some of our products directly through their warehouse operations. Most notably, SBG executed a distribution agreement with AB-InBev, for distribution with their own operations, AB ONE. This provides SBG very effective distribution capabilities.

Intellectual Property

During the fiscal year ended December 31, 2023, we were granted a trademark for Copa DI Vino®. The United States Patent and Trademark Office issued the trademark on March 12, 2024, providing our company exclusive rights to use the trademark in connection with the product categories specified in this Form 10-K.

Employees

 We have 32 full-time employees, including non-officer employees and our executive officers. None of our employees are represented by a labor union. We have not experienced any work stoppages and consider our relations with our employees to be good.

Listing on the NYSE American

Our common stock and warrants are listed on the NYSE American exchange under the ticker symbols “SBEV” and “SBEV WT,” respectively.

Recent Developments

In January 2024, the Company entered into a convertible note with an individual in the amount of $250,000. The note has an eighteen-month term, accrues interest at 12% and is convertible into shares of common stock of the Company at $0.50 per share, which also includes 200% warrants at $0.25

In January 2024, the Company entered into a commercial loan in the amount of $500,000. The total cost of the loan is $250,000 and is paid in weekly increments of 6.97% of the current receivable balance.

In February 2024, the Company entered into a convertible note with an individual in the amount of $150,000. The note has an eighteen-month term, accrues interest at 12% and is convertible into shares of common stock of the Company at $0.40 per share, which also includes 250% warrants at $0.25.

In March 2024, the Company received a $109,000 cash advance from our chief executive officer, resulting in a related party payable. This note bears 0% interest.


Corporate Information

Splash was originally incorporated in the State of Colorado by mergingNevada under the name TapouT Beverages, Inc. for the purpose of acquiring the rights under a license agreement with TapouT, LLC (Authentic Brands Group) for the right to use the TapouT brand in connection with manufacturing and selling certain beverages.

Splash executed a reverse merger with a newly formed Colorado subsidiary.


During August 2014,fully reporting, public entity called Canfield Medical Supply, Inc. and became a person who has no connection or relationship withwholly-owned subsidiary of Canfield Medical Supply Inc. on March 31, 2020. At the Corporation fraudulently accessedtime of the Corporation's filemerger Canfield’s state of incorporation was Colorado. At the time of the merger Canfield’s common stock was quoted on the Colorado Secretary of State's website andOTCQB.

On July 31, 2021, we changed the registered agent to himself. In March 2015, he fraudulently changed theour name of the Corporation from Canfield Medical Supply, Inc. to Business SolutionsSplash Beverage Group, Inc.  In April 2015 he dissolved

On June 11, 2021, our common stock and warrants to purchase common stock began trading on the corporation.


The above actions were discoveredNYSE American under the symbols “SBEV” and SBEV WT,” respectively.

On November 8, 2021, we changed our state of incorporation from Colorado to Nevada.

Our principal offices are located at 1314 E. Las Olas Blvd, Suite 221, Fort Lauderdale, Florida 33301. Our website address is www.splashbeveragegroup.com. We have not incorporated by reference into this Annual Report on Form 10-K the Corporationinformation that can be assessed through our website and you should not consider it to be part of this Annual Report on Form 10-K.

Available Information

We file annual, quarterly, and current reports, proxy statements and other information with the U.S. Securities Exchange Commission (the “SEC”). These filings are available to the public through the SEC’s website at http://www.sec.gov. All statements made in April 2016, and after contacting the Colorado Secretaryany of State, the Corporation was advised to file Articles of Reinstatement, which would have the result that the existenceour securities filings, including all forward-looking statements or information, are made as of the Corporation would be deemed for all purposes to have continued without interruption as if the dissolution never occurred.  The Corporation was also advised that it would need to file Articles of Amendment to change its name back to Canfield Medical Supply, Inc.  Immediately after receiving approval from the Majority shareholder and the Board of Directors, the Corporation filed the Articles of Reinstatement and the Articles of Amendment with the Colorado Secretary of State.


We commenced our operations in September 1992.  Initially we operated as a compounding pharmacy providing Intradialytic Parenteral Nutrition (a means of providing additional nutrition to patients on dialysis) to patients with End Stage Renal Disease who had experienced excessive weight loss due to intestinal malabsorption.  We also provided pharmacy services to patients who required intravenous antibiotic therapy, home total parenteral nutrition and home enteral nutrition. (Enteral nutrition involves absorptiondate of the drug throughdocument in which the gastrointestinal tract and parenteral nutrition involves administering the drug/nutrition in some way other than the digestive tract.)  We also provided various nebulizer medications for patients with chronic obstructive pulmonary disease. (A nebulizerstatement is a device used to administer medication in the form of a mist inhaled into the lungs.) We ceased pharmacy operations in May 2002 in response to significant reductions in reimbursement by Medicare, Medicaid, and Private Insurance Companies, and changed our focus to providing quality home medical equipment and supplies to patients in our geographical area.

Business

We are a provider of home medical equipment, supplies, and services (which relate to the equipment sales) in Ohio's Mahoning Valley, with an emphasis on providing for patients with mobility-related limitations.  We also sell to patients in Western Pennsylvania and Northern West Virginia.  We typically provide equipment, supplies, and services to people who have had strokes, hip or knee replacements, and other surgeries after they are discharged from a hospital or rehab center.  We provide almost any medical equipment and supplies these persons need to enable them to remain in their homes. We have been in the home health care business since 1992 and have developed relationships with many of the local physicians, discharge planners for hospitals and rehab facilities, nursing services, and home health agencies.

We operate in only one segment, which is home medical equipment and supplies.  We also provide the services described below along with the equipment and supplies, but most of our revenue is derived from the sale of equipment and supplies.  Most of the equipment and supplies that we sell are prescribed by a physician and are part of a care plan.  We provide substantial benefits to both patients and payors by allowing patients to receive necessary care and services in the comfort of their own home while reducing the cost of treatment.  Our services include:


2




1.Providing in-home delivery, set-up, and maintenance of equipment;
2.Providing patients and caregivers with written instructions about home safety, self-care, and the proper use of equipment;
3.Processing claims to third-party payors and billing/collecting patient co-pays and deductibles.

We supply a wide range of home medical equipment to help improve the quality of life for patients with special needs, particularly those who face unique mobility challenges as they try to remain independent in their homes.  The use of home medical equipment provides a significant relative cost advantage to our patients and payors.  The basic categories of equipment we carry are:

1.Electric wheelchairs, scooters, and lift chairs
2.Manual wheelchairs and ambulatory equipment, such as wheeled walkers, canes, and crutches;
3.Hospital beds;
4.Bathroom equipment, such as bedside commodes, shower chairs, grab bars, and toilet risers;
5.Support surfaces, such as pressure pads and mattresses, for patients at risk for developing pressure sores or decubitus ulcers;
6.Threshold ramps, folding ramps, and lift systems for cars or vans that make it easy to exit the home or transport electric wheelchairs or scooters.

Industry Overview

The home healthcare market comprises a broad range of products and services – including respiratory therapy, infusion therapy (which deals with all aspects of fluid and medication infusion, usually via the intravenous route), home medical equipment, home healthcare nursing, orthotics and prosthetics, and general medical supplies.

We expect to benefit from the following trends within the home healthcare market:

Favorable industry dynamics.  Favorable demographic trends and the continued shift to in-home healthcare have resulted in patient volume growth in the United States and are expected to continue to drive growth.  As the baby boomer population ages and life expectancy increases, the elderly – who comprise the majority of our patients – will represent a higher percentage of the overall population.  According to a 2010 U.S. Census Bureau projection, the U.S. population aged 65 and over is expected to grow substantially from 13 % of the population in 2010 to 19 % of the population by 2030.

Compelling in-home economics.  Between 2010 and 2020, the nation's healthcare spending is projected to increase to $4.6 trillion, growing at an average annual rate of 5.8 % according to the Centers for Medicare and Medicaid Services ("CMS").  The rising cost of healthcare has caused many payors to look for ways to contain costs and home healthcare is increasingly sought out as an attractive, cost-effective, clinically appropriate alternative to expensive facility-based care.

Increased prevalence of in-home care.  Improved technology has resulted in a wider variety of treatments being administered in patients' homes.  Based on its experience, management believes that these improvements have allowed for earlier patient discharge and have lengthened the portion of the recuperation period spent outside of an institutional setting.  In addition, medical advancements have also made medical equipment simpler, and more adaptable and cost-effective for use in the home.

Preference for in-home care.  Based on its experience, management believes that many patients prefer the convenience and typical cost advantages of home healthcare over institutional care, as it provides patients with greater independence, increased responsibility, and improved responsiveness to treatment.


3



Our Competitive Strength

Our principal competitive strength is that we are an established local company in the Mahoning Valley with a reputation for good service and good quality.  If a patient has any problems with a piece of equipment they purchase from us, they can call usincluded unless otherwise specified, and we will take caredo not assume or undertake any obligation to update any of the problem. Historically we have not experienced significant returnsthose statements or refunds. We contract with Medicare, Medicaid, most major health insurance companies, and a number of other payors.  We are especially known as a business that can provide almost anything a patient with reduced mobility needs, including home modifications necessary to remain independent in the home.

We also qualify as a "small supplier" under the Medicare competitive bidding program, since our annual revenues are less than $3.5 million.  The Medicare regulations have established a 30 percent target for small supplier participation, which improves our chances of winning small bids from Medicare.  As a supplier in the Medicare program,documents unless we are required to meet and adheredo so by law.

Item 1A. Risk Factors.

You should carefully consider the risks described below as well as other information provided to certain standards set by Medicare.


We also participateyou in this document, including information in the Ohio Medicaid program.  Our agreement with the Ohio Departmentsection of Jobs and Family Services expires on July 31, 2017, at which time we must apply for a new agreement.

Our Business Strategy

We are attempting to grow our revenue and increase our market share in our primary market, which is the Mahoning Valley with an estimated population in excess of 900,000 persons.  In addition to continuing our marketing activities in the Mahoning Valley, we intend to build a website designed for patients located both inside and outside of our primary market area who might be interested in looking for better prices on certain equipment or supplies.  These persons would not be buying products because of physician referrals or under their health insurance policies.  Instead, they would merely be buying products online and paying with a credit card.

In 2012, we submitted bids in Medicare's Round 2 of competitive bidding.  In addition to our local Youngstown-Warren market area, we also submitted bids in four additional Ohio markets of Akron, Columbus, Dayton and Toledo.  We won the bid for our local market area for wheel chairs, enteral tube feeding, and pressure reduction surfaces.  As a direct result of winning these bids, our patient census has increased from approximately 85 prior to July 1, 2013 to about 1,250 by December 31, 2016.

We are also attempting to increase our private pay business because of the continuing reduction in Medicare reimbursement rates.  We offer the same home medical equipment and supplies to private pay customers that we offer to Medicare and Medicaid customers.  Our private pay customers include persons who have private (non-government) health insurance and persons who have no insurance or are buying something that is not covered by their insurance policy.  In this regard, we are contacting home care coordinators from private insurance companies and Bureau of Worker's Compensation in order to gain additional referrals. The amount of revenue earned from each classification as a percent of total revenues is as follows:

  December 31, 
  2016  2015 
Medicare  27%  13%
Medicaid  13%  12%
Private pay/private insurance  47%  63%
Other  13%  12%
Total  100%  100%


We do not manufacturedocument entitled “Cautionary Note Concerning Forward Looking Statements.” If any of the productsfollowing risks actually occur, the Company’s business, financial condition or results of operations could be materially adversely affected, the value of the Company’s Common Stock could decline, and supplies that we sellyou may lose all or part of your investment.

RISKS RELATED TO OUR BUSINESS

Risks Related to our customers.  We do notBusiness

Our auditors have exclusive relationships with any of these suppliers/manufacturers.  When the products we sell come with warranties, we are usually the person who the customer contacts when they have any kind of issue covered by a warranty.  We then go to the manufacturer and order the part needed or otherwise take care of the problem.  We do not warranty any products ourselves.



4



We are also attempting to increase our exposure to assisted living facilities, nursing homes, and acute rehabilitation facilitiesincluded an explanatory paragraph in order to gain additional referrals.  We have experienced some success due to recent marketing efforts in these areas.  We will continue to provide in-service education programs to the staff of these facilities in order to make them aware of the services we are able to provide for their patients.  We would not need any additional level of accreditation to make sales to patients in these facilities.

We are always evaluatingopinion regarding our ability to provide equipment and servicescontinue as a going concern. If we are unable to continue as a going concern, our patients and trying to improve wherever we can.  We are not operating close tosecurities will have little or no value.

Rose, Snyder & Jacobs LLP, our capacity and we have roomindependent registered public accounting firm for substantial growth without needing to add any significant overhead.


Organization and Operations

Organization.  Our only facility is our office/showroom located at 4120 Boardman-Canfield Road in Canfield, Ohio, about eight miles southwest of Youngstown, Ohio.  From this location we deliver our home healthcare products and services to patients in their homes and to other care sites using our delivery vehicle and our employees.

Payors.  We derive substantially all of our revenues from third-party payors, including private insurers, Medicare, Medicaid, and managed care organizations.  For the fiscal year ended December 31, 2016, approximately 40%2023, has included an explanatory paragraph in their opinion that accompanies our audited consolidated financial statements as of our net revenues were derived from Medicare and Medicaid.  Generally, each third-party payor has specific requirements, which must be met before claim submission will result in payment.  We have procedures in place to manage the claims submission process, including verification procedures to facilitate complete and accurate documentation.  Notwithstanding these measures, violation of these requirements may still occur and could result in the termination of a contract with a payor, the repayment of amounts previously received, or other potentially significant liability.  When the third-party payor is a governmental entity, violations of these requirements could subject us to civil, administrative, and criminal enforcement actions.  We are subject to periodic audits by Medicare and Medicaid, the results of which have not identified any violations by us of these governmental entities' claim submission requirements.

Medicare Claims.  Most Medicare claims are paid within 30 to 60 days of submission. High dollar claims such as power chairs and pressure reduction surfaces require increased scrutiny by Medicare.  Such high dollar claims frequently are singled out for pre-payment audits, which require all hard copy documentation of the patient's condition by the physician be sent in to Medicare prior to receiving payment.  These claims take a minimum of 60 days to process and denials must be appealed.  All subsequent claims to Medicare for rental payments for the denied equipment continue to be denied until the appeal process is finished.  All of these claims require additional time to be completed and sometimes require phone calls to patients and doctors to reconcile.  Management is constantly reviewing unpaid claims to determine their status and claims are not written off until all attempts to collect payment from Medicare have been exhausted.  We historically write off approximately 5% of Medicare payments due to unsuccessful collection attempts.

Medicaid Claims.  Based on our results for the last three years, approximately 70% of our Medicaid claims are paid within 30 days.  Any claims not paid within 30 days usually have a billing error that has not been resolved by management and end up getting resolved and paid within an additional 30 to 60 days.

Self-pay Claims.  Approximately 5% of our business during the year ended December 31, 2016 was comprised of self-pay business.  This business represents persons who come into our store and purchase items not covered by insurance and patients who already may be purchasing something from us that is covered by insurance and they desire to purchase something additional that is not covered by insurance.  Some of these customers pay for their product at the time of purchase and we send or deliver invoices to the others.  These invoices request payment on receipt of the invoice.  We consider these receivables delinquent once they are 180 days late.  We rely on our past collection experience with other patients for similar or different products to determine if any of such receivables are still collectible.  At December 31, 2016, we determined that no allowance for such items was necessary.

With respect to our claims submitted to third party payors, our billing system generates contractual adjustments based on fee schedules for the patient's insurance plan for each claim.



5


Receivables Management.  We operate in an environment with complex requirements governing billing and reimbursement for our products and services.  We are expanding our use of technology in areas such as electronic claims submission and electronic funds transfer whenever we can to more efficiently process business transactions.  This use of technology can expedite claims processing and reduce the administrative cost associated with this activity for both us and our customers/payors.  Our policy is to collect co-payments from the patient or applicable secondary payor.  In the absence of a secondary payor, we generally require the co-payment at the time the patient is initially established with the product/service.  Subsequent months' co-payments are billed to the patient.

With respect to rentals of power chairs, once initial delivery of rental equipment is made to the patient, a monthly billing cycle is established based on the initial date of delivery.  The Company recognizes rental revenue ratably over the 13-month service period.  Routine maintenance and servicing of the equipment is the responsibility of the Company.

Marketing

We market our products and services primarily to physicians, discharge planners for hospitals and rehab facilities, nursing services, companies that provide home care companions and aides, home health agencies, and case managers.  Our marketing is primarily done by our President who has developed relationships with many of the persons to whom we market in the course of his dealings with prior patients who purchased our products or services over the past 24 years that we have been in business.  Most of our marketing consists of face-to-face meetings and in-service education with the staff at facilities to which we provide services.  We also provide educational pamphlets and product specific brochures to go along with marketing materials such as pens, scratch pads, calendars, and prescription pads.

One of the marketing steps we have taken is to be accredited by The Joint Commission, which is a nationally recognized organization that develops standards for various healthcare industry segments and monitors compliance with those standards through voluntary surveys of participating providers.  We have been accredited by The Joint Commission since 2008.  As the home healthcare industry has grown and accreditation has become a mandatory requirement for Medicare DMEPOS providers, the need for objective quality measurements has increased.  Accreditation is also widely considered a prerequisite for entering into contracts with managed care organizations and is required for Medicare competitive bidding.  Because accreditation is expensive and time consuming, not all providers choose to undergo the process.

Sales

Our President has primary responsibility for generating new referrals and for maintaining existing relationships for our products and services.  Our customers are typically the patients who purchase and utilize our products and services, but these patients are usually referred to us by physicians and their staffs, the discharge planners in hospitals and rehab facilities, nursing services and services that provide home care companions, and aides.  We have several rehabilitation facilities that refer a significant amount of patients to us that account for in excess of 25% of our gross revenues.  These facilities include Briarfield Manor, Heritage Manor, Maplecrest, Park Vista Rehabilitation, and Sunrise Senior Living.  However, these facilities also refer business to other providers.


6



Website

We currently have a website which shows pictures of most of the products we sell with links to the manufacturers/suppliers of the products.  This allows viewers to obtain more information on the products.  The website is not designed to be used for online sales, and instead it is more used to show new or existing patients what products we can obtain and sell to them.  There is also no product pricing on the website.

We intend to enhance this website so that online sales can be made on the website once we have funding available.  We intend to contract with a leading web store builder program that offers a wealth of features to expand our business and provide support as our business grows.  This program will make it easy to launch and maintain our web store.  We hope to build a state-of-the-art e-commerce site that reflects our brands and puts our Company on a fast track to leveraging the sales opportunities on the Internet.  This whole process could be accomplished in only a manner of weeks once funding is available, and will not require the purchase of new computers or software licenses, or hiring of additional staff.

Competition

The segment of the healthcare market in which we compete is highly competitive.  In our line of products and services, there are a limited number of national providers and numerous regional and local providers.  The competitive factors most important in our local market are:

1.Reputation with referral sources, including local physicians and hospital-based professionals;
2.Price of products and services;
3.Accessibility and overall ease of doing business;
4.Quality of patient care and associated services;
5.Range of home healthcare products and services;
6.Ability to provide local maintenance service on products sold.

The primary national provider with which we compete is Apria Healthcare Group, Inc., and the primary regional providers with which we compete in Northeastern Ohio and Western Pennsylvania are Boardman Medical Supply, Inc., Community Home Medical, Inc., and Seeley Medical, Inc.  Depending on their business strategies and financial position, a very large percentage of our competitors have access to significantly greater financial and marketing resources than we do.  This may increase pricing pressure and limit our ability to maintain or increase our market share.

Government Regulation

We are subject to extensive government regulation, including numerous laws directed at regulating reimbursement of our products and services under various government programs and preventing fraud and abuse, as more fully described below. We maintain certain safeguards intended to reduce the likelihood that we will engage in conduct or enter into arrangements in violation of these restrictions.  All contracts with Insurance Companies are fairly standard and do not require legal opinions, and all our policies and procedures have been reviewed by The Joint Commission and meet Industry standards and requirements.  Federal and state laws require that we obtain facility and other regulatory licenses and that we enroll as a supplier with federal and state health programs.  Notwithstanding these measures, due to changes in and new interpretations of such laws and regulations, and changes in our business, among other factors, violations of these laws and regulations may still occur, which could subject us to civil and criminal enforcement actions; licensure revocation, suspension, or non-renewal; severe fines and penalties; and even the termination of our ability to provide services, including those provided under certain government programs such as Medicare and Medicaid.

Medicare and Medicaid Revenues.  In the years ended December 31, 2016 and 2015, approximately 40% and 25% of our net revenues were reimbursed by the Medicare and state Medicaid programs, respectively.  No other third-party payor represented more than 10% of our total net revenues for the year ended December 31, 2016.  The majority of2023, indicating that our revenuescurrent liquidity position raises substantial doubt about our ability to continue as a going concern. If we are derived from sales of equipmentunable to improve our liquidity position, we may not be able to continue as a going concern.

We have sustained recurring losses and supplies we sell to patients for patient care under fee-for-service arrangements.   Fee-for-service is a payment model where services are unbundled and paid for separately, and occurs when doctors and other health care providers receive a fee for each service, such as an office visit, test, or procedure.  Since most of the manufacturers of the products we sell do not provide direct patient care, our services primarily involve providing in-home-delivery, set-up, and maintenance of home medical equipment.  We do not have ongoing arrangements with patients or medical providers, other than rental agreements that we have for wheel chairshad working capital and hospital beds.

stockholders’ equity deficits. These prior losses and expected future losses have had,



7



Medicare Reimbursement. There are a number of legislative

and regulatory initiatives in Congress and at CMS that affect or may affect Medicare reimbursement policies for products and services we provide. Specifically, a number of important legislative changes that affect our business were included in the Medicare Prescription Drug, Improvement and Modernization Act of 2003 ("MMA"); the Deficit Reduction Act of 2005 ("DRA"); MIPPA, which became law in 2008; and the comprehensive healthcare reform law signed in March 2010 ("the Reform Package").  These Acts and their implementing regulations and guidelines contain numerous provisions that are significant to us andwill continue to have, an impactadverse effect on our financial condition. In addition, continued operations today.


DMEPOS Competitive Bidding. The MMA required implementationand our ability to continue as a going concern may be dependent on our ability to obtain additional financing in the near future and thereafter, and there are no assurances that such financing will be available to us at all or will be available in sufficient amounts or on reasonable terms. Our financial statements do not include any adjustments that may result from the outcome of this uncertainty. If we are unable to generate additional funds in the future through sales of our products, financing or from other sources or transactions, we will exhaust our resources and will be unable to continue operations. If we cannot continue as a competitive bidding program for certain DMEPOS items. By statute, CMS wasgoing concern, our shareholders would likely lose most or all of their investment in us.

Management recognizes that it may be required to implementobtain additional resources via issuances of indebtedness or equity to successfully execute its business plans. No assurances can be given that management will be successful in raising additional capital, if needed, or on acceptable terms. These conditions raise substantial doubt about the DMEPOS competitive bidding program over time, with Round 1 of competition occurring in portions of 10 of the largest Metropolitan Statistical Areas ("MSAs") in 2007, launch of the program in 2008 and in 70 additional markets in 2009, and in additional markets after 2009.


Under the competitive bidding program, suppliers competeCompany’s ability to continue as a going concern for the rightnext 12 months. These financial statements do not include any adjustments relating to provide itemsthe recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to beneficiariescontinue as a going concern.

We have experienced recurring losses from operations and negative cash flows from operating activities and anticipate that we will continue to incur significant operating losses in a defined region. CMS selects contract suppliers that agreethe future.

We have experienced recurring losses from operations and negative cash flows from operating activities. We expect to receive as paymentcontinue to incur significant expenses related to our ongoing operations and generate operating losses for the "single payment amount" calculated by CMS after bids are submitted.  Bids are evaluated basedforeseeable future. The size of our losses will depend, in part, on the supplier meeting eligibilityrate of future expenditures, our ability to execute on our acquisition strategy and financial requirements, and contracts are awardedour ability to Medicare suppliers that offergenerate revenues. We incurred a net loss of $21.0 million for the best price and meet these standards.  CMS determines a supplier's financial viability based on certain financial ratios and the supplier's credit report and score.  Based on the information requested in the bid forms, we believe that the CMS may also consider other factors, suchyear ended December 31, 2023. Our accumulated deficit increased to $133.3 million as the volume which the bidder is offering to provide asof December 31, 2023, compared to the volume it previously provided, whether the bidder has the staff and facilities to handle the volume it is bidding for,prior year’s deficit of $112.3 million.

We may encounter unforeseen expenses, difficulties, complications, delays, and other miscellaneous items.


Every bidder sets forth its estimated capacity of each item for which it is biddingunknown factors that may adversely affect our financial condition. Our prior losses and it sets forth a bid price.  It isexpected future losses have had, and will continue to have, an adverse effect on our understanding that the CMS will set a bid price as low as possible that will still result in afinancial condition. If our products do not achieve sufficient number of bidders, based on their estimated capacity, to supply the number of units the CMS estimates need to be provided for the particular market acceptance and our revenues do not increase significantly, we may never become profitable. Even if we achieve profitability in the next year.  We also believe that the CMS will attempt to award up to 30% of the bids to small businesses.  There are no material costs associated with submitting bids and obtaining contracts.

In 2007 and 2008, CMS sought and reviewed bids and developed a plan to implement Round 1 on July 1, 2008.

The bidding process for Round 1 was controversial and complex, which resulted in deadline extensions. Moreover, CMS was subject to numerous lawsuits seeking a delay of Round 1. Then on July 15, 2008, MIPPA was enacted which, among other provisions, delayed the DMEPOS competitive bidding program by requiring that Round 1 competition commence in 2009, and required a number of program reforms prior to CMS re-launching the program. Changes mandated by MIPPA include requirements for the government to administer the program more transparently, exemption of certain DMEPOS products from the program, and a new implementation schedule.

In November 2010, CMS published a final rule containing several provisions related to the competitive bidding program. The rule included a list of 21 additional MSAs to be included in Round 2.


8



Under MIPPA, the initial competitive bidding areas ("CBAs") and product categories subject to rebidding in the Round 1 Rebid are very similar to those of Round 1. However, MIPPA excludes Negative Pressure Wound Therapy Pumps and Related Supplies and Accessories as a competitive bidding product category in Round 1 and permanently excludes Group 3 Complex Rehabilitative Power Wheelchairs and Related Accessories as a competitive bidding product category.

Notwithstanding the changes MIPPA requires, competitive bidding imposes a significant risk to DMEPOS suppliers under the rules governing the program. If a DMEPOS supplier such as us operating in a CBA is not awarded a contract for that CBA, the supplier generally willfuture, we may not be able to billsustain profitability in subsequent periods. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, expand our business, diversify our product offerings or continue our operations. A decline in the value of our company could cause you to lose all or part of your investment.

If we are not able to successfully execute on our future operating plans and objectives, our financial condition and results of operation may be reimbursed by Medicare for DMEPOS items supplied inmaterially adversely affected, and we may not be able to continue as a going concern.

It is important that CBA for the time period covered by the competitive bidding program unless the supplier meets certain exceptions or acquires a winning bidder. Because the applicable statutes mandatewe meet our sales goals and increase sales going forward as our operating plan already reflects prior significant cost containment measures and may make it difficult to achieve top-line growth if further significant reductions become necessary. If we do not meet our sales goals, our available cash and working capital will decrease and our financial savings from the competitive bidding program, a winning contract suppliercondition will receive lower Medicare payment rates under competitive bidding than the otherwise applicable DMEPOS fee schedule rates. As competitive bidding is phased in across the country under the revised MIPPA and Reform Package implementation schedule,be negatively impacted.

In order to be successful, we believe that we will experience a reduction in reimbursement.  In addition, there is an increasing risk that the competitive bidding prices will become a benchmark for reimbursement from other payors, as evidenced by the Administration's fiscal budget proposal which would cap state Medicaid reimbursement levels at competitive bid rates using an as-yet-undetermined methodology. Neither MIPPA nor the Reform Package prevents CMS from adjusting prices for DMEPOS items in non-bid areas; however, before using its authority to adjust prices in non-bid areas, MIPPA requires that CMS issue a regulation that specifies the methodology to be used and consider how prices through competitive bidding compare to costs for those items and services in the non-bid areas.


The Reform Package also includes changes to the Medicare DMEPOS competitive bidding program. Significantly, Round 2 of the competitive bidding program has been expanded from 70 to 91 of the largest MSAs. In August 2011, CMS announced the product categories that would be included in Round 2.  Round 2 included the majority of the same product categories, but CMS expanded the program by,must, among other things, (i) combining standard power wheelchairs and manual wheelchairs into a single new product category, and (ii) expanding the Support Surfaces (Group 2 mattresses and overlays) category across all Round 2 markets.

On July 1, 2016, the Medicare fee schedule was reduced in non-competitive bid areas on certain DME items, but the new 2016 fee schedule is still higher than the competitive bid pricing in adjacent areas. In addition, efforts to repeal the competitive bidding program altogether or mandate significant program changes continue. In March 2011, the Fairness in Medicare Bidding Act of 2011 ("FIMBA") was introduced into the U.S. House of Representatives and referred to the House Subcommittee on Health. FIMBA would repeal the program without specifying a reduction in the industry's current reimbursement levels. Other efforts are underway by independent economists who seek to alter certain critical aspects of the program. Specifically, those efforts are designed to change the way in which CMS conducts the auction process itself, establishes the single payment rates, determines supplier capacity needed and related aspects which, if adopted by CMS in their entirety or in part, would change how Round 2 would be administered. things:

increase the sales volume and gross margins for our products and those that we will acquire;
maintain efficiencies in operations;
manage our operating expenses to sufficiently support operating activities;
maintain fixed costs at or near current levels; and
avoid significant increases in variable costs relating to production, marketing and distribution.

We cannot predict whether these or other efforts to repeal or amend the program will be successful, or their potential impact on us.


We believe that our relationships with persons who refer business to us will allow us to maintain market share under Medicare competitive bidding. However, the bidding rules are complex and it is possible for bidders to be disqualified for technical reasons other than pricing. There is no guarantee that we will be selected as a winning contract supplier in any future phases of the program and be awarded competitive bidding contracts by CMS or that we will maintain or increase market share. Under the current competitive bidding regulations, if we are not selected as a winning contract supplier for a particular CBA, we will generallymay not be allowedable to supply Medicare beneficiaries in the CBA with products subject to competitive bidding for the contract term of program, unless we elect to continue to service existing patients under the "grandfathering provision" of the program's final rule for certain products.  Because of our combination of both managed care and traditional business, we believe we can nevertheless maintain a favorable overall market position in a particular CBA even if we are not selected as a contract supplier.


9



Enrollment and Accreditation of Durable Medical Equipment Suppliers; Surety Bond Requirements.  While we support the elimination of fraudulent suppliers, some of the CMS initiatives and developments with respect to the enrollment and accreditation of providers could impact our operations in the future. For example, all durable medical equipment providers who bill the Medicare program for DMEPOS services and products are required by MIPPA to be accredited. Although we currently are accredited, if we lose accreditation, thatmeet these objectives, which could have a material adverse effect on our results of operations, cash flow,operations. We have incurred significant operating expenses in the past and capital resources.
may do so again in the future and, as a result, will need to increase revenues in order to improve our results of operations. Our ability to increase sales will depend primarily on success in expanding our current markets, improving our distribution base, entering into Direct-To-Retail (DTR) arrangements with national accounts,


CMS also requires that all durable medical equipment providers who bill

and introducing new brands, products or product extensions to the Medicare program maintain a surety bondmarket. Our ability to successfully enter new distribution areas and obtain national accounts will, in turn, depend on various factors, many of $50,000 per National Provider Identifier ("NPI") number which Medicare has approved for billing privileges. We obtainedare beyond our control, including, but not limited to, the required surety bondcontinued demand for our location beforebrands and products in target markets, the October 2009 deadline,ability to price our products at competitive levels, available positions within the retailer’s planograms, the ability to establish and it is automatically renewed annually on August 1.


Other Issues.

Medical Necessity & Other Documentation Requirements.  In order to ensure that Medicare beneficiaries only receive medically necessary and appropriate items and services, the Medicare program has adopted a number of documentation requirements. For example, the DME MAC Supplier Manuals provide that clinical information from the "patient's medical record" is required to justify the initial and ongoing medical necessity for the provision of DME. Some DME MACs, CMS staff and government subcontractors have taken the position, among other things, that the "patient's medical record" refers not to documentation maintainedmaintain relationships with distributors in each geographic area of distribution and the ability in the future to create, develop and successfully introduce one or more new brands, products, and product extensions.

Demand for our products may be adversely affected by the DME supplier but instead to documentation maintained by the patient's physician, healthcare facility or other clinician, and that clinical information created by the DME supplier's personnel and confirmed by the patient's physician is not sufficient to establish medical necessity. It may be difficult, and sometimes impossible, for us to obtain documentation from other healthcare providers. Moreover, auditors' interpretations of these policies are inconsistent and subject to individual interpretation. This is then translated to individual supplier significant error rates and aggregated into a DMEPOS industry error rate, which is significantly higher than other Medicare provider/supplier types. High error rates lead to further audit activity and regulatory burdens. In fact, DME MACs have continued to conduct extensive pre-payment reviews across the DME industry and have determined a wide range of error rates. For example, error rates for CPAP claims have ranged from 50% to 80%. DME MACs have repeatedly cited medical necessity documentation insufficiencies as the primary reason for claim denials. If these or other burdensome positions are generally adopted by auditors, DME MACs, other contractors or CMS in administering the Medicare program, we would have the right to challenge these positions as being contrary to law. If these interpretations of the documentation requirements are ultimately upheld, however, it could result in our making significant refunds and other payments to Medicare and our future revenues from Medicare may be significantly reduced. We have adjusted certain operational policies to address the current expectations of Medicare and its contractors. We cannot predict the adverse impact, if any, these interpretations of the Medicare documentation requirements or our revised policies might have on our operations, cash flow, and capital resources, but such impact could be material.


The impact of changes in Medicare reimbursementconsumer preferences or any inability on our part to innovate, market or distribute our products effectively, and any significant reduction in demand could adversely affect our business, financial condition or results of operations.

Our beverage portfolio is comprised of a number of unique brands with reputations and consumer imagery that have been enactedbuilt over time. Our investments in marketing as well as our strong commitment to dateproduct quality are reflectedintended to have a favorable impact on brand image and consumer preferences. If we do not adequately anticipate and react to changing demographics, consumer and economic trends, health concerns and product preferences, our financial results could be adversely affected.

Additionally, failure to introduce new brands, products or product extensions into the marketplace as current ones mature and to meet the changing preferences of consumers could prevent us from gaining market share and achieving long-term profitability. Product lifecycles can vary and consumer preferences and loyalties change over time. Although we try to anticipate these shifts and innovate new products to introduce to our consumers, we may not succeed. Consumer preferences also are affected by factors other than taste, such as health and nutrition considerations and obesity concerns, shifting consumer needs, changes in consumer lifestyles, increased consumer information and competitive product and pricing pressures. Sales of our products may be adversely affected by negative publicity associated with these issues. If we do not adequately anticipate or adjust to respond to these and other changes in consumer preferences, we may not be able to maintain and grow our brand image and our sales may be adversely affected.

Volatility in the price or availability of the inputs we depend on, including raw materials, packaging, energy and labor, could adversely impact our financial results.

The principal raw materials we use include glass bottles, aluminum cans, PET, fiber-board, labels and cardboard cartons, flavorings and sweeteners. These component and ingredient costs are subject to fluctuation. If there were to be substantial increases in the prices of our ingredients, raw materials and packaging materials, to the extent that they cannot be recouped through increases in the prices of finished beverage products, would increase our operating costs and could reduce our profitability. If our supply of these raw materials is impaired or if prices increase significantly, it could affect the affordability of our products and reduce sales.

If we are unable to secure sufficient ingredients or raw materials including glass, sugar, and other key supplies, we might not be able to satisfy demand on a short-term basis.

Changes in government regulation or failure to comply with existing regulations could adversely affect our business, financial condition and results of operations foroperations.

Our business and properties are subject to various federal, state and local laws and regulations, including those governing the applicable periodsproduction, packaging, quality, labeling and distribution of beverage products. In addition, various governmental agencies have enacted or are considering additional taxes on soft drinks and other sweetened beverages. Changes in existing laws or regulations could require material expenses and negatively affect our financial results through December 31, 2016. lower sales or higher costs.

We cannot estimatecompete in an industry that is brand-conscious, so brand name recognition and acceptance of our products are critical to our success.

Our business is dependent upon awareness and market acceptance of our products and brands by our target markets. In addition, our business depends on acceptance by our independent distributors and retailers of our brands as beverage brands that have the combined possible impactpotential to provide incremental sales growth. If we are not successful in the revitalization and growth of all legislative, regulatoryour brand and contemplated reimbursement changes thatproduct offerings, we may not achieve and maintain satisfactory levels of acceptance by independent distributors and retail consumers. Any failure of our brand to maintain or increase acceptance or market penetration would likely have a material adverse effect on our revenues and financial results.


Our brands and brand images are keys to our business and any inability to maintain a positive brand image could have a material adverse effect on our results of operations, cash flow,operations.

Our success depends on our ability to maintain brand image for our existing products and capital resources. Moreover,effectively build up brand image for new products and brand extensions. We cannot predict whether our estimatesadvertising, marketing and promotional programs will have the desired impact on our products’ branding and on consumer preferences. In addition, negative public relations and product quality issues, whether real or imagined, could tarnish our reputation and image of the affected brands and could cause consumers to choose other products. Our brand image can also be adversely affected by unfavorable reports, studies and articles, litigation, or regulatory or other governmental action, whether involving our products or those of our competitors.

Competition from traditional and large, well-financed non-alcoholic and alcoholic beverage manufacturers may adversely affect our distribution relationships and may hinder development of our existing markets, as well as prevent us from expanding our markets.

The beverage industry is highly competitive. We compete with other beverage companies not only for consumer acceptance but also for shelf space in retail outlets and for marketing focus by our distributors, all of whom also distribute other beverage brands. Our products compete with all non-alcoholic and alcoholic beverages, most of which are marketed by companies with substantially greater financial resources than ours. Some of these competitors are placing severe pressure on independent distributors not to carry competitive brands such as ours. We also compete with regional beverage producers and “private label” brands.

Increased competitor consolidations, market-place competition, particularly among branded beverage products, and competitive product and pricing pressures could impact our earnings, market share and volume growth. If, due to such pressure or other competitive threats, we are unable to sufficiently maintain or develop our distribution channels, we may be unable to achieve our current revenue and financial targets. Competition, particularly from companies with greater financial and marketing resources than ours, could have a material adverse effect on our existing markets, as well as on our ability to expand the market for our products.

Legislative or regulatory changes that affect our products, including new taxes, could reduce demand for products or increase our costs.

Taxes imposed on the sale of certain of these changes appearingour products by federal, state and local governments in the United States, or other countries in which we operate could cause consumers to shift away from purchasing our beverages. Several municipalities in the United States have implemented or are considering implementing taxes on the sale of certain “sugared” beverages, including non-diet soft drinks, fruit drinks, teas and flavored waters to help fund various initiatives. These taxes could materially affect our business and financial results.

Our reliance on distributors, retailers and brokers could affect our ability to efficiently and profitably distribute and market our products, maintain our existing markets and expand our business into other geographic markets.

Our ability to maintain and expand our existing markets for our products, and to establish markets in new geographic distribution areas, is dependent on our ability to establish and maintain successful relationships with reliable distributors, retailers and brokers strategically positioned to serve those areas. Most of our distributors, retailers and brokers sell and distribute competing products, including non-alcoholic and alcoholic beverages, and our products may represent a small portion of their businesses. The success of this "Government Regulation" sectionnetwork will depend on the performance of the distributors, retailers and brokers of this network. There is a risk that the mentioned entities may not adequately perform their functions within the network by, without limitation, failing to distribute to sufficient retailers or positioning our products in localities that may not be receptive to our product. Our ability to incentivize and motivate distributors to manage and sell our products is affected by competition from other beverage companies, some of which may have greater resources than we do. To the extent that our distributors, retailers and brokers are baseddistracted from selling our products or do not employ sufficient efforts in managing and selling our products, including re-stocking the retail shelves with our products, our sales and results of operations could be adversely affected. Furthermore, such third-parties’ financial position or market share may deteriorate, which could adversely affect our distribution, marketing and sales activities.


Our ability to maintain and expand our distribution network and attract additional distributors, retailers and brokers will depend on a number of assumptions andfactors, some of which are subject to uncertainties and there can be no assurance that the actual impact was not or will not be different fromoutside our estimates. However, given the recent significant increases in industry audit volume and the increasing regulatory burdens associated with responding to those audits, it is likely that the negative pressures from legislative and regulatory changes will continue and accelerate.



10



Medicaid Reimbursement.  State Medicaid programs implement reimbursement policies for the items and services we provide that may orcontrol. Some of these factors include:

the level of demand for our brands and products in a particular distribution area;

our ability to price our products at levels competitive with those of competing products; and

our ability to deliver products in the quantity and at the time ordered by distributors, retailers and brokers.

We may not be similarable to thosesuccessfully manage all or any of these factors in any of our current or prospective geographic areas of distribution. Our inability to achieve success with regards to any of these factors in a geographic distribution area will have a material adverse effect on our relationships in that particular geographic area, thus limiting our ability to maintain or expand our market, which will likely adversely affect our revenues and financial results.

It is difficult to predict the timing and amount of our sales because our distributors are not required to place minimum orders with us.

Our independent distributors and national accounts are not required to place minimum monthly or annual orders for our products. In order to reduce their inventory costs, independent distributors typically order products from us on a “just in time” basis in quantities and at such times based on the demand for the products in a particular distribution area. Accordingly, we cannot predict the timing or quantity of purchases by any of our independent distributors or whether any of our distributors will continue to purchase products from us in the same frequencies and volumes as they may have done in the past. Additionally, our larger distributors and national partners may make orders that are larger than we have historically been required to fill. Shortages in inventory levels, supply of raw materials or other key supplies could negatively affect us.

If we do not adequately manage our inventory levels, our operating results could be adversely affected.

We need to maintain adequate inventory levels to be able to deliver products to distributors on a timely basis. Our inventory supply depends on our ability to correctly estimate demand for our products. Our ability to estimate demand for our products is imprecise, particularly for new products, seasonal promotions and new markets. If we materially underestimate demand for our products or are unable to maintain sufficient inventory of raw materials, we might not be able to satisfy demand on a short-term basis. If we overestimate distributor or retailer demand for our products, we may end up with too much inventory, resulting in higher storage costs, increased trade spend and the risk of inventory spoilage. If we fail to manage our inventory to meet demand, we could damage our relationships with our distributors and retailers and could delay or lose sales opportunities, which would unfavorably impact our future sales and adversely affect our operating results. In addition, if the inventory of our products held by our distributors and retailers is too high, they will not place orders for additional products, which would also unfavorably impact our sales and adversely affect our operating results.

If we fail to maintain relationships with our independent contract manufacturers, our business could be harmed.

We do not manufacture SALT Tequila, Pulpoloco Sangria or TapouT performance drinks but instead outsource the manufacturing process to third-party bottlers and independent contract manufacturers (co-packers). We do not own the plants or the majority of the Medicare program. Budget pressures onequipment required to manufacture and package these state programs often resultbrands. Our ability to maintain effective relationships with contract manufacturers and other third parties for the production and delivery of our beverage products in pricinga particular geographic distribution area is important to the success of our operations within each distribution area. We may not be able to maintain our relationships with current contract manufacturers or establish satisfactory relationships with new or replacement contract manufacturers, whether in existing or new geographic distribution areas. The failure to establish and coverage changesmaintain effective relationships with contract manufacturers for a distribution area could increase our manufacturing costs and extended payment practicesthereby materially reduce gross profits from the sale of our products in that area. Poor relations with any of our contract manufacturers could adversely affect the amount and timing of product delivered to our distributors for resale, which would in turn adversely affect our revenues and financial condition. In addition, our agreements with our contract manufacturers are terminable at any time, and any such termination could disrupt our ability to deliver products to our customers.


The volatility of energy and increased regulations may have a detrimentalan adverse impact on our operations and/gross margin.

Over the past few years, volatility in the global oil markets has resulted in variable fuel prices, which many shipping companies have passed on to their customers by way of higher base pricing and increased fuel surcharges. If fuel prices increase, we expect to experience higher shipping rates and fuel surcharges, as well as energy surcharges on our raw materials. It is hard to predict what will happen in the fuel markets in 2024 and beyond. Due to the price sensitivity of our products, we may not always be able to pass such increases on to our customers.

Disruption within our supply chain, contract manufacturing or distribution channels could have an adverse effect on our business, financial performance. States sometimes have interposed intermediariescondition and results of operations.

Our ability, through our suppliers, business partners, contract manufacturers, independent distributors and retailers, to administer their Medicaid programs,make, move and sell products is critical to our success. Damage or have adopted alternative pricing methodologies for certain drugs, biologicals,disruption to our suppliers or to manufacturing or distribution capabilities due to weather, natural disaster, fire or explosion, terrorism, pandemics such as influenza COVID-19, labor strikes or other reasons, could impair the manufacture, distribution and home medical equipment under their Medicaid programs that reducesale of our products. Many of these events are outside of our control. Failure to take adequate steps to protect against or mitigate the levellikelihood or potential impact of reimbursement received by us without a corresponding offsetsuch events, or increase to compensate for the service costs incurred.  effectively manage such events if they occur, could adversely affect our business, financial condition and results of operations.

We periodically evaluate the possibility of stopping or reducingrely upon our Medicaid business in any stateongoing relationships with reimbursement or administrative policies that make it difficult for usour key flavor suppliers. If we are unable to safely care for patients or conduct operations profitably. Moreover, the Reform Package increases Medicaid enrollment over a number of years and imposes additional requirementssource our flavors on states which, combined with the current economic environment and state deficits,acceptable terms from our key suppliers, we could further strain state budgets and therefore result in additional policy changes or rate reductions. The President's most recent budget proposal, would limit the amount state Medicaid programs pay for DMEPOS to be no higher than Medicare payment levels, including those impacted by Medicare competitive bidding. We cannot currently predict the adverse impact, if any, that any such change to or reductionsuffer disruptions in our Medicaid business mightbusiness.

We currently purchase our flavor concentrate from various flavor concentrate suppliers, and continually develop other sources of flavor concentrate for each of our products. Generally, flavor suppliers hold the proprietary rights to their flavor-specific ingredients. Although we have the exclusive rights to flavor concentrates developed with our current flavor concentrate suppliers, and while we have the rights to the ingredients for our products, we do not have the list of ingredients for our flavor extracts and concentrates. Consequently, we may be unable to obtain these exact flavors or concentrates from alternative suppliers on short notice. If we have to replace a flavor supplier, we could experience disruptions in our operations, cash flow and capital resources, but such impactability to deliver products to our customers, which could be material. In addition, we cannot predict whether states will consider similar or other reimbursement reductions, whether or how healthcare reform provisions pertaining to Medicaid will ultimately be implemented or whether any such changes would have a material adverse effect on our results of operations.

If we are unable to attract and retain key personnel, our efficiency and operations cash flowwould be adversely affected; in addition, management turnover causes uncertainties and capital resources.


HIPAA. The Health Insurance Portabilitycould harm our business.

Our success depends on our ability to attract and Accountability Act of 1996 ("HIPAA") is comprised of a number of components pertainingretain highly qualified employees in such areas as finance, sales, marketing and product development. We compete to the privacyhire new employees, and, security of certain protected health information ("PHI"), as well as the standard formatting of certain electronic health transactions. Many states have similar, butin some cases, must train them and develop their skills and competencies. We may not identical, restrictions. Existingbe able to provide our employees with competitive salaries, and any new lawsour operating results could be adversely affected by increased costs due to increased competition for employees, higher employee turnover or regulations have a significant effect on the manner in which we handle healthcare related data and communicate with payors. Among other provisions, the HITECH Act of the American Recovery and Reinvestment Act of 2009 ("ARRA") includes additional requirements relatedincreased employee benefit costs.

Changes to the privacy and security of PHI, clarifies and increases penalties of HIPAA and provides State Attorneys General with HIPAA enforcement authority. We have adopted a number ofoperations, policies and procedures, which can often occur with the appointment of new personnel, can create uncertainty, may negatively impact our ability to conform to HIPAA requirements,execute quickly and effectively, and may ultimately be unsuccessful. In addition, management transition periods are often difficult as modified by the HITECH Actnew employees gain detailed knowledge of ARRA, throughout our operations, and friction can result from changes in strategy and management style. Management turnover inherently causes some loss of institutional knowledge, which can negatively affect strategy and execution.

Further, to the extent we have educatedexperience additional management turnover, our employees about theseoperations, financial condition and employee morale could be negatively impacted. In addition, competition for top management is high and it may take months to find a candidate that meets our requirements. If we are unable to attract and retain qualified management personnel, our business could suffer.

If we fail to protect our trademarks and trade secrets, we may be unable to successfully market our products and compete effectively.

We cannot, however, guarantee that we will not haverely on a HIPAA privacycombination of trademark and trade secrecy laws, confidentiality procedures and contractual provisions to protect our intellectual property rights. Failure to protect our intellectual property could harm our brand and our reputation, and adversely affect our ability to compete effectively. Further, enforcing or data security concerndefending our intellectual property rights, including our trademarks,


copyrights, licenses and trade secrets, could result in the future.expenditure of significant financial and managerial resources. We face potential administrative, civilregard our intellectual property, particularly our trademarks and possible criminal sanctions iftrade secrets to be of considerable value and importance to our business and our success, and we doactively pursue the registration of our trademarks in the United States and internationally. However, the steps taken by us to protect these proprietary rights may not comply with the existingbe adequate and may not prevent third parties from infringing or new lawsmisappropriating our trademarks, trade secrets or similar proprietary rights. In addition, other parties may seek to assert infringement claims against us, and regulations dealing with the privacy and securitywe may have to pursue litigation against other parties to assert our rights. Any such claim or litigation could be costly. In addition, any event that would jeopardize our proprietary rights or any claims of PHI. Imposition of any such sanctionsinfringement by third parties could have a material adverse effect on our operations.


Enforcementability to market or sell our brands, profitably exploit our products or recoup our associated research and development costs.

As part of Healthcare Fraudthe licensing strategy of our brands, we enter into licensing agreements under which we grant our licensing partners certain rights to use our trademarks and Abuse Laws. In recent years,other designs. Although our agreements require that the federal government has madeuse of our trademarks and designs is subject to our control and approval, any breach of these provisions, or any other action by any of our licensing partners that is harmful to our brands, goodwill and overall image, could have a policy decision to significantly increase and accelerate the financial resources allocated to enforcing the healthcare fraud and abuse laws. Moreover, Congress adopted a number of additional provisionsmaterial adverse impact on our business.

We may be required in the Reform Packagefuture to record a significant charge to earnings if our goodwill or intangible assets become impaired.

Under United States Generally Accepted Accounting Principles (“U.S. GAAP”), we are required to review our intangible assets for impairment at least annually or when events or changes in circumstances indicate the carrying value may not be recoverable. Factors that are designedmay be considered a change in circumstances indicating that the carrying value of our intangible assets may not be recoverable include, declining or slower than anticipated growth rates for certain of our existing products, a decline in stock price and market capitalization, and slower growth rates in our industry.

We may be required in the future to reduce healthcare fraudrecord a significant charge to earnings during the period in which we determine that our intangible assets have been impaired. Any such charge would adversely impact our results of operations. As of December 31, 2023, our intangible assets totaled approximately $4.71 million.

If we encounter product recalls or other product quality issues, our business may suffer.

Product quality issues, real or imagined, or allegations of product contamination, even when false or unfounded, could tarnish our image and abuse.could cause consumers to choose other products. In addition, private insurers and various state enforcement agencies have increased their levelbecause of scrutinychanging government regulations or implementation thereof, or allegations of healthcare claims in an effort to identify and prosecute fraudulent and abusive practices in the healthcare area. Fromproduct contamination, we may be required from time to time to recall products entirely or from specific markets. Product recalls could affect our profitability and could negatively affect brand image.

Our business is subject to many regulations and noncompliance is costly.

The production, marketing and sale of our beverages, including contents, labels, caps and containers, are subject to the rules and regulations of various federal, provincial, state and local health agencies. If a regulatory authority finds that a current or future product or production batch or “run” is not in compliance with any of these regulations, we may be fined, or production may be stopped, which would adversely affect our financial condition and results of operations. Similarly, any adverse publicity associated with any noncompliance may damage our reputation and our ability to successfully market our products. Furthermore, the rules and regulations are subject to change from time to time and while we closely monitor developments in this area, we cannot anticipate whether changes in these rules and regulations will impact our business adversely. Additional or revised regulatory requirements, whether labeling, environmental, tax or otherwise, could have a material adverse effect on our financial condition and results of investigationsoperations.

Significant additional labeling or warning requirements may inhibit sales of affected products.

Various jurisdictions may seek to adopt significant additional product labeling or warning requirements relating to the chemical content or perceived adverse health consequences of certain of our products. These types of requirements, if they become applicable to one or more of our products under current or future environmental or health laws or regulations, may inhibit sales of such products. In California, a law requires that a specific warning appear on any product that contains a component listed by the state as having been found to cause cancer or birth defects. This law recognizes no generally applicable quantitative thresholds below which a warning is not required. If a component found in one of our products is added to the list, or if the increasing sensitivity of detection methodology that may become available under this law and related regulations as they currently exist, or as they may be amended, results in the detection of an infinitesimal quantity of a listed substance in one of our beverages produced for sale in California, the resulting warning requirements or adverse publicity could affect our sales.


Litigation or legal could expose us to significant liabilities and damage our reputation.

We may become party to litigation claims and legal proceedings. Litigation involves significant risks, uncertainties and costs, including distraction of management attention away from our business operations. We evaluate litigation claims and legal proceedings to assess the likelihood of unfavorable outcomes and to estimate, if possible, the amount of potential losses. Based on these assessments and estimates, we establish reserves and disclose the relevant litigation claims or legal proceedings, as appropriate. These assessments and estimates are based on the information available to management at the time and involve a significant amount of management judgment. Actual outcomes or losses may differ materially from those envisioned by our current assessments and estimates. Our policies and procedures require strict compliance by our employees and agents with all U.S. and local laws and regulations applicable to our business operations, including those prohibiting improper payments to government officials. Nonetheless, our policies and procedures may not ensure full compliance by our employees and agents with all applicable legal requirements. Improper conduct by our employees or agents could damage our reputation or lead to litigation or legal proceedings that could result in civil or criminal penalties, including substantial monetary fines, as well as disgorgement of profits.

Additionally, there has been public attention directed at the beverage alcohol industry, which we believe is due to concern over problems related to harmful use of alcohol, including drinking and driving, underage drinking and health consequences from the misuse of alcohol. We could be exposed to lawsuits relating to product liability or marketing or sales practices with respect to our alcoholic products. Adverse developments in lawsuits concerning these types of matters or a party to additional litigation which alleges violationssignificant decline in the social acceptability of law. If any of those matters were successfully asserted against us, therebeverage alcohol products that may result from lawsuits could behave a material adverse effect on our business, liquidity, financial position,condition and results of operations.

We are subject to risks inherent in sales of products in international markets.

Our operations outside of the United States, contribute to our revenue and profitability, and we believe that developing and emerging markets could present future growth opportunities for us. However, there can be no assurance that existing or new products that we manufacture, distribute or sell will be accepted or be successful in any particular foreign market, due to local or global competition, product price, cultural differences, and consumer preferences or otherwise. There are many factors that could adversely affect demand for our products in foreign markets, including our inability to attract and maintain key distributors in these markets; volatility in the economic growth of certain of these markets; changes in economic, political or social conditions, the status and renegotiations of the North American Free Trade Agreement, imposition of new or increased labeling, product or production requirements, or other legal restrictions; restrictions on the import or export of our products or ingredients or substances used in our products; inflationary currency, devaluation or fluctuation; increased costs of doing business due to compliance with complex foreign and U.S. laws and regulations. If we are unable to effectively operate or manage the risks associated with operating in international markets, our business, financial condition or results of operations or prospects.


Anti-Kickback Statutes. Ascould be adversely affected.

Water scarcity and poor quality could negatively impact our costs and capacity.

Water is a providermain ingredient in substantially all of services underour products, is vital to the Medicare and Medicaid programs, we must comply with a provisionproduction of the federal Social Security Act, commonly knownagricultural ingredients on which our business relies and is needed in our manufacturing process. It also is critical to the prosperity of the communities we serve. Water is a limited resource in many parts of the world, facing unprecedented challenges from overexploitation, increasing demand for food and other consumer and industrial products whose manufacturing processes require water, increasing pollution and emerging awareness of potential contaminants, poor management, lack of physical or financial access to water, sociopolitical tensions due to lack of public infrastructure in certain areas of the world and the effects of climate change. As the demand for water continues to increase around the world, and as water becomes scarcer and the "federal anti-kickback statute." The federal anti-kickback statute prohibitsquality of available water deteriorates, we may incur higher costs or face capacity constraints and the offerpossibility of reputational damage, which could adversely affect our profitability or receiptnet operating revenues in the long run.


Fluctuations in quantity and quality of grape supply could adversely affect our business.

A shortage in the supply of quality grapes may result from a variety of factors that determine the quality and quantity of our grape supply, including weather conditions, pruning methods, diseases and pests, the ability to buy grapes on long and short-term contracts and the number of vines producing grapes. Any shortage in grape production could cause a reduction in the amount of wine we are able to produce, which could reduce sales and adversely impact our results from operations. Factors that reduce the quantity of our grapes may also reduce their quality, which in turn could reduce the quality or amount of wine we produce. Deterioration in the quality of our wines could harm our brand name, reduce sales and adversely impact our business and results of operations.

Contamination of our wines could harm our business.

We are subject to certain hazards and product liability risks, such as potential contamination, through tampering or otherwise, of ingredients or products. Contamination of any bribe, kickback,of our wines could force us to destroy wine held in inventory and could cause the need for a product recall, which could significantly damage our reputation for product quality. We maintain insurance against certain of these kinds of risks, and others, under various insurance policies. However, the insurance may not be adequate or rebate in return for the referralmay not continue to be available at a price or arranging for the referral of patients, products or services covered by federal healthcare programs. Federal healthcare programs have been definedon terms that are satisfactory to include plansus and programs that provide health benefits funded by the United States Government, including Medicare, Medicaid, and TRICARE (formerly known as the Civilian Health and Medical Program of the Uniformed Services or CHAMPUS), among others. Some courts and the OIG interpret the statutethis insurance may not be adequate to cover any arrangement where even one purposeresulting liability.

Our business and operations would be adversely impacted in the event of a failure or interruption of our information technology infrastructure or as a result of a cybersecurity attack.

The proper functioning of our own information technology (IT) infrastructure is critical to the efficient operation and management of our business. We may not have the necessary financial resources to update and maintain our IT infrastructure, and any failure or interruption of our IT system could adversely impact our operations. In addition, our IT is vulnerable to cyberattacks, computer viruses, worms and other malicious software programs, physical and electronic break-ins, sabotage and similar disruptions from unauthorized tampering with our computer systems. We believe that we have adopted appropriate measures to mitigate potential risks to our technology infrastructure and our operations from these IT-related and other potential disruptions. However, given the unpredictability of the remuneration is to influence referrals. Violationstiming, nature and scope of the federal anti-kickback statute may result in civil and criminal penalties and exclusion from participation in federal healthcare programs.



11



Some states have enacted statutes and regulations similar to the federal anti-kickback statute, but which apply not only to the federal healthcare programs, but also to any payor source of the patient. These state laws may contain exceptions and safe harbors that are different from those of the federal law and that may vary from state to state.   The states in whichsuch IT failures or disruptions, we operate have laws that prohibit fee-splitting arrangements between healthcare providers, if such arrangements are designed to induce or encourage the referral of patients to a particular provider.

Physician Self-Referral. Certain provisions of the Omnibus Budget Reconciliation Act of 1993 (the "Stark Law") prohibit healthcare providers such as us,could potentially be subject to certain exceptions,downtimes, transactional errors, processing inefficiencies, operational delays, other detrimental impacts on our operations or ability to provide products to our customers, the compromising of confidential or personal information, destruction or corruption of data, security breaches, other manipulation or improper use of our systems and networks, financial losses from submitting claims to the Medicare and Medicaid programs for designated health services if we have a financial relationship with the physician making the referral for such services or with a member of such physician's immediate family. The term "designated health services" includes several services commonly performed or supplied by us, including durable medical equipment and home health services. In addition, "financial relationship" is broadly defined to include any ownership or investment interest or compensation arrangement pursuant to which a physician receives remuneration from the provider at issue. The Stark Law prohibition applies regardless of the reasons for the financial relationship and the referral; and therefore, unlike the federal anti-kickback statute, an intent to violate the law is not required.

Violations of the Stark Law may result inremedial actions, loss of Medicare and Medicaid reimbursement, civil penalties, and exclusion from participation in the Medicare and Medicaid programs.

In addition, Ohio, Pennsylvania, and West Virginia have similar prohibitions against physician self-referrals, which may not necessarily be limited to Medicarebusiness or Medicaid services and may not include the same statutory and regulatory exceptions found in the Stark Law.

False Claims. The federal False Claims Act imposes civil and criminalpotential liability, on individuals or entities that submit false or fraudulent claims for payment to the government. Violations of the federal civil False Claims Act may result in treble damages, civil monetary penalties, and exclusion from the Medicare, Medicaid, and other federally funded healthcare programs. If certain criteria are satisfied, the federal civil False Claims Act allows a private individual to bring a qui tam suit on behalf of the government and, if the case is successful, to share in any recovery. Federal False Claims Act suits brought directly by the government or private individuals against healthcare providers, like us, are increasingly common and are expected to continue to increase.

The federal government has used the federal False Claims Act to prosecute a wide variety of alleged false claims and fraud allegedly perpetrated against Medicare and state healthcare programs. The government and a number of courts also have taken the position that claims presented in violation of certain other statutes, including the federal anti-kickback statute or the Stark Law, can be considered a violation of the federal False Claims Act, based on the theory that a provider impliedly certifies compliance with all applicable laws, regulations, and other rules when submitting claims for reimbursement.

On May 20, 2009, President Obama signed into law the Fraud Enforcement and Recovery Act of 2009 ("FERA"). Among other things, FERA modifies the federal False Claims Act by expanding liability to contractors and subcontractors who do not directly present claims to the federal government. FERA also expanded the False Claims Act liability for what is referred to as a "reverse false claim" by explicitly making it unlawful to knowingly conceal or knowingly and improperly avoid or decrease an obligation owed to the federal government.

Ohio and Pennsylvania have enacted false claims acts that are similar to the federal False Claims Act.  In addition, there is a corresponding increase in state-initiated false claims enforcement efforts.


12



Other Fraud and Abuse Laws. HIPAA created, in part, two new federal crimes: "Healthcare Fraud" and "False Statements Relating to Healthcare Matters." The Healthcare Fraud statute prohibits executing a knowing and willful scheme or artifice to defraud any healthcare benefit program.  A violation of this statute is a felony and may result in fines and/or imprisonment. The False Statements statute prohibits knowingly and willfully falsifying, concealing, or covering up a material fact by any trick, scheme, or device or making any materially false, fictitious, or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items, or services. A violation of this statute is a felony and may result in fines and/or imprisonment.

The increased public focus on waste, fraud, and abuse, and their related cost to society will likely result in additional Congressional hearings, CMS regulatory changes, and/or new laws. The Reform Package also provides for new regulatory authority, and additional fines and penalties. More recently, additional legislation has been proposed in the U.S. Senate which would further expand the government's oversight of the healthcare industry via new regulatory authority. In addition, a Senate bill released in June 2011 (S. 1251) would require pre-payment review of all claims for durable medical equipment that are at high risk for fraud and abuse. At this time, we cannot predict whether these or other reforms will ultimately become law, or the impact of such reforms on our business operations and financial performance.

Facility Licensure.  We only have one facility and it is located in Canfield, Ohio.  We are regulated by and licensed with the Ohio Respiratory Care Board, and we also have a home medical equipment vendor's license from the State of Ohio.  We are committed to complying with all applicable licensing requirements.

Healthcare Reform. Economic, political, and regulatory influences are causing fundamental changes in the healthcare industry in the United States. Various healthcare reform proposals are formulated and proposed by the legislative and administrative branches of the federal government on a regular basis.  In addition, Ohio and Pennsylvania periodically consider various healthcare reform proposals. Even with the passage of the Reform Package, we anticipate that federal and state governments will continue to review and assess alternative healthcare delivery systems and payment methodologies and public debate of these issues will continue in the future.

The elections since the passage of the Reform Package changed the composition of Congress and affected certain priorities related to healthcare. Congress is debating the potential to repeal or amend the Reform Package altogether. A number of other parties, including some State governments, are challenging the Reform Package, and we cannot predict the outcome of such challenges. Changes in the law or new interpretations of existing laws can have a substantial effect on permissible activities, the relative costs associated with doing business in the healthcare industry and the amount of reimbursement by governmental and other third-party payors. Also, the government has begun to promulgate the implementing rules and regulations of the Reform Package, including additional requirements relateddamage to our business and that of our customers. Until those rules are more clearly understood, and due to uncertainties regarding the ultimate features of additional reform initiatives and their enactment and implementation over the next few years, we cannot predict which, ifreputation, any of such reform proposals will be adopted, or when they may be adopted, or that any such reforms will notwhich could have a material adverse effect on our cash flows, competitive position, financial condition or results of operations.

If we fail to comply with personal data protection and privacy laws, we could be subject to adverse publicity, government enforcement actions and/or private litigation, which could negatively affect our business and operating results.

In the ordinary course of our business, we receive, process, transmit and store information relating to identifiable individuals (“personal data”), primarily employees, former employees and consumers with whom we interact. As a result, we are subject to various U.S. federal and state and foreign laws and regulations relating to personal data. These laws have been subject to frequent changes, and new legislation in this area may be enacted in other jurisdictions at any time. These laws impose operational requirements for companies receiving or processing personal data, and many provide for significant penalties for noncompliance. These requirements with respect to personal data have subjected and may continue in the future to subject the Company to, among other things, additional costs and expenses and have required and may in the future require costly changes to our business practices and information security systems, policies, procedures and practices. Our security controls over personal data, the training of employees and vendors on data privacy and data security, and the policies, procedures and practices we implemented or may implement in the future may not prevent the improper disclosure of personal data by us or the third-party service providers and vendors whose technology, systems and services we use in connection with the receipt, storage and transmission of personal data. Unauthorized access or improper disclosure of personal data in violation of personal data protection or privacy laws could harm our reputation, cause loss of consumer confidence, subject us to regulatory enforcement actions (including fines), and result in private litigation against us, which could result in loss of revenue, increased costs, liability for monetary damages, fines and/or criminal prosecution, all of which could negatively affect our business and operating results.


If our third-party service providers and business partners do not satisfactorily fulfill their commitments and responsibilities, our financial results could suffer.

In the conduct of our business, we rely on relationships with third parties, including cloud data storage and other information technology service providers, suppliers, distributors, contractors, joint venture partners and other external business partners, for certain functions or for services in support of key portions of our operations. These third-party service providers and business partners are subject to similar risks as we are relating to cybersecurity, privacy violations, business interruption, and systems and employee failures, and are subject to legal, regulatory and market risks of their own. Our third-party service providers and business partners may not fulfill their respective commitments and responsibilities in a timely manner and in accordance with the agreed-upon terms. In addition, while we have procedures in place for selecting and managing our relationships with third-party service providers and other business partners, we do not have control over their business operations or governance and compliance systems, practices and procedures, which increases our financial, legal, reputational and operational risk. If we are unable to effectively manage our third-party relationships, or for any reason our third-party service providers or business partners fail to satisfactorily fulfill their commitments and responsibilities, our financial results could suffer.

Our results of operations cash flow, capitalmay fluctuate from quarter to quarter for many reasons, including seasonality.

Our sales are seasonal, and we experience fluctuations in quarterly results as a result of many factors. Companies similar to ours have historically generated a greater percentage of our revenues during the warm weather months of April through September. Timing of customer purchases will vary each year and sales can be expected to shift from one quarter to another. As a result, management believes that period-to-period comparisons of results of operations are not necessarily meaningful and should not be relied upon as any indication of future performance or results expected for the fiscal year.

Changes in accounting standards and subjective assumptions, estimates and judgments by management related to complex accounting matters could significantly affect our financial results.

The U.S. GAAP and related pronouncements, implementation guidelines and interpretations with regard to a wide variety of matters that are relevant to our business, such as, but not limited to, stock-based compensation, trade spend and promotions, and income taxes are highly complex and involve many subjective assumptions, estimates and judgments by our management. Changes to these rules or their interpretation or changes in underlying assumptions, estimates or judgments by our management could significantly change our reported results.

If we are unable to maintain effective disclosure controls and procedures and internal control over financial reporting, our stock price and investor confidence could be materially and adversely affected.

We are required to maintain both disclosure controls and procedures and internal control over financial reporting that are effective. Because of their inherent limitations, internal control over financial reporting, however well designed and operated, can only provide reasonable, and not absolute, assurance that the controls will prevent or detect misstatements. Because of these and other inherent limitations of control systems, there is only the reasonable assurance that our controls will succeed in achieving their goals under all potential future conditions. The failure of controls by design deficiencies or absence of adequate controls could result in a material adverse effect on our business and financial results, which could also negatively impact our stock price and investor confidence.

We are dependent on a distiller in Mexico to provide us with our finished SALT tequila product. Failure to obtain satisfactory performance from them or a loss of their services could cause us to lose sales, incur additional costs, and lose credibility in the marketplace.

We depend on a distiller in Mexico, a company in Jalisco, for the production, bottling, labeling, capping and packaging of our finished tequila product. We do not have a written agreement with our distiller in Mexico obligating it to produce our product. The termination of our relationship with our distiller in Mexico distiller or an adverse change in the terms of its services could have a negative impact on our business. If our distiller in Mexico increases its prices, we may not have alternative sources of supply at comparable prices and may not be able to raise the prices of our products to cover all, or even a portion, of the increased costs. In addition, if our distiller in Mexico fails to perform satisfactorily, fails to handle increased orders, or the loss of the services of our distiller in Mexico, along with delays in shipments of products, could cause us to fail to meet orders, lose sales, incur additional costs, and/or expose us to product quality issues. In turn, this could cause us to lose credibility in the marketplace and damage our relationships with our customers and consumers, ultimately leading to a decline in our business and results of operations.


Regulatory decisions and changes in the legal, regulatory and tax environment where our tequila is produced and where we operate could limit our business activities or increase our operating costs and reduce our margins.

Our business is subject to extensive regulation regarding production, distribution, marketing, advertising and labeling of beverage alcohol products in the U.S. and in Mexico, where our tequila is produced. We are required to comply with these regulations and maintain various permits and licenses. We are also required to conduct business only with holders of licenses to import, warehouse, transport, distribute, and sell spirits. We cannot assure you that these and other governmental regulations, applicable to our industry, will not change or become more stringent. Moreover, because these laws and regulations are subject to interpretation, we may not be able to predict when, and to what extent, liability may arise. Additionally, due to increasing public concern over alcohol-related societal problems, including driving while intoxicated, underage drinking, alcoholism and health consequences from the abuse of alcohol, various levels of government may seek to impose additional restrictions or limits on advertising or other marketing activities promoting beverage alcohol products. Failure to comply with any of the current or future regulations and requirements relating to our industry and products, could result in monetary penalties, suspension or even revocation of our licenses and permits. Costs of compliance with changes in regulations could be significant and could harm our business, as we may find it necessary to raise our prices in order to maintain profit margins, which could lower the demand for our products and reduce our sales and profit potential.

In addition, the distribution of beverage alcohol products is subject to extensive taxation both in the United States and internationally (and, in the United States, at both the federal and state government levels), and beverage alcohol products themselves are the subject of national import and excise duties in most countries around the world. An increase in taxation or in import or excise duties could also significantly harm our sales revenue and margins, both through the reduction of overall consumption and by encouraging consumers to switch to lower-taxed categories of beverage alcohol.

We face substantial competition in the alcoholic and non-alcoholic beverage industry, and we may not be able to effectively compete.

Consolidation among spirits producers, distributors, wholesalers, or retailers could create a more challenging competitive landscape for our products. Consolidation at any level could hinder the distribution and sale of our products as a result of reduced attention and resources allocated to our brands, both during and liquidity.

after transition periods, because our brands might represent a smaller portion of the new business portfolio. Expansion into new product categories by other suppliers, or innovation by new entrants into the market, could increase competition in our product categories. Changes to our route-to-consumer models or partners in important markets could result in temporary or longer-term sales disruption, higher implementation-related or fixed costs, and could negatively affect other business relationships we might have with that partner. Distribution network disruption or fluctuations in our product inventory levels with distributors, wholesalers, or retailers could negatively affect our results for a particular period.

Our competitors may respond to industry and economic conditions more rapidly or effectively than we do. Our competitors offer products that compete directly with ours for shelf space, promotional displays, and consumer purchases. Pricing, (including price promotions, discounting, couponing, and free goods), marketing, new product introductions, entry into our distribution networks, and other competitive behavior by our competitors could adversely affect our sales margins, and profitability.

Our business operations may be adversely affected by social, political and economic conditions affecting market risks and the demand for and pricing of our products. These risks include:

Unfavorable economic conditions and related low consumer confidence, high unemployment, weak credit or capital markets, sovereign debt defaults, sequestrations, austerity measures, higher interest rates, political instability, higher inflation, deflation, lower returns on pension assets, or lower discount rates for pension obligations;

Changes in laws, regulations, or policies – especially those that affect the production, importation, marketing, sale, or consumption of our beverage alcohol products;


Employees
Tax rate changes (including excise, sales, tariffs, duties, corporate, individual income, dividends, capital gains), or changes in related reserves, changes in tax rules or accounting standards, and the unpredictability and suddenness with which they can occur;

Dependence upon the continued growth of brand names;

Changes in consumer preferences, consumption, or purchase patterns – particularly away from tequila, and our ability to anticipate and react to them; bar, restaurant, travel, or other on-premise declines;

Unfavorable consumer reaction to our products, package changes, product reformulations, or other product innovation;

Decline in the social acceptability of beverage alcohol products in our markets;

Production facility or supply chain disruption;

Imprecision in supply/demand forecasting;

Higher costs, lower quality, or unavailability of energy, input materials, labor, or finished goods;

Route-to-consumer changes that affect the timing of our sales, temporarily disrupt the marketing or sale of our products, or result in higher implementation related or fixed costs;

Inventory fluctuations in our products by distributors, wholesalers, or retailers; Competitors’ consolidation or other competitive activities, such as pricing actions (including price reductions, promotions, discounting, couponing, or free goods), marketing, category expansion, product introductions, or entry or expansion in our geographic markets;

Insufficient protection of our intellectual property rights;

Product recalls or other product liability claims; product counterfeiting, tampering, or product quality issues;

Significant legal disputes and proceedings; government investigations (particularly of industry or company business, trade or marketing practices);

Failure or breach of key information technology systems;

Negative publicity related to our company, brands, marketing, personnel, operations, business performance or prospects; and

Business disruption, decline, or costs related to organizational changes, reductions in workforce, or other cost-cutting measures, or our failure to attract or retain key executive or employee talent.

Uncertainty in the financial markets and other adverse changes in general economic or political conditions in any of the major countries in which we do business could adversely affect our industry, business and results of operations.

Global economic uncertainties, including foreign currency exchange rates, affect businesses such as ours in a number of ways, making it difficult to accurately forecast and plan our future business activities. There can be no assurance that economic improvements will occur, or that they would be sustainable, or that they would enhance conditions in markets relevant to us.


Our limited operating history makes it difficult to forecast our future results, making any investment in us highly speculative.

We have a limited operating history, and our historical financial and operating information is of limited value in predicting our future operating results. We may not accurately forecast customer behavior and recognize or respond to emerging trends, changing preferences or competitive factors facing us, and, therefore, we may fail to make accurate financial forecasts. Our current and future expense levels are based largely on our investment plans and estimates of future revenue. As a result, we may be unable to adjust our spending in a timely manner to compensate for any unexpected revenue shortfall, which could then force us to curtail or cease our business operations.

Risks Related to Our Securities

An investment in our common stock is speculative and there can be no assurance of any return on any such investment.

An investment in our common stock is speculative and there is no assurance that investors will obtain any return on their investment. Investors will be subject to substantial risks involved in an investment in the Company, including the risk of losing their entire investment.

Future sales of common stock, or the perception of such future sales, by some of our existing stockholders could cause our stock price to decline.

The market price of our common stock could decline as a result of sales of a large number of shares of our common stock in the market or the perception that these sales may occur. These sales, or the possibility that these sales may occur, also might make it more difficult for us to sell shares in the future at a time and at a price that we deem appropriate.

From time to time, certain of our stockholders may be eligible to sell all or some of their common shares by means of ordinary brokerage transactions in the open market pursuant to Rule 144 promulgated under the Securities Act of 1933, as amended (the “Securities Act”), subject to certain limitations. In general, pursuant to Rule 144, non-affiliate stockholders may sell freely after six months subject only to the current public information requirement. Affiliates may sell after six months subject to the Rule 144 volume, manner of sale (for equity securities), and current public information and notice requirements.

Our Board of Directors may issue and fix the terms of shares of our Preferred Stock without stockholder approval, which could adversely affect the voting power of holders of our Common Stock or any change in control of our Company.

Our Articles of Incorporation authorize the issuance of up to 5,000,000 shares of “blank check” preferred stock, with par value $0.001 per share, with such designation rights and preferences as may be determined from time to time by the Board of Directors. Our Board of Directors is empowered, without shareholder approval, to issue shares of preferred stock with dividend, liquidation, conversion, voting or other rights which could adversely affect the voting power or other rights of the holders of our common stock. In the event of such issuances, the preferred stock could be used, under certain circumstances, as a method of discouraging, delaying or preventing a change in control of our company. Any such issuance would be subject to terms and conditions of any current offering that may disallow any such issuance.

Because certain principal stockholders own a large percentage of our voting stock, other stockholders’ voting power may be limited.

As of December 31, 2016, we had eight full-time and two part-time employees.  None2023, our ten (10) largest shareholders own or controlled approximately 21.2% of our employees were represented byoutstanding common stock. If those stockholders act together, they would have the ability to have a labor unionsubstantial influence on matters submitted to our stockholders for approval, including the election and removal of directors and the approval of any merger, consolidation or sale of all or substantially all of our assets. As a result, our other stockholders may have little or no influence over matters submitted for shareholder approval. In addition, the ownership of such stockholders could preclude any unsolicited acquisition of us, and consequently, adversely affect the price of our common stock. These stockholders may make decisions that are adverse to your interests.


We do not expect to pay dividends and investors should not buy our Common Stock expecting to receive dividends.

We do not anticipate that we will declare or pay any dividends in the foreseeable future. Consequently, you will only realize an economic gain on your investment in our common stock if the price appreciates. You should not purchase our common stock expecting to receive cash dividends. Therefore, our failure to pay dividends may cause you to not see any return on your investment even if we are successful in our business operations.

There can be no assurances that our common stock will not be subject to potential delisting if we do not continue to maintain the listing requirements of the NYSE American.

Since June 11, 2021, our common stock has been listed on the NYSE American, under the symbol “SBEV”. The NYSE American has rules for continued listing, including, without limitation, minimum market capitalization and other requirements. Failure to maintain our listing (i.e., being de-listed from the NYSE American), would make it more difficult for shareholders to sell our common stock and more difficult to obtain accurate price quotations on our common stock. This could have an adverse effect on the price of our common stock. Our ability to issue additional securities for financing or other labor organization.



13



Item 1A.   Risk Factors.

Aspurposes, or otherwise to arrange for any financing we may need in the future, may also be materially and adversely affected if our common stock is not traded on a smaller reportingnational securities exchange.

On October 6, 2023, the NYSE American notified the Company that we were not in compliance with Section 1003(a)(i) of the continued listing standards set forth in the NYSE American Company Guide (the “Company Guide”), requiring a listed company to have stockholders’ equity of (i) at least $2.0 million if it has reported losses from continuing operations or net losses in two of its three most recent fiscal years. The notice had no immediate impact on the listing of our common stock, subject to our compliance with the other continued listing requirements. In accordance with applicable NYSE American procedures, we submitted a plan of compliance (the “Plan”) advising of the definitive action(s) the Company has taken, is taking, or would take, that would bring us into compliance with the continued listing standards within the 18 months of receipt of the notice. The NYSE American reviewed and accepted the Plan as a reasonable demonstration of an ability to conform to the relevant standards in the 18-month period. On December 20, 2023, we received a notification (the “Plan Letter”), with NYSE American acceptance of the proposed plan and further deficiency notice. In the Plan Letter the NYSE American indicated that in addition to Section 1003(a)(i), the Company was also not in compliance with Section 1003(a)(ii) of the Company Guide, requiring a listed company to have stockholders’ equity of at least $4.0 million if it has reported losses from continuing operations or net losses in three of its four most recent fiscal years.

Our common stock will continue to be listed and traded on the NYSE American during the 18-month period, subject to the Company’s compliance with the other continued listing standards of the NYSE American and continued periodic review by the NYSE American of the Company’s progress with respect to its Plan. There can be no assurance that the Company will be able to meet its goals set forth in the Plan. If we are unable to satisfy the NYSE American rules and listing standards, or are unable to make progress on our Plan, our securities could be subject to delisting.

If the NYSE American were to delist our securities from trading, we could face significant consequences, including, but not requiredlimited to, provide the information required by this item.

following:

a limited availability for market quotations for our securities;

reduced liquidity with respect to our securities;

a determination that our common stock is a “penny stock,” which will require brokers trading in our common stock to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading market for our common stock;

limited amount of news and analyst coverage; and

a decreased ability to issue additional securities or obtain additional financing in the future.


Our common stock could be further diluted as the result of the issuance of additional common stock, convertible securities, warrants or options.

Our issuance of additional common stock, convertible securities, options and warrants could affect the rights of our stockholders, result in a reduction in the overall percentage holdings of our stockholders, could put downward pressure on the market price of our common stock, could result in adjustments to conversion and exercise prices of outstanding notes and warrants, and could obligate us to issue additional common stock to certain of our stockholders.

Item 1B. Unresolved Staff Comments.


None.

Item 1C. Cybersecurity

We have established policies and processes for assessing, identifying, and managing material risk from cybersecurity threats, and have integrated these processes into our overall risk management systems and processes. We routinely assess material risks from cybersecurity threats, including any potential unauthorized occurrence on or conducted through our information systems that may result in adverse effects on the confidentiality, integrity, or availability of our information systems or any information residing therein.

We conduct periodic risk assessments to identify cybersecurity threats, as well as assessments in the event of a material change in our business practices that may affect information systems that are vulnerable to such cybersecurity threats. These risk assessments include identification of reasonably foreseeable internal and external risks, the likelihood and potential damage that could result from such risks, and the sufficiency of existing policies, procedures, systems, and safeguards in place to manage such risks.

Following these risk assessments, we re-design, implement, and maintain reasonable safeguards to minimize identified risks; reasonably address any identified gaps in existing safeguards; and regularly monitor the effectiveness of our safeguards. Primary responsibility for assessing, monitoring and managing our cybersecurity risks rests with the President who reports to our Chief Executive Officer, to manage the risk assessment and mitigation process.

We engage consultants, or other third parties in connection with our risk assessment processes. These service providers assist us to design and implement our cybersecurity policies and procedures, as well as to monitor and test our safeguards. We require each third-party service provider to certify that it has the ability to implement and maintain appropriate security measures, consistent with all applicable laws, to implement and maintain reasonable security measures in connection with their work with us, and to promptly report any suspected breach of its security measures that may affect our company.

We have not encountered cybersecurity challenges that have materially impaired our operations or financial standing.

Governance

Our board of directors addresses the Company’s cybersecurity risk management as part of its general oversight function. The board of directors’ audit committee is responsible for overseeing Company’s cybersecurity risk management processes, including oversight and mitigation of risks from cybersecurity threats.

Our cybersecurity risk assessment and management processes are implemented and maintained by certain Company management, including the information technology team at the direction of our President. Our executive team including our Chief Executive Officer, and Chief Financial Officer are responsible for hiring appropriate personnel, helping to integrate cybersecurity risk considerations into the Company’s overall risk management strategy, and communicating key priorities to relevant personnel. This executive team is responsible for approving budgets, helping prepare for cybersecurity incidents, approving cybersecurity processes, and reviewing security assessments and other security-related reports.


None.

Our cybersecurity incident response and vulnerability management policies are designed to escalate certain cybersecurity incidents to members of management depending on the circumstances, including our Chief Executive Officer, and Chief Financial Officer. In addition, the Company’s incident response and vulnerability management policies include reporting to the audit committee of the board of directors for certain cybersecurity incidents including significant breaches to the Company’s networks or systems. The audit committee receives regular reports from the information technology team concerning the Company’s significant cybersecurity threats and risk and the processes the Company has implemented to address them. The audit committee also has access to various reports, summaries or presentations related to cybersecurity threats, risk and mitigation.

Item 2. Properties.


Our

Splash’s physical offices are located at 4120 Boardman-Canfield Road, Canfield, Ohio 44406.  We rent1500 Cordova Rd; Fort Lauderdale, FL 33316 and 1491 2nd Street, Sarasota FL 34236 while our offices pursuant to a three-year lease extension which expires in June 2017.  Our monthly rentbusiness office is approximately $2,700, plus costs.


located at 1314 East Las Olas Blvd, Suite 221, Fort Lauderdale, FL 33301. Copa’s office/manufacturing facility is located at 901 E. 2nd Street; The Dalles, OR 97058. Currently, the Company does not own any real property.

Item 3. Legal Proceedings.


No

We are not currently a party to any pending legal proceedings are currently pendingthat we believe will have a material adverse effect on our business or threatenedfinancial conditions. We may, however, be subject to various claims and legal actions arising in the bestordinary course of our knowledge.


business from time to time.

Item 4. Mine Safety Disclosures.


Not applicable.



14



PART II


Item 5. Market for Registrant'sRegistrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.


Price Ranges of

 The Company’s Common Stock


Our stock has not yet commenced trading.

and tradeable warrants are publicly traded on the NYSE American under the symbol “SBEV” and “SBEV WS”.

Aggregate Number of Holders of Common Stock


The number

As of March 29, 2024, there were 45,129,687 shares of Common Stock issued and outstanding. As of March 29, 2024, at our transfer agent owners totaled approximately 273 holders of record holders of our common stock on March 21, 2017 was approximately 120.


Common Stock.

Dividends


Holders of our common stock are entitled to receive dividends as may be declared from time to time by our Board of Directors.

We have not paiddeclared any cash dividends on our common stock since inception and do not anticipate paying anysuch dividends in the foreseeable future. Management's current policy isWe plan to retain any future earnings if any, for use in our operationsbusiness operations. Any decisions as to future payment of cash dividends will depend on our earnings and for expansionfinancial position and such other factors as the Board of the business.


Directors deems relevant.

Securities Authorized for Issuance under Equity Compensation Plans


None.


Equity Compensation Plan Information


We do not have any

The information required by this item with respect to securities authorized for issuance under equity compensation plans oris set forth in Part III, Item 12 of this Annual Report on Form 10-K, and is incorporated herein by reference.


Purchases of Equity Securities by the Issuer.

There were no repurchases of our common stock option plans.


Recent Salesduring the year ended December 31, 2023.

Use of Unregistered Securities


DuringProceeds

On June 7, 2021, our Registration Statement, as amended, and originally filed on Form S-1 (File No. 333-255091) was declared effective by the last three monthsSEC for our initial public offering of 20167,500,000 units, including 3,750,000 additional shares of common stock and the first month3,750,000 warrants to purchase shares of 2017, we sold a total of 750,000 shares to one accredited investor, who was alreadycommon stock, each at an existing shareholder, at aoffering price of $.10$4.00 per share, for $75,000.  We reliedaggregate gross proceeds of approximately $15.0 million. After deducting underwriting discounts and commissions and other estimated offering expenses incurred by us of approximately $1.2 million, the net proceeds from the offering were approximately $13.8 million. Kingswood Capital Markets, a division of Benchmark Investments, LLC acted as sole book-running manager and the representative of the underwriters of the underwritten public offering. No offering costs were paid or are payable, directly, or indirectly, to our directors or officers, to persons owning 10% or more of any class of our equity securities, or to any of our affiliates. Our common stock and warrants are traded on Nasdaq under the exemption provided by Rule 506 under Regulation D.


symbols “SBEV” and “SBEV WS”, respectively.

There has been no material change in the expected use of the net proceeds from our underwritten public offering as described in our final prospectus filed with the SEC on June 14, 2021. Upon receipt, the net proceeds from our underwritten public offering were held in cash and cash equivalents. As of December 31, 2023, we have used approximately all of the net proceeds from the underwritten public offering, primarily on working capital and general corporate purposes.

Item 6. Selected Financial Data.


This item is not required for Smaller Reporting Companies.


{Reserved}

Item 7. Management'sManagement’s Discussion and Analysis of Financial Condition and Results of Operations.


The following discussion and analysis should be read in conjunction with the Audited Consolidated Financial Statements and Notes to Audited Consolidated Financial Statements filed herein.


15



Business Overview

We provide servicesherewith. This Management’s Discussion and Analysis of Financial Condition and Results of Operations contains statements that are forward-looking. These statements are based on current expectations and assumptions that are subject to the rehabilitation market, which consists primarily of home medical equipment and supplies.  More than 50% of our revenues are derived from the sale and rental of durable home medical equipment including such items as wheeled walkers, manual and power wheelchairs, hospital beds, ramps, bedside commodes, and miscellaneous bathroom equipment.  The balance of our revenue is from the sale of various home medical supplies including diabetic testing, incontinence, ostomy, wound care, and catheter care.  Our emphasis is on helping patients with mobility related limitations, but our overall business is aimed at helping patients remain in their homes instead of having to go to hospitals, rehab centers,risk, uncertainties, and other factors. These statements are often identified by the use of words such as “may,” “will,” “expect,” “believe,” “anticipate,” “intend,” “could,” “estimate,” or “continue,” and similar facilities.  Mostexpressions or variations. Actual results could differ materially because of the equipmentfactors discussed in “Risk Factors” elsewhere in this Annual Report, and suppliesother factors that we sell are prescribedmay not know.

Business Overview

Canfield Medical Supply, Inc. (“CMS”) a company’s whose common stock was quoted on the OTCQB entered into an Agreement and Plan of Merger with SBG Acquisition Inc. (“Merger Sub”), a Nevada Corporation wholly-owned by Canfield, and Splash Beverage Group, II Inc.. a Nevada corporation (“Splash”) pursuant to which Merger Sub merged with and into Splash (the “Merger”) with Splash as the surviving company and a wholly-owned subsidiary of Canfield. The Merger was consummated on March 31, 2020.

As the owners and management of Splash had voting and operating control of CMS following the Merger, the Merger transaction was accounted for as a reverse acquisition (that is with Splash as the acquiring entity), followed by a physician asrecapitalization.

On July 31, 2020, CMS changed its name to Splash Beverage Group, Inc. (“SBG”). On June 11, 2021, SBG’s common stock and warrant to purchase common stock began trading on the NYSE American under the symbols “SBEV” and SBEV WT,” respectively.

On November 8, 2021, SBG reincorporated into the State of Nevada and became a Nevada corporation.

Our principal offices are located at 1314 E. Las Olas Blvd, Suite 221, Fort Lauderdale, Florida 33301. Our website address is www.splashbeveragegroup.com. We have not incorporated by reference into this Annual Report on Form 10-K the information that can be assessed through our website and you should not consider it to be part of an overall care plan.

this Annual Report on Form 10-K.


Results of OperationOperations for the year endedYear Ended December 31, 2016 as2023, compared to the year endedYear Ended December 31, 2015


2022.

Revenue

Revenues for the year ended December 31, 20162023 were $1,102,291 as$18.9 million compared to the revenues of $897,341$18.1 million for the year ended December 31, 2015.2022. The 23% increase in sales is primarilywas mainly due to winning the Medicare competitive bidding for wheel chairs and a few other itemsan increase in our local market as well as a shiftE-commerce segment of $0.4 million and an increase in customer focus away from Medicare and Medicaid towards private pay/private insurance customers due to continually decreasing Medicare and Medicaid reimbursement rates.


our Splash Beverage Group segment of $0.3 million.

Cost of Goods Sold

Cost of goods sold for the year ended December 31, 20162023 were $484,908 as$13.3 million compared to costscost of goods sold for the year ended December 31, 20152022 of $426,980.$12.2 million. The 14%$1.1 million increase in the latest yearcost of goods sold was due to the increase in theour increased sales volume, combined with the fact that Medicare has reduced the amount it is paying the Company for its products.


and inflation.

Operating Expenses

Operating expenses for the year ended December 31, 20162023 were $577,384 as$20.9 million compared to $451,462$27.3 million for the year ended December 31, 2015.2022. Non cash-operating expenses related to share issuance was $1.2 million as of December 31, 2023 compared to $7.4 million in December 31, 2022. The 28% increase in the latest one year periodremaining operating expense decrease of $0.2 million was primarily due to a $53,096decreases in sales and marketing expense and other general and administrative expenses of $1.0 million, which were offset by an increase of $0.8 million in salariessalary and wages resulting from the hiring of a sales representative, and a $47,628 increase in professional fees resulting from the completion of our 2014 and 2015 audits and 10K and 10Q filings, as well as our 2016 10Q filings, to bring our filings current with the SEC.


The net losswages.

Other Income/(Expense)

Other expense for the year ended December 31, 2016 was $48,846 as2023 were $5.7 million compared to a net income of $19,153$0.2 million for the year ended December 31, 2015.2022. The primary reasons for the change from a profitother expense increase of $19,153 in 2015 to a $48,846 loss in 2016 were the$5.5 million is mainly driven by an increase in salariesamortization of debt discount of $3.8 million and wages and thea $1.9 million increase in professional fees as explained above.




16



interest expense.

LIQUIDITY AND CAPITAL RESOURCES

Liquidity is the ability of a company to generate funds to support its current and Capital Resources


future operations, satisfy its obligations, and otherwise operate on an ongoing basis. Significant factors in the management of liquidity are funds generated by operations, levels of accounts receivable and accounts payable and capital expenditures. In addition, the Company has an active registration statement on Form S-3 to facilitate raising additional funds.

As of December 31, 2016,2023, we had working capitaltotal cash of $2,784$379,978, as compared to negative working capital of $(24,069) as ofwith $4,431,745 at December 31, 2015.


2022. The decrease was primarily due to expenses relating to operating the business.

Net cash provided byused for continuing operating activities during the year ended December 31, 20162023, was $32,113$10.2 million as compared to the net cash providedused by continuing operating activities infor the year ended December 31, 20152022, of $13,075.$14.0 million. The primary reason for the improvementchange in net cash used was thedue to an increase of $57,022$3.8 million in gross profit due primarily to $114,950amortization of debt and a decrease of $0.6 million in increased revenues, which was only partiallylosses of the business, offset by a decrease of $16.5 million in working capital. Net cash used for discontinued operating activities during the increased salaries and professional fees.  Although we experienced a $25,997 increase in depreciation in 2016 overyear ended December 31, 2023, was $0 as compared to $0.03 million for the 2015 period, this is non-cash operating expense and thus does not affect cash flows from operations..


year ended December 31, 2022.

Net cash used for investing activities during the year ended December 31, 20162023, was $52,076 which represented $58,424 used for the purchase of equipment which was offset by $6,348 received from the sale of equipment$0.01 as compared to $26,880the net cash used for the purchase of equipment and $6,295 received from the sale of equipmentinvesting activities during the year ended December 31, 2015.


2022, of $0.1 million. The net cash used in the year 2023 was for a capital expenditure for building improvements.

Net cash provided by (used for) financing activities during the year ended December 31, 20162023, was $74,279 as$6.1 million compared to $10,055 used for$14.4 million provided from financing activities infor the year ended December 31, 2015.  The Company sold shares of its common stock during2022. During the year ended December 31, 20162023, we received $0 from the issuance of common stock compared to $11.4 million during the year ending December 31, 2022. We received $6.6 million and $4.0 million proceeds from the issuance of debt in years ending December 31, 2023 and 2022, respectively. In the year ending December 31, 2023, $0.2 million was received from a shareholder advance and a $0.4 million shareholder advance was repaid in the year ending December 31, 2022. Principal repayment of debt of $1.0 million and $0.6 million were made in years ending December 31, 2023 and 2022 respectively. In the year ending December 31, 2023 a cash advance from related party of $0.4 million was received.


In order to have sufficient cash to fund our operations, we will need to raise $90,000additional equity or debt capital. There can be no assurance that additional funds will be available when needed from any source or, if available, will be available on terms that are acceptable to help payus. We will be required to pursue sources of additional capital through various means, including debt or equity financings. Future financings through equity investments are likely to be dilutive to existing stockholders. Also, the terms of securities we may issue in future capital transactions may be more favorable for new investors. Newly issued securities may include preferences, superior voting rights, the issuance of warrants or other derivative securities, and the issuance of incentive awards under equity employee incentive plans, which may have additional dilutive effects. Further, we may incur substantial costs associatedin pursuing future capital and/or financing, including investment banking fees, legal fees, accounting fees, printing and distribution expenses and other costs. We may also be required to recognize non-cash expenses in connection with being a public company.  Othercertain securities we may issue, such as convertible notes and warrants, which will adversely impact our financial condition. Our ability to obtain needed financing may be impaired by such factors as the capital markets and our history of losses, which could impact the availability or cost of future financings. If the amount of capital we are able to raise from financing activities consisted of principal payments on long-term debt of $8,844 and $7,053 during 2016 and 2015, respectively, and net payments ontogether with our line of credit of $6,877 and $3,002 during 2016 and 2015, respectively.

We believerevenues from operations, is not sufficient to satisfy our capital needs, even to the extent that we reduce our recent private offerings will provide sufficient capital in the short term for our current level ofoperations accordingly, we may be required to curtail or cease operations.  Additional resources will be needed to build our web store and to otherwise increase advertising and marketing.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors.

Critical Accounting Policies and Estimates


The preparation of our consolidated financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and liabilities andexpenses, as well as the disclosure of contingent assets and liabilities atliabilities. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the date of the financial statements and the reported amounts of revenues and expenses during the reporting period.circumstances. Actual results could differ from those estimates.


Revenue

The Company faces significant judgment in revenue recognition due to the complexities of the beverage industry’s competitive landscape and diverse distribution channels. Determining the timing of revenue recognition involves assessing factors such as control transfer, returns, allowances, trade promotions, and distributor sell-through data. Historical analysis, market trends assessment, and contractual term evaluations inform revenue recognition judgments. However, inherent uncertainties persist, underscoring the critical nature of revenue recognition as it significantly impacts financial statements and performance evaluation.

Allowance for Doubtful Accounts

The allowance for doubtful accounts is established based on historical experience, current economic conditions, and specific customer collection issues. Management evaluates the collectability of accounts receivable on an ongoing basis and adjusts the allowance as necessary. Changes in economic conditions or customer creditworthiness could result in adjustments to the allowance for doubtful accounts, impacting our reported financial results.

Inventory Valuation

We value inventory at the lower of cost or net realizable value. Estimating the net realizable value of inventory involves significant judgment, particularly when market conditions change rapidly or when excess or obsolete inventory exists. Management regularly assesses inventory quantities on hand, future demand forecasts, and market conditions to determine whether write-downs to inventory are necessary.

Fair Value Measurements

We measure certain financial assets and liabilities at fair value on a recurring basis. Fair value measurements involve significant judgment and estimation, particularly when observable inputs are limited or not available. Management utilizes valuation techniques such as discounted cash flow models, market comparables, and third-party appraisals to determine fair values.

Item 7A. Quantitative and Qualitative Disclosures about Market Risk.


Not applicable for smaller reporting companies.


Item 8. Financial Statements and Supplementary Data.




17


CANFIELD MEDICAL SUPPLY, INC.
Financial Statements

TABLE OF CONTENTS


Financial Statements Page
 
REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRMReport of Independent Registered Public Accounting Firm (PCAOB ID: 229)F-1F-2
 
FINANCIAL STATEMENTSReport of Independent Registered Public Accounting Firm (PCAOB ID: 468) 
     Balance SheetsF-2
     Statements of OperationsF-3
 Consolidated Balance Sheets December 31, 2023 and December 31, 2022F-4
Consolidated Statements of Operations For the Years Ended December 31, 2023 and December 31 2022F-5
Consolidated Statements of Changes in Stockholders' DeficitStockholders’ Equity For the years ended December 31, 2023 and 2022F-4F-6
Consolidated Statements of Cash Flows For the Year Ended December 30, 2023 and 2022F-5F-7
 Notes to the Consolidated Financial StatementsF-6 - F-12F-8



18


PRITCHETT,SILER & HARDY, P.C.
CERTIFIED PUBLIC ACCOUNTANTS
A PROFESSIONAL CORPORATION
1438 N. HIGHWAY 89 STE. 130
FARMINGTON, UTAH  84025
_______________

(801) 447-9572     FAX (801) 447-9578

Report of Independent Registered Public Accounting Firm

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM


To the Board of Directors

Canfield Medical Supply, and Stockholders
Splash Beverage Group,
Inc.
Canfield, Ohio


Fort Lauderdale, Florida

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheetssheet of Canfield Medical Supply,Splash Beverage Group, Inc. (the Company) as of“Company”) at December 31, 2016 and 2015,2022, and the related consolidated statements of operations, stockholders'changes in stockholders’ equity (deficit), and cash flows for the years then ended.  The Company's management is responsibleyear ended December 31, 2022, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2022, and the results of its operations and its cash flows for thesethe year ended December 31, 2022, in conformity with accounting principles generally accepted in the United States of America.

Basis for Opinion

These financial statements.statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on thesethe Company’s financial statements based on our audits.


audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our auditsaudit in accordance with the standards of the Public Company Accounting Oversight Board (United States).PCAOB. Those standards require that we plan and perform the auditsaudit to obtain reasonable assurance about whether the financial statements are free of material misstatement.misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. Our audits included considerationAs part of our audit, we are required to obtain an understanding of internal control over financial reporting, as a basis for designing audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company'sCompany’s internal control over financial reporting. Accordingly, we express no such opinion.  An

Our audit includesincluded performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence supportingregarding the amounts and disclosures in the financial statements, assessingstatements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statement presentation.statements. We believe that our audits provideaudit provides a reasonable basis for our opinion.

Critical Audit Matters

The critical audit matter communicated below is a matter arising from the December 31, 2022 audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of a critical audit matter does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which they relate.

Intangible Assets Impairment Assessments

As described in Note 2 to the consolidated financial statements, the Company has intangible assets of approximately $4.9 million at December 31, 2022. In most cases, no directly observable market inputs are available to measure the fair value to determine if the asset is impaired. Therefore, an estimate is derived indirectly and is based on valuation techniques utilizing undiscounted and discounted after-tax cash flows and discount rates. The estimates that management used in calculating the net present values depend on assumptions specific to the nature of the management service activities with regard to the amount and timing of projected future cashflows; long-term forecasts; actions of competitors (competing services), future tax and discount rates.

The principal considerations for our determination that performing procedures relating to the intangible assets impairment assessment is a critical audit matter are the significant judgment by management when developing the net present value of the intangible assets. This in turn led to a high degree of auditor judgment, subjectivity, and effort in performing procedures and evaluating management’s significant assumptions related to the amount and timing of projected future cash flows and the discount rate. In addition, the audit effort involved the use of professionals with specialized skill and knowledge.

Addressing the matter involved performing procedures and evaluating audit evidence in connection with forming our overall opinion on the consolidated financial statements These procedures included testing management’s process for developing the fair value estimate; evaluating the appropriateness of the net present value techniques; testing the completeness and accuracy of underlying data used in the model; and evaluating the significant assumptions used by management, including the amount and timing of projected future cash flows and the discount rate. Evaluating management’s assumptions related to the amount and timing of projected future cash flows and the discount rate involved evaluating whether the assumptions used by management reasonable considering the current and past performance of the intangible assets, the consistency with external market and industry data, and whether these assumptions were consistent with evidence obtained in other areas of the audit.

/s/ Daszkal Bolton LLP

Daszkal Bolton LLP

Fort Lauderdale, Florida

March 31, 2023

We served as the Company’s auditor from 2020 to March 2023.


Report of Independent Registered Public Accounting Firm

To the Board of Directors and Stockholders

Splash Beverage Group, Inc.

Fort Lauderdale, Florida

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheet of Splash Beverage Group, Inc. at December 31, 2023, and the related consolidated statements of operations, changes in stockholders’ equity and cash flows for the year ended December 31, 2023, and the related notes (collectively referred to as the financial statements). In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of the Company as ofat December 31, 2016 and 2015,2023, and the results of its operations and its cash flows for the years thenyear ended December 31, 2023, in conformity with accounting principles generally accepted in the United States of America.


Going Concern Uncertainty

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 73 to the consolidated financial statements, the Company has incurredsuffered recurring losses since its inception,from operations and has an accumulated deficit and a working capital deficit, and has not yet established profitable operations.  These factorsdeficiency that raise substantial doubt about theits ability of the Company to continue as a going concern. Management'sManagement’s plans in regards toregarding these matters are also described in Note 7.  These3. The consolidated financial statements do not include any adjustments that might result from the outcome of these uncertainties.

this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

Critical Audit Matters

Critical audit matters are matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.

Rose, Snyder & Jacobs LLP

We have served as the Company’s auditor since 2023

Encino, CA

March 29, 2024


/s/ Pritchett, Siler & Hardy, P.C.

PRITCHETT, SILER & HARDY, P.C.

Farmington, Utah
March 27, 2017


F-1


CANFIELD MEDICAL SUPPLY, INC. 
BALANCE SHEETS 
       
       
    December 31,  December 31, 
ASSETS 2016  2015 
       
       
Current Assets      
Cash $61,659  $7,343 
Accounts receivable, net  206,254   167,063 
Inventory  25,231   21,589 
Total Current Assets  293,144   195,995 
         
Equipment, net of accumulated depreciation of $76,197 and $40,771  62,190   43,753 
         Total Assets $355,334  $239,748 
         
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)        
Current Liabilities        
Accounts payable and accrued liabilities $209,069  $135,211 
Line of credit  70,373   77,250 
Current portion of long-term debt  10,918   7,603 
Total Current Liabilities  290,360   220,064 
         
Long-term debt  25,305   21,169 
          Total Liabilities  315,665   241,233 
         
Stockholders' Equity (Deficit)        
Preferred stock, no par value; 5,000,000 shares authorized; no shares        
 issued and outstanding  -   - 
Common stock, no par value; 100,000,000 shares authorized;        
10,927,200 and 10,027,200 shares issued and outstanding, respectively  208,515   118,515 
Accumulated deficit  (168,846)  (120,000)
Total Stockholders' Equity (Deficit)  39,669   (1,485)
Total Liabilities and Stockholders' Equity (Deficit) $355,334  $239,748 
         
         
         
The accompanying footnotes are an integral part of these financial statements. 


F-2


CANFIELD MEDICAL SUPPLY, INC. 
STATEMENTS OF OPERATIONS 
       
   Year Ended  Year Ended 
   December 31, 2016  December 31, 2015 
       
       
Sales (net of returns) $1,012,291  $897,341 
Cost of goods sold  484,908   426,980 
Gross profit  527,383   470,361 
         
Operating expenses:        
Salaries and wages  298,368   245,272 
Professional fees  87,198   39,570 
Depreciation  55,760   29,763 
Other selling, general and administrative  136,058   136,857 
    Total operating expenses  577,384   451,462 
         
Income (loss) from operations  (50,001)  18,899 
         
Other income (expense):        
Interest expense  (4,671)  (5,368)
Gain on sale of fixed assets  5,826   5,622 
   1,155   254 
         
Income (loss) before provision for income taxes  (48,846)  19,153 
Provision for income tax  -   - 
         
Net income (loss) $(48,846) $19,153 
         
Net income (loss) per share (basic and fully diluted) $(0.00) $0.00 
         
Weighted average number of common shares outstanding  10,484,113   10,027,200 
         
         
         

Splash Beverage Group, Inc.
Consolidated Balance Sheets
December 31, 2023 and December 31, 2022

         
  December 31, 2023 December 31, 2022
Assets        
Current assets:        
Cash and cash equivalents $379,978  $4,431,745 
Accounts Receivable, net  890,631   1,812,110 
Prepaid Expenses  220,320   348,036 
Inventory  2,252,469   3,721,307 
Other receivables  233,850   344,376 
Total current assets  3,977,248   10,657,574 
         
Non-current assets:        
Deposit  49,446   49,290 
Goodwill  256,823   256,823 
Intangibles assets, net  4,459,309   4,851,377 
Investment in Salt Tequila USA, LLC  250,000   250,000 
Right of use assets  556,140   750,042 
Property and equipment, net  349,802   489,597 
Total non-current assets  5,921,520   6,647,129 
         
Total assets $9,898,768  $17,304,703 
         
Liabilities and Stockholders’ Equity        
         
Liabilities:        
Current liabilities        
Accounts payable and accrued expenses $4,444,286  $3,383,187 
Right of use liability, current portion  262,860   268,749 
Related party notes payable  380,000    
Notes payable, net of discounts  7,748,518   1,080,257 
Liability to issue shares     91,800 
Shareholder advances  200,000    
Accrued interest payable  1,714,646   141,591 
Total current liabilities  14,750,310   4,965,584 
         
Long-term Liabilities:        
Notes payable, net of discounts  457,656   2,536,319 
Right of use liability, net of current portion  296,128   480,666 
Total long-term liabilities  753,784   3,016,985 
         
Total liabilities $15,504,094  $7,982,569 
         
Stockholders’ equity:        
Preferred stock, $0.001 par value, 5,000,000 shares authorized, no shares issued      
Common Stock, $0.001 par, 300,000,000 shares authorized, 44,330,099 and 41,085,520 shares issued and outstanding, at December 31, 2023 and December 31, 2022, respectively  44,330   41,086 
Additional paid in capital  127,701,710   121,632,547 
Accumulated Other Comprehensive Income  (16,583)  (20,472)
Accumulated deficit  (133,334,783)  (112,331,027)
Total stockholders’ equity  (5,605,326)  9,322,134 
         
Total liabilities and stockholders’ equity $9,898,768  $17,304,703 

The accompanying footnotesnotes are an integral part of these consolidated financial statements.


F-3


CANFIELD MEDICAL SUPPLY, INC. 
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) 
  
             
  Common Stock (No Par)  Accumulated  Stockholders' 
  Shares  Amount  Deficit  Equity (Deficit) 
             
             
Balances at December 31, 2014  10,027,200  $118,515  $(139,153) $(20,638)
                 
Net income for the year  -   -   19,153   19,153 
                 
Balances at December 31, 2015  10,027,200   118,515   (120,000)  (1,485)
                 
Sales of common stock  900,000   90,000   -   90,000 
                 
Net (loss) for the year  -   -   (48,846)  (48,846)
                 
Balances at December 31, 2016  10,927,200  $208,515  $(168,846) $39,669 
                 
Splash Beverage Group, Inc.
Consolidated Statements of Operations
For the Years Ended December 31, 2023 and December 31, 2022

         
  2023 2022
Net revenues $18,850,152  $18,087,486 
Cost of goods sold  (13,281,457)  (12,168,621)
Gross margin  5,568,695   5,918,865 
         
Operating expenses:        
Contracted services  1,402,572   1,505,788 
Salary and wages  5,003,392   4,179,403 
Non-cash share-based compensation  1,169,858   7,409,884 
Other general and administrative  10,786,011   11,411,535 
Sales and marketing  2,493,520   2,806,888 
 Total operating expenses  20,855,353   27,313,498 
         
Loss from continuing operations  (15,286,658)  (21,394,633)
         
Other income/(expense):        
Other Income/expense  (30,328)   
Interest income  2,634   6,068 
Interest expense  (1,856,777)  (251,497)
Amortization of debt discount  (3,832,628)   
Total other expense  (5,717,099)  (245,429)
         
Provision for income taxes      
         
Net (loss) from continuing operations, net of tax  (21,003,757)  (21,640,062)
         
Net (loss) income from discontinued operations, net of tax     (199,154)
         
 Gain on discontinued operations     148,747 
         
Net income (loss) from discontinued operations, net of tax     (50,407)
         
Net loss $(21,003,757) $(21,690,469)
Other comprehensive loss        
Foreign currency translation gain (loss)  3,889   (20,472)
         
Total comprehensive loss  (20,999,868)  (21,710,941)
         
Loss per share - continuing operations        
Basic and Diluted  (0.49)  (0.58)
         
Weighted average number of common shares outstanding - continuing operations        
Basic and Diluted  42,449,631   37,389,990 
         
Income (loss) per share - discontinued operations        
Basic and Diluted  (0.00)  (0.00)
         
Weighted average number of common shares outstanding - discontinued operations        
Basic and Diluted  42,449,631   37,389,990 

The accompanying footnotesnotes are an integral part of these consolidated financial statements.

F-4


CANFIELD MEDICAL SUPPLY, INC. 
STATEMENTS OF CASH FLOWS 
       
   December 31,  December 31, 
  2016  2015 
       
Cash Flows From Operating Activities:      
Net income (loss) $(48,846) $19,153 
Adjustments to reconcile net loss to net cash provided by operating activities:     
Gain on sale of fixed assets  (5,826)  (5,622)
Depreciation  55,760   29,763 
Changes in current assets and liabilities        
Increase in accounts receivable  (39,191)  (86,880)
Increase in inventory  (3,642)  (7,275)
Increase in accounts payable and accrued liabilities  73,858   63,936 
     Net cash provided by operating activities  32,113   13,075 
         
Cash Flows From Investing Activities:        
Proceeds from sale of fixed assets  6,348   6,295 
Purchases of property and equipment  (58,424)  (26,880)
     Net cash (used for) investing activities  (52,076)  (20,585)
         
Cash Flows From Financing Activities:        
Net payments on line of credit  (6,877)  (3,002)
Payments on long-term debt  (8,844)  (7,053)
Proceeds from sales of common stock.  90,000   - 
       Net cash provided by (used for) financing activities  74,279   (10,055)
         
Net Increase (Decrease) in Cash  54,316   (17,565)
Cash At The Beginning Of The Period  7,343   24,908 
Cash At The End Of The Period $61,659  $7,343 
         
Schedule Of Non-Cash Investing And Financing Activities     $- 
Purchase of equipment with long-term debt $16,295  $19,446 
         
Supplemental Disclosure        
Cash paid for interest $4,671  $5,460 
Cash paid for income taxes $-  $- 
         
         
  

Splash Beverage Group, Inc.
Consolidated Statements of Changes in Stockholders’ Equity
For the Years ended December 31, 2023 and 2022

                         
  Common stock Additional   Paid-in Accumulated Other Comprehensive Accumulated Total Stockholders’ Equity
  Shares Amount Capital Income Deficit (Deficit)
Balances at December 31, 2021  33,596,232   33,596   99,480,188      (90,640,557)  8,873,227 
Issuance of common stock on convertible instruments  377,796   378   1,514,533         1,514,911 
Issuance of warrants for services        3,849,144          3,849,144 
Issuance of warrants on convertible instruments        1,898,265         1,898,265 
Issuance of common stock for services  2,215,363   2,215   3,466,722         3,468,937 
Issuance of common stock and warrants for cash  4,896,129   4,896   11,423,695          11,428,591 
Accumulated Comprehensive Income - Translation           (20,472)     (20,472)
Net loss                 (21,690,469)  (21,690,469)
Balances at December 31, 2022  41,085,520   41,086   121,632,547   (20,472)  (112,331,026)  9,322,134 
                         
Note discount created from issuance of common stock and warrants on convertible instruments  2,275,000   2,275   4,585,975         4,588,250 
Share based compensation        840,817         840,817 
Conversion of notes payable to common stock  452,914   453   229,891         230,344 
Issuance of common stock for services  516,665   516   412,481         412,997 
Accumulated Comprehensive Income - Translation           3,889      3,889 
Net loss              (21,003,757)  (21,003,757)
Balances at December 31, 2023  44,330,099   44,330   127,701,710   (16,583)  (133,334,783)  (5,605,326)

The accompanying footnotesnotes are an integral part of these consolidated financial statements


Splash Beverage Group, Inc.
Consolidated Statements Cash Flows
For the Year Ended December 30, 2023 and 2022

         
  2023 2022
     
Net loss $(21,003,757) $(21,690,469)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization  545,977   936,020 
ROU assets, net  3,474   4,093 
Amortization of debt discount  3,832,628    
Gain from sale of discontinued operation     84,375 
Non-cash share based compensation  1,169,858   7,318,081 
Changes in working capital items:        
Accounts receivable, net  921,479   (697,658)
Inventory, net  1,468,838   (1,797,828)
Prepaid expenses and other current assets  238,241   (43,294)
Deposits  (157)  281,596 
Accounts payable and accrued expenses  1,061,101   1,594,300 
Accrued Interest payable  1,573,055   (29,861)
Net cash used in operating activities - continuing operations  (10,189,263)  (14,040,644)
         
Net cash used in operating activities - discontinued operations     (32,774)
         
Cash Flows from Investing Activities:        
Capital Expenditures  (14,113)  (102,698)
         
Net cash used in investing activities -– continuing operations  (14,113)  (102,698)
         
 Net cash used in investing activities - discontinued operations      
         
Cash Flows from Financing Activities:        
Proceeds from issuance of Common stock     11,428,591 
Cash advance (repayment) from shareholder  200,000   (390,500)
Related party cash advance  380,000    
Proceeds from issuance of debt  6,610,681   4,045,420 
Principal repayment of debt  (1,042,961)  (636,560)
         
Net cash provided by financing activities - continuing operations  6,147,720   14,446,951 
         
 Net cash provided by financing activities - discontinued operations      
         
Net cash effect of exchange rate changes on cash  3,889   (20,472)
         
Net Change in Cash and Cash Equivalents  (4,051,767)  250,362 
         
Cash and Cash Equivalents, beginning of year  4,431,745   4,181,383 
         
Cash and Cash Equivalents, end of year $379,978  $4,431,745 
         
Supplemental Disclosure of Cash Flow Information:        
Cash paid for Interest $243,087  $204,594 
         
Supplemental Disclosure of Non-Cash Investing and Financing Activities        
Convertible notes payable and accrued interest converted to common stock (377,796 shares) $  $1,514,911 
Convertible notes payable and accrued interest converted to common stock (452,914 shares) $230,000  $ 

The accompanying notes are an integral part of these consolidated financial statements.

F-5


CANFIELD MEDICAL SUPPLY, INC.
NOTES TO FINANCIAL STATEMENTS
December 31, 2016

Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 1 – Business Organization and 2015


NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Operations

Splash Beverage Group (“SBG” or “Splash”), formally Canfield Medical Supply, Inc. (the "Company"(“CMS”), was incorporated in the State of Ohio on September 3, 1992, and changed domicile to Colorado on April 18, 2012. The Company isCMS was in the business of home health services, primarily the selling of durable medical equipment and medical supplies to the public, nursing homes, hospitals and other end users.

On December 31, 2019, CMS entered into an Agreement and Plan of Merger (the “Merger Agreement”) with SBG Acquisition Inc. (“Merger Sub”), a Nevada Corporation wholly owned by CMS, and Splash Beverage Group, Inc. a Nevada corporation (“Splash”) pursuant to which Merger Sub merged with and into Splash (the “Merger”) with Splash as the surviving company and a wholly-owned subsidiary of CMS. The Merger was consummated on March 31, 2020.

As the owners and management of Splash have voting and operating control of CMS following the Merger, the Merger transaction was accounted for as a reverse acquisition (that is with Splash as the acquiring entity), followed by a recapitalization.

As part of the recapitalization, previously issued shares of SBG preferred stock have been reflected as shares of common stock that were received in the Merger. These common shares have been retrospectively presented as outstanding for all periods.

Splash specializes in the manufacturing process, distribution, and sales & marketing of various beverages across multiple channels. Splash operates in both the non-alcoholic and alcoholic beverage segments. Additionally, Splash operates its own vertically integrated B-to-B and B-to-C E-commerce distribution platform called Qplash, further expanding its distribution abilities and visibility.

In July 2020 the Company filed a Certificate of Amendment of Articles of Incorporation of CMS with the Secretary of State of the State of Colorado, pursuant to which the Company changed its name from CMS. to Splash Beverage Group, Inc. On July 31, 2020, we received approval from FINRA to change the Company’s name from CMS to Splash Beverage Group, Inc. Our new ticker symbol is SBEV.

On December 24, 2020, SBG consummated an Asset Purchase Agreement (the “Copa APA”) with Copa DI Vino® Corporation (“CdV”), to purchase certain assets and assume certain liabilities that comprise the Copa DI Vino® business for a total purchase price of $5,980,000, payable in the combination of $2,000,000 in cash (“Cash Consideration”), $2,000,000 convertible promissory note (the “Convertible Note”) to Seller and a variable number of shares of the Company’s common stock based on a attainment of revenue hurdles. CdV is one of the leading producers of premium wine by the glass in the United States with its primary offices and facilities in The Dalles, Oregon.

On February 2021, Management initiated a plan to divest its CMS business. As a result, the assets and operations of CMS have been retrospectively reflected as discontinued operations. On November 12, 2021 the Company changed its state of Domicile from Colorado to Nevada.

In coordination with up listing to the NYSE on June 11, 2021 the Company consummated a 1.0 for 3.0 reverse stock split. All common stock shares stated herein have been adjusted to reflect the split.

Note 2 – Summary of Significant Accounting Policies

Basis of Presentation and Consolidation

These consolidated financial statements include the accounts of Splash and its wholly owned subsidiaries, Holdings and Splash Mex, CMS (as discontinued operations), and CdV. All intercompany balances have been eliminated in consolidation.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 2 – Summary of Significant Accounting Policies, continued

Our investment in Salt Tequila USA, LLC is accounted for at cost, as the company does not have the ability to exercise significant influence.

Our accounting and reporting policies conform to accounting principles generally accepted in the United States of America (GAAP).

Certain reclassifications have been made to the prior period financial statements to conform to the current period classifications. These reclassifications had no impact on net loss.

Use of Estimates


The preparation of consolidated financial statements in conformity with generally accepted accounting principlesGAAP requires our management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosuredisclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.


Cash Equivalents and cash equivalents


The Company considersConcentration of Cash Balance

We consider all highly liquid investmentssecurities with an original maturity of three months or less asto be cash equivalents.


Accounts receivable

The majority of the Company's revenues are received from Medicare, Medicaid, and private insurance companies.  As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates.  The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company has determined that We had no cash equivalents at December 31, 20162023 or December 31, 2022.

Our cash in bank deposit accounts, at times, may exceed federally insured limits of $250,000. At December 31, 2023, the Company’s cash on deposit with financial institutions, at times, had not exceed federally insured limits of $250,000. The Company had approximately $3.8 million over the federally insured limits in 2022. Our cash in uninsured foreign bank accounts was $0 and 2015 no allowance$1,941 at December 31, 2023 and December 31, 2022, respectively.

Accounts Receivable and Allowance for bad debtsDoubtful Accounts

Accounts receivables are carried at their estimated collectible amounts and are periodically evaluated for collectability based on past credit history with clients and other factors. We establish provisions for losses on accounts receivable on the basis of loss experience, known and inherent risk in the account balance, and current economic conditions. At December 31, 2023 and December 31, 2022, our accounts receivable amounts are reflected net of allowances of $183,089 and $13,683, respectively.

Inventory

Inventory is stated at the lower of cost or net realizable value, accounted for using the weighted average cost method. The inventory balances at December 31, 2023 and December 31, 2022 consisted of raw materials, work-in-process, and finished goods held for distribution. The cost elements of inventory consist of purchase of products, transportation, and warehousing. We establish provisions for excess or inventory near expiration based on management’s estimates of forecast turnover of inventories on hand and under contract. A significant change in the timing or level of demand for certain products as compared to forecast amounts may result in recording additional provisions for excess or expired inventory in the future. Provisions for excess inventory are included in cost of goods sold and have historically been adequate to provide for losses on inventory. We manage inventory levels and purchase commitments in an effort to maximize utilization of inventory on hand and under commitments. The amount of our reserve was necessary.


$290,524 and $66,146 at December 31, 2023 and December 31, 2022, respectively.

Property and Equipment

We record property and equipment

at cost when purchased. Depreciation is recorded for property, equipment, and software using the straight-line method over the estimated economic useful lives of assets, which range from 3-20 years. Company management reviews the recoverability of all long-lived assets, including the related useful lives, whenever events or changes in circumstances indicate that the carrying amount of a long-lived asset might not be recoverable.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 2 – Summary of Significant Accounting Policies, continued

Depreciation expense totaled $153,908 and $182,886 for the years ended December 31, 2023 and 2022 respectively. Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.

Inventory

consisted of the following:

Schedule of property and equipment        
  2023 2022
Auto  45,420   45,420 
Machinery & equipment  1,160,578   1,108,870 
Buildings & Tanks  233,323   282,988 
Leasehold improvements  723,638   713,068 
Computer Software  5,979    
Office furniture & equipment  9,157   13,636 
Total cost  2,178,095   2,163,983 
Accumulated depreciation  (1,828,293)  (1,674,385)
Property, plant & equipment, net  349,802   489,597 

Excise taxes

The Company carries inventorypays alcohol excise taxes based on product sales to both the Oregon Liquor Control Commission and to the U.S. Department of durable medical equipmentthe Treasury, Alcohol and medical suppliesTobacco Tax and Trade Bureau (TTB). The Company also pays taxes to the State of Florida – Division of Alcoholic Beverages and Tobacco. The Company is liable for resale.  Inventory is accounted forthe taxes upon the removal of product from the Company’s warehouse on a first–per gallon basis. The federal tax rate is affected by a small winery tax credit provision which decreases based upon the number of gallons of wine production in first-out basis.


Reclassification
Certain minimal priora year items have been reclassifiedrather than the quantity sold.

Fair Value of Financial Instruments

Financial Accounting Standards (“FASB”) guidance specifies a hierarchy of valuation techniques based on whether the inputs to conformthose valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to current year presentation.  Formerly, proceeds received fromunadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the sale of fixed assets have been lumped together with fixed asset purchases in the investing sectionlowest priority to unobservable inputs (Level 3 measurement). The three levels of the Statement of Cashflows, but have been segregatedfair value hierarchy are as follows:

Level 1 -Unadjusted quoted prices in active markets for identical assets or liabilities that the reporting entity has the ability to access at the measurement date. Level 1 primarily consists of financial instruments whose value is based on quoted market prices such as exchange-traded instruments and listed equities.

Level 2 -Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly (e.g., quoted prices of similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active).

Level 3 -Unobservable inputs for the asset or liability. Financial instruments are considered Level 3 when their fair values are determined using pricing models, discounted cash flows or similar techniques and at least one significant model assumption or input is unobservable.

The liabilities and indebtedness presented on the current year to more clearly represent the flow of cash in relation to property and equipment.


F-6

CANFIELD MEDICAL SUPPLY, INC.
NOTES TO FINANCIAL STATEMENTS
consolidated financial statements approximate fair values at December 31, 20162023 and 2015


NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

December 31, 2022, consistent with recent negotiations of notes payable and due to the short duration of maturities.

Revenue recognition


Recognition

We recognize revenue under ASC 606, Revenue from product sales is recognized subsequentContracts with Customers (Topic 606). This guidance sets forth a five-step model which depicts the recognition of revenue in an amount that reflects what we expect to a patient (customer) ordering a product at an agreed upon price, andreceive in exchange for the transfer of goods or services to customers.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 2 – Summary of Significant Accounting Policies, continued

We recognize revenue when delivery has occurred, and collectability is reasonably assured. A purchase arrangement is evidenced byour performance obligations under the terms of a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract with revenue recognized when rentthe customer are satisfied. Product sales occur once control of our products is earned.


The Company's primary sourcetransferred upon delivery to the customer. Revenue is measured as the amount of revenueconsideration that we expect to receive in exchange for transferring goods and is reimbursement from Medicare, Medicaid,presented net of provisions for customer returns and private insurance companies for the procurement and sale of medical equipment and supplies to patients.allowances. The amount of consideration we receive and revenue earnedwe recognize varies with changes in customer incentives we offer to our customers and their customers. Sales taxes and other similar taxes are excluded from revenue.

Distribution expenses to transport our products, and warehousing expense after manufacture are accounted for in Other General and Administrative cost.

Cost of Goods Sold

Cost of goods sold include the costs of products, packaging, transportation, warehousing, and costs associated with valuation allowances for expired, damaged or impaired inventory. The cost of transportation from production site to other 3rd party warehouses or customer is included in Other General and Administrative cost.

Other General and Administrative Expenses

Other General and Administrative expenses include Amazon selling fees, royalty cost for selling TapouT, cost of transportation from production site to other 3rd party warehouses or customers, insurance cost, consulting cost, legal and audit fees, investor relations expenses, travel & entertainment expenses, occupancy cost and other cost.

Stock-Based Compensation

We account for stock-based compensation in accordance with ASC 718,”Compensation - Stock Compensation”. Under the fair value recognition provisions, cost is measured at the grant date based on the fair value of the award and is recognized as expense ratably over the requisite service period, which is generally the option vesting period. We use the Black-Scholes option pricing model to determine the fair value of stock options. We early adopted ASU 2018-07, “Improvements to Nonemployee Share-Based Payment Accounting”, which aligns accounting treatment for such awards to non-employees with the existing guidance on employee share-based compensation in ASC 718.

We measure stock-based awards at the grant-date fair value for employees, directors and consultants and recognize compensation expense on a straight-line basis over the vesting period of the award. Determining the appropriate fair value of stock-based awards requires the input of subjective assumptions, including the fair value of our common stock, and for stock options and warrants, the expected life of the option and warrant, and expected stock price volatility and exercise price. We used the Black-Scholes option pricing model to value its stock-based awards. The assumptions used in calculating the fair value of stock-based awards represent management’s best estimates and involve inherent uncertainties and the application of management’s judgment. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards. The expected life of stock options/warrants were estimated using the “simplified method,” which calculates the expected term as the midpoint between the weighted average time to vesting and the contractual maturity, we have limited historical information to develop reasonable expectations about future exercise patterns. The simplified method is based on the average of the vesting tranches and the contractual life of each classificationgrant. For stock price volatility, we use comparable public companies as a percentbasis for its expected volatility to calculate the fair value of total revenuesaward. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected life of the award. The estimation of the number of awards that will ultimately vest requires judgment, and to the extent actual results or updated estimates differ from the Company’s current estimates, such amounts are recognized as follows:

an adjustment in the period in which estimates are revised.


  December 31,
  2016 2015
Medicare 27% 13%
Medicaid 13% 12%
Private pay/private insurance 47% 63%
Other 13% 12%
Total 100% 100%

Advertising costs

Advertising costs are expensed as incurred. The Company had advertising costs in 2016 and 2015

Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 2 – Summary of $4,912 and $2,676, respectively.


Significant Accounting Policies, continued

Income tax


The Company accountsTaxes

We use the liability method of accounting for income taxes pursuant toas set forth in ASC 740.740,”Income Taxes”. Under ASC 740,the liability method, deferred taxes are provided for usingdetermined based on the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amountsfinancial statement and tax basis of assets and liabilities and theirusing tax bases. Deferred tax assets are reduced byrates expected to be in effect during the years in which the basis differences reverse. We record a valuation allowance when init is not more likely than not that the opiniondeferred tax assets will be realized.

Company management assesses its income tax positions and records tax benefits for all years subject to examination based upon its evaluation of management, itthe facts, circumstances and information available at the reporting date. In accordance with ASC 740-10, for those tax positions where there is a greater than 50% likelihood that a tax benefit will be sustained, our policy is to record the largest amount of tax benefit that is more likely than not to be realized upon ultimate settlement with a taxing authority that some portion orhas full knowledge of all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.



F-7

CANFIELD MEDICAL SUPPLY, INC.
NOTES TO FINANCIAL STATEMENTS
December 31, 2016 and 2015

NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Income tax

Through February 2012, the Company was an S-Corporation forrelevant information.

For those income tax purposes, and thereforepositions where there is less than 50% likelihood that a pass-through entity payingtax benefit will be sustained, no income tax atbenefit will be recognized in the corporate level.  Thefinancial statements. Company hadmanagement has determined that there are no material loss carryforwards as of December 31, 2011.  Included in the Company's accumulated deficit from February 2012 forward is approximately $99,000 in undistributed S-Corporation losses.  At December 31, 2016 and 2015 the Company had net operating loss carryforwards (NOL's) of approximately $70,000 and $21,000 respectively, which may be applied against future taxable income and which expire beginning in 2034.  However, if certain substantial changes in the Company's ownership should occur, there could be an annual limitation on the amount of net operating loss carryforwards that can be utilized.  The amount of and ultimate realization of the benefits from the operating loss carryforwards for incomeuncertain tax purposes is dependent, in part, upon the tax laws in effect, the future earnings of the Company, and other future events, the effects of which cannot be determined.  Because of the uncertainty surrounding the realization of the loss carryforwards, the Company has established a valuation allowance equal to the tax effect (35% - 30% federal and 5% state) of the loss carryforwards of approximately $24,500 and $7,350positions at December 31, 20162023 and 2015, respectively, and therefore, no deferred tax asset has been recognized for the loss carryforwards.  The change in valuation allowance is approximately $17,150 and $6,650 for the periods ended December 31, 2016 and 2015, respectively.  The tax effect of remaining NOL's and resulting deferred tax assets of $24,500 remain fully reserved by valuation allowance, due to continued uncertainty as to their utilization.


2022. See not 13.

Net income (loss) per share


The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company'sCompany’s convertible debt or preferred stock (if any), are not included in the computation if the effect would be anti-dilutive.

Weighted average number of shares outstanding excludes anti-dilutive common stock equivalents, including warrants to purchase shares of common stock and would increasewarrants granted by our Board that have not been exercised totaling 74,007,680.

Advertising

We conduct advertising for the earningspromotion of our products. In accordance with ASC 720-35, advertising costs are charged to operations when incurred. We recorded advertising expense of $1,721,547 and $732,618 for the years ended December 30, 2023 and 2022, respectively.

Goodwill and other intangibles

Goodwill represents the excess of acquisition cost over the fair value of the net assets acquired and is not subject to amortization. The Company reviews goodwill annually in the fourth quarter for impairment or decrease loss per share.

when circumstances indicate carrying value may exceed the fair value. This evaluation is performed at the reporting unit level. If a qualitative assessment indicates that it is more likely than not that the fair value is less than carrying value, a quantitative analysis is completed using either the income or market approach, or a combination of both. The income approach estimates fair value based on expected discounted future cash flows, while the market approach uses comparable public companies and transactions to develop metrics to be applied to historical and expected future operating results.

The gross amounts and accumulated amortization of the Company’s acquired identifiable intangible assets with finite useful lives, included in other intangible assets, net in the accompanying consolidated balance sheets, were as follows:

Schedule of identifiable intangible assets            
  December 31, 2023  
  Gross
Amount
 Accumulated
Amortization
 Amortization
Period
Finite:     (in years)
Brands $4,459,000  $891,803   15 
Customer Relationships  957,000   191,400   15 
License  360,000   233,488   11 
Total Intangible Assets $5,776,000  $1,316,691     


There we no potentially dilutive debt or equity instruments issued or outstanding

Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 2 – Summary of Significant Accounting Policies, continued

At the time of acquisition, the Company estimates the fair value of the acquired identifiable intangible assets based upon the facts and circumstances related to the particular intangible asset. Inherent in such estimates are judgments and estimates of future revenue, profitability, cash flows and appropriate discount rates for any present value calculations. The Company preliminarily estimates the value of the acquired identifiable intangible assets and then finalizes the estimated fair values during the twelvepurchase allocation period, which does not extend beyond 12 months ended December 31, 2016from the date of acquisition. The Company’s amortization expense for acquired identifiable intangible assets with finite useful lives was $392,068 for fiscal years 2023 and 2022. Estimated amortization expense for acquired identifiable intangible assets for fiscal year 2024 and the succeeding years is as follows:

Schedule of future intangible asset amortization expense useful lives     
  Future Intangible Asset
Amortization Expense
Fiscal Year:  
2024  $392,068 
2025   392,068 
2026   392,068 
2027   392,068 
2028   363,580 
Thereafter   2,527,457 
Total  $4,459,309 

Long-lived assets

The Company evaluates long-lived assets for impairment on an annual basis, when relocating or 2015.


Financial Instruments

Theclosing a facility, or when events or changes in circumstances may indicate the carrying amount of the asset group, generally an individual warehouse, may not be fully recoverable. For asset groups held and used, including warehouses to be relocated, the carrying value of the Company's financial instruments,asset group is considered recoverable when the estimated future undiscounted cash flows generated from the use and eventual disposition of the asset group exceed the respective carrying value. In the event that the carrying value is not considered recoverable, an impairment loss is recognized for the asset group to be held and used equal to the excess of the carrying value above the estimated fair value of the asset group. For asset groups classified as reportedheld-for-sale (disposal group), the carrying value is compared to the disposal group’s fair value less costs to sell. The Company estimates fair value by obtaining market appraisals from third party brokers or using other valuation techniques.

Foreign Currency Gain/Losses

Foreign subsidiaries’ functional currency is the local currency of operations and the net assets of foreign operations are translated into U.S. dollars using current exchange rates. Gain or losses from these translation adjustments are included in the accompanying balance sheets, approximates fair value.



F-8

CANFIELD MEDICAL SUPPLY, INC.
NOTES TO FINANCIAL STATEMENTS
December 31, 2016consolidated statement of operations and 2015


NOTE 1.  ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Continued):

Concentrations

Financial instrumentsother comprehensive (loss) income as foreign currency translation gains or losses. Translation gains and losses that potentially subjectarise from the Companytranslation of net assets from functional currency to concentrations of credit risk include cashthe reporting currency, as well as exchange gains and cash equivalents.losses on intercompany balances, are included in Other Comprehensive Losses. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits.

The Company receivesincurred a significant amount of its revenues in reimbursements from Medicare and Medicaid.  Duringforeign currency translation net gain during the yearsyear ended December 31, 20162023 of $3,889 and 2015,a foreign currency translation net loss during the year ended December 31, 2022 of $20,472.

Recent Accounting Pronouncements

Adoption of FASB ASU 2020-06

In August 2020, the Financial Accounting Standards Board (FASB) issued ASU No. 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity.” ASU 2020-06 simplifies the accounting for convertible instruments and contracts by removing certain models that were previously required to be applied. The amendments are effective for the fiscal years beginning after December 15, 2023, with early adoption permitted. The Company is currently evaluating the impact this update will have on its consolidated financial Statements.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 3 – Liquidity, Capital Resources and Going Concern Considerations

During 2023, the Company received 40% and 25%, respectively,$6.6 million from the issuance of its net revenues from Medicare and Medicaid.  debt. This event served to mitigate the conditions that previously raised substantial doubt about the Company’s ability to continue as a going concern.

The Company’s consolidated financial statements have been prepared on the basis of US GAAP for a going concern, on the premise that the Company is able to obtain reimbursements through competitive bidding processes,meet its obligations as they come due in the normal course of business. The Company sustained a net loss of approximately $21.0 million and negative cash flows from operating activities of approximately $10.2 million for the year ended December 31, 2023. To date the Company has generated cash flows from issuances of equity and indebtedness.

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As of March 29, 2024, the Company has incurred significant losses from operations and has experienced negative cash flows from operating activities. Additionally, the Company’s current liabilities exceed its current assets, and it has a working capital deficit.

Management’s plans in regard to these matters include actions to sustain the Company’s operations, such as seeking additional funding to meet its obligations and implement its business plan. However, there is no guaranteeassurance that the Company will be selected as a winning contract supplier under future bidding rounds.


Long-Lived Assets

In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of factssuccessful in implementing its plans or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.

Products and services, geographic areas and major customers

The Company's business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.

Other selling, general and administrative expenses

Other selling, general and administrative expenses included the following:
  December 31, 
  2016  2015 
Rent $27,492  $27,492 
Office expenses  43,107   44,829 
Other SG&A  
65,459
   
64,536
 
Total $136,058  $136,857 

F-9

CANFIELD MEDICAL SUPPLY, INC.
NOTES TO FINANCIAL STATEMENTS
December 31, 2016 and 2015


NOTE 2.  EQUIPMENT

Property and equipment are recorded at cost and consist of the following:
  December 31, 
  2016  2015 
       
Office equipment $2,934  $2,934 
Vehicles  58,577   42,282 
Wheelchair/hospital bed rental pool  76,876   39,308 
Total property and equipment  138,387   84,524 
Accumulated depreciation  (76,197)  (40,771)
Net property and equipment $62,190  $43,753 

Depreciation is computed using the straight-line method based upon estimated useful lives as follows:

Office equipment
7 yeas
Vehicles
5 years
Wheelchair/hospital bed rental pool
13 months

Depreciation for 2016 and 2015 was $55,760 and $29,763, respectively.

The wheelchair/hospital bed rental pool consists of wheelchairs and hospital beds rented to customers over the shorter of the 13 month use period as mandated by Medicare and Medicaid, or the period over which the customer requires use of a wheelchair or hospital bed.  At the end of the use period, the chairs and beds are either returned to the pool to be rented to another customer, or title of the item is transferred to the customer.

NOTE 3.  LINE OF CREDIT

At December 31, 2016 and 2015, the Company owed a bank $70,373 and $77,250, respectively, under a line of credit note payable. The line of credit is secured by all Company assets, due on demand, and bears interest at variable rates approximating 4%. Interest expense under the note in 2016 and 2015 was $3,597 and $2,958, respectively.  During 2016 and 2015, the Company made principal payments of $6,877 and $3,002, respectively.


F-10

CANFIELD MEDICAL SUPPLY, INC.
NOTES TO FINANCIAL STATEMENTS
December 31, 2016 and 2015


NOTE 4.  LONG-TERM DEBT

Long-term debt consists of the following:
  December 31, 
 2016  2015 
3.53% installment note payable $352 monthly, including interest, through July 2019, collateralized by vehicle with carrying value of $7,503. $10,426  $14,213 
2.99% installment note payable $350 monthly, including interest, through August 2019, collateralized by vehicle with carrying value of $9,723  10,745   14,559 
3.79% installment note payable $299 monthly, including interest, through July 2021, collateralized by vehicle with carrying value of $14,665  15,052   0 
   36,223   28,772 
         
Less principal due within one year  (10,918)  (7,603)
TOTAL LONG-TERM DEBT
 $25,305  $21,169 
    
Principal payments due on long-term debt subsequent to December 31, 2016, are as follows: 
 2017 $10,918 
 2018  11,296 
 2019  8,511 
 2020  3,434 
 2021  2,064 
TOTAL $36,223 

F-11

CANFIELD MEDICAL SUPPLY, INC.
NOTES TO FINANCIAL STATEMENTS
December 31, 2016 and 2015


NOTE 5.  COMMON STOCK

 In March and December 2016, the Company received net proceeds of $90,000 from the sale to primarily unaffiliated investors of 900,000 shares of no-par value common stock at $0.10 per share.  

NOTE 6.  LEASE COMMITMENTS

The Company rents office space under a non-cancellable lease through May 2017 with monthly payments of approximately $2,700 plus costs.

Lease expense incurred in each of the years ended 2016 and 2015 was approximately $33,000. Subsequent to December 31, 2016, future minimum payments under the leases total approximately $13,500 through May 2017, at which point the Company plans to renew the lease for anraising additional term.

NOTE 7.  GOING CONCERN

The Company has suffered losses from operations and has working capital and stockholders' equity deficits. In all likelihood, the Company will be required to make significant future expenditures in connection with marketing efforts along with general administrative expenses.funds. These conditions raise substantial doubt about the Company'sCompany’s ability to continue as a going concern.

The Company may raise additional capital throughfinancial statements do not include any adjustments that might result from the saleoutcome of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so,this uncertainty. If the Company hopes to generate sufficient capital to execute its business plan of selling medical supplies on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Companyis unable to continue as a going concern.

concern, adjustments would be necessary to the carrying values of its assets and liabilities and the reported amounts of revenues and expenses could be materially affected.


NOTE 8.  SUBSEQUENT EVENTS

Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 4 – Notes Payable, Related Party Notes Payable, and Revenue Financing Arrangements

Notes payable are generally nonrecourse and secured by all Company owned assets.

Schedule of notes payable            
  Interest Rate December 31, 2023 December 31, 2022
Notes Payable            
             
In March 2014, the Company entered into a short-term loan agreement with an entity in the amount of $200,000. The note included warrants for 272,584 shares of common stock at $0.94 per share. The warrants expired unexercised on February 28, 2017. The loan and interest was paid off in February 2023  8%     200,000 
             
In December 2020, the Company entered into a 56- month loan with a company in the amount of $1,578,237. The loan requires payments of 3.75% through November 2022 and 4.00% through September 2025 of the previous month’s revenue. Note is due September 2025. Note is guaranteed by a related party see note 6.  17%  371,693   1,044,445 
             
In April 2021, the Company entered into various six-month loans with individuals totaling in the amount of $168,000. The loans had an original maturity of October 2021 with principal and interest due at maturity with conversion price of $3.30 per share. The loans were extended to March 31, 2024.  7%  168,000   168,000 
             
In May 2021, the Company entered into various six-month loans with individuals totaling in the amount of $60,000. The loans had an original maturity of October 2021 with principal and interest due at maturity with conversion price of $3.30 per share. The loans were extended to March 31, 2024.  7%  60,000   60,000 
             
In August 2022, we entered into a 56-months auto loan in the amount of $45,420.  2.35%  32,996   42,396 
             
In December 2022, the Company entered into various eighteen-month loans with individuals totaling in the amount of $4,000,000. The notes included 100% warrant coverage. The loans mature in June 2024 with principal and interest due at maturity with conversion price of $1.00 per share.  12%  4,000,000   4,000,000 
             
In February 2023, the Company entered into a twelve-month loan with an entity in the amount of $2,000,000. The convertible note included the issuance of 1,500,000 shares of common stock . The loan matures in February 2024 with conversion price of $0.85 per share and is non-interest bearing  %  1,769,656    
             
In May 2023, the Company entered into various eighteen-month loans with individuals totaling in the amount of $800,000. The notes included 50% warrant coverage. The loans mature in November 2024 with principal and interest due at maturity with conversion price of $1.00 per share.  12%  800,000    
             
 In June 2023, the Company entered into various eighteen-month loans with individuals totaling in the amount of $350,000. The notes included 50% warrant coverage. The loans mature in December 2024 with principal and interest due at maturity with conversion price of $1.00 per share.  12%  350,000    
             
In July 2023, the Company entered into a twelve-month loan with an individual in the amount of $750,000. The note included 50% warrant coverage. The loan matures in July 2024 with principal and interest due at maturity with conversion price of $1.00 per share.  12%  750,000    
             
In July 2023, the Company entered into a twelve-month loan with an individual in the amount of $100,000. The note included 50% warrant coverage. The loan matures in January 2025 with principal and interest due at maturity with conversion price of $1.00 per share.  12%  100,000    
             
 In August 2023, the Company entered into a twelve-month loan with an individual in the amount of $300,000. The convertible note included the issuance of 150,000 shares of common stocks. The loan matures in August 2024 with principal and interest due at maturity with conversion price of $0.85 per share and is non-interest bearing.     300,000    
             
 In October 2023, the Company entered into a three-month loan with an individual in the amount of $500,000. The loan matures in January 2024 with principal and interest due at maturity. The loan was extended to March 2024.  10%  500,000    
             
In October 2023, the Company entered into a loan with an individual in the amount of $196,725 The loan matures in March 2024. Note is guaranteed by a related party.     91,785    
             
In October 2023, the Company entered into a loan with an individual in the amount of $130,000. The loan requires payment of 17% of daily Shopify sales.     88,431    
             
In October 2023, the Company entered into a eighteen-month loan with individuals totaling in the amount of $1,250,000. The note included 100% warrant coverage. The loan matures in April 2025 with principal and interest due at maturity with conversion price of $1.00 per share  12%  1,250,000    
             
In December 2023, we entered into a 2.5-month loan with an individual in the amount of $450,000. The loan had a maturity of March 2024 with principal and interest due at maturity.  10%  450,000    
             
   Total notes payable  $11,082,561  $5,514,841 
             
   Less notes discount   (2,876,387)  (1,898,265)
             
   Less current portion   (7,748,518)  (1,080,257)
             
   Long-term notes payable  $457,656  $2,536,319 


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 4 – Notes Payable, Shareholder Notes Payable, and Revenue Financing Arrangements, continued

Interest expense on notes payable was $1,836,377 and $246,090 for the years ended December 31, 2023 and 2022, respectively. Accrued interest was $1,714,646 and $141,591 at December 31, 2023 and December 31, 2022, respectively. The Company’s effective interest rate was 60.17% for the year ended December 31, 2023.

As of December 31, 2023, the Company’s convertible note balances are convertible into 11,127,500 shares of common stock.

Notes discount of $2,876,387 and $1,898,265 for the year ending December 31, 2023 and 2022 respectively is related to the discounted warrants and common shares issued in connection with the notes.

Schedule of notes payable          
  Interest Rate December
31, 2023
 December
31, 2022
Shareholder Notes Payable       
           
In February 2023, we entered into a loan with an individual in the amount of $200,000. The annual interest rate is 12% 12%  200,000    
           
  Less current portion  (200,000)   
           
  Long-term notes payable $  $ 

Interest expense on related party notes payable was $20,400 and $5,407 for the years ended December 31, 2023 and 2022, respectively.

Note 5 – Licensing Agreement and Royalty Payable

We have a licensing agreement with ABG TapouT, LLC (“TapouT”), providing us with licensing rights to the brand “TapouT” on (i) energy drinks, (ii) energy bars, (iii) coconut water, (iv) electrolyte gum/chews, (v) energy shakes, (vi) powdered drink mix, (viii) water (including enhanced water), (vii) energy shots, (viii) teas, and (ix) sports drinks sold in the North America (including US Territories and Military Bases), United Kingdom, Brazil, South Africa, Australia, Scandinavia, Peru, Colombia, Chile and Guatemala. Under the terms of the agreement, we are required to pay a 6% royalty on net sales, as defined. In January 2017,2023 and 2022, we are required to make monthly payments of $55,000 and $54,450, respectively.

There were no unpaid royalties at December 31, 2023 and 2022. We paid the guaranteed minimum royalty payments of $660,000 and $653,400 for the years ended December 31, 2023 and 2022, which is included in general and administrative expenses.

In connection with the Copa Asset Purchase Agreement, we acquired the license to certain patents from 1/4 Vin SARL (“1/4 Vin”) On February 16, 2018, the Copa DI Vino® entered into three separate license agreements with 1/4 Vin SARL, (1/4 Vin). 1/4 Vin has the right to license certain patents and patent applications relating to inventions, systems, and methods used in the Company’s manufacturing process. In exchange for notes payable, 1/4 Vin granted the Company sold 350,000a nonexclusive, royalty-bearing, non-assignable, nontransferable, terminable license which would continue until the subject equipment is no longer in service or the patents expire. Amortization is approximately $31,000 annually until the license agreement is fully amortized. The asset is being amortized over a 10-year useful life.

Note 6 – Stockholders’ Equity

Common Stock

During the twelve-months ended December 31, 2022, we issued 4,596,129 shares of common stock as part of the public offerings, 1,834,404 shares in exchange for services, 380,959 shares in connection with the purchase of Copa DI Vino®, 377,796 shares on conversion of convertible instruments, and 300,000 shares for cash.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 6 – Stockholders’ Equity, continued

Private Placement Memorandum (PPM)

In July 2022, we issued 100,000 shares of common stock of the Company, at a purchase price of $1.10 per share. In December 2022, we issued 200,000 shares of common stock of the Company, at a purchase price of $1.00 per share this placement included 100% warrant coverage.

In December 2022, we issued Convertible Notes for 4,000,000 shares at $1.00 per share with warrants to purchase 4,000,000 shares of common stock at $0.25 per share.

Stock Plans

A summary of the Company’s stock option plan and changes during the year ended is as follows:

Schedule of stock option plan            
Plan Category No. of Shares to be Issued Upon Exercise or Vesting of Outstanding Stock Options Weighted Average Exercise Price of Outstanding Stock Options Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (Excluding Securities
Equity compensation plan approved by board of directors  4,259,008   1.13   2,846,068 
             
Total  4,259,008   1.13   2,846,068 

In August 2020, the Board adopted the 2020 Stock Incentive Plan (the “2020 Plan”), which provides for the grant of Options, Restricted Stock Awards, Stock Appreciation Rights, Performance Units and Performance Bonuses to consultants and eligible recipients.

The 2020 Plan has an “evergreen” feature, which provides for the annual increase in the number of shares issuable under the plan by an amount equal to 5% of the number of issued and outstanding common shares at year end, unless otherwise adjusted by the Board of Directors. At January 1, 2023 and 2022, the number of shares issuable under the 2020 plan increased by 2,054,276 and 1,679,812 shares, respectively.

In October 2023, the shareholders voted to increase the number of shares issuable under the Plan to 7.5%.

At December 31, 2023 the number of shares authorized under the 2020 plan is 2,846,068.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 6 – Stockholders’ Equity, continued

The following is a summary of the Company’s stock option activity:

Schedule of stock option activity                 
Options   December 31, 2023 December 31, 2022
  Number of Options Weighted Average Exercise Price Number of Options Weighted Average Exercise Price
         
Balance - January 1, 2023*   1,151,000  $1.12   1,065,000   2.60 
                  
Granted   3,441,008   1.13   146,000  $2.31 
Exercises             
Cancelled   333,000   1.18   60,000   2.60 
                  
Balance – December 31, 2023   4,259,008  $1.13   1,151,000  $2.56 
                  
 Exercisable – December 31, 2023   3,910,787  $1.12   732,746  $2.58 

*These prices are reflective of the price modification made on April 24, 2023.

In May 2022, we granted 146,000 options to purchase common stock to employees and consultants, these options vest between one and four years and were valued at $336,926 on the grant date. ..

In the three months ending June 30, 2023, the Company granted 3,376,008 options to employees and directors at weighted average strike price of $1.13, weighted average expected life of 6.0 years, weighted average volatility of 264.3%, weighted average risk-free rate of 3.6% and no dividend. On April 24, 2023, the Company modified the price of 4,134,008 options to $1.12 from a weighted average price of $2.56. The options have a weighted average expected life of 6.3 years, weighted average volatility of 266.7%, weighted average risk-free rate of 3.6% and no dividend. Following ASC Topic 718 the Company recognized an incremental expense from the modification of the option pricing resulting in an expense of $7,348 that was reflected in the quarter.

The Company determined the grant date fair value of the options granted using the Black Scholes Method using the following assumptions:

Schedule of stock option assumption        
  December 31, 2023 December 31, 2022
Risk-free interest rates  0.84%  0.84%
Exercise price $1.081.36  $2.60 
Expected life  5 years   5 years 
Expected volatility  160.0%  160.0%
Expected dividends      

During the year ended December 31, 2023, the fair value of options granted amounted to $1,060,602. As of December 31, 2023, the intrinsic value of stock options outstanding and exercisable was $0. Stock compensation expense for the years ended December 31, 2023 and 2022 was $840,817 and $1,146,965, respectively.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 6 – Stockholders’ Equity, continued

At December 31, 2023, there was approximately $300,000 of unrecognized compensation costs related to stock options which will be recognized over the weighted average remaining years of 0.84.

The following is a summary of the Company’s Warrant activity

Schedule of warrant activity        
Warrants   December 31, 2023 December 31, 2022
  Number of Warrants Weighted Average Exercise Price Number of Warrants Weighted Average Exercise Price
         
Balance – beginning of the year  14,343,896  $1.85   10,143,896  $2.51 
                 
Granted  2,250,000   0.58   4,200,000   0.25 
Exercises  68,146   2.19       
Cancelled  2,345,677   2.32       
                 
Balance - end of the year  14,180,073  $1.56   14,343,896  $1.85 

The fair value of warrants recognized in the period has been estimated using the Black-Scholes option pricing model with the following assumptions.

Schedule of assumptions used in Black-Scholes option pricing model        
  December 31, 2023 December 31, 2022
Risk-free interest rates  3.84%  3.99%
Exercise price $0.55  $0.96 
Expected life   5 years   5 years 
Expected volatility  228.3%  228.3%
Expected dividends      

Note 7 – Related Parties

During the normal course of business, we incurred expenses related to services provided by our CEO or Company expenses paid by our CEO, resulting in related party payables. In conjunction with the acquisition of Copa DI Vino®, the Company also entered into a Revenue Loan and Security Agreement (the “Loan and Security Agreement”) by and among the Company, Robert Nistico, additional Guarantor and each of the subsidiary guarantors from time-to-time party thereto (each a “Guarantor”, and, collectively, the “Guarantors”), and Decathlon Alpha IV, L.P. (the “Lender”). The Loan and Security Agreement provided for a revenue-based credit facility of $1,578,237 (the “Gross Amount”) with the Lender (the “Credit Facility”). There was $371,693 outstanding and $989,702 accrued interest under this agreement as of December 31, 2023. Additionally, the Company is subject to $757,554 of penalties associated with this agreement as of December 31, 2023. The lender has agreed to waive the penalties in the event the Company repays the loan obligation in full prior to maturity. The Company intends to pay off the obligation prior to maturity.

On September 29, 2023, the Company also entered into a Purchase and Sales Future Receivables Agreement (the “Loan and Security Agreement”) by and among the Company, Robert Nistico, additional Guarantor and each of the subsidiary guarantors from time-to-time party thereto (each a “Guarantor”, and, collectively, the “Guarantors”), and Knightsbridge Funding LLC (the “Lender”). The Loan and Security Agreement provided a loan of $165,000, with the gross and interest amount of $241,725 with the Lender (the “Credit Facility”). There was $99,185 outstanding under this agreement as of December 31, 2023.

There were related party advances from our chief executive officer in the amount of $0.4 million outstanding as of December 31, 2023 and a shareholder note payable outstanding in the amount of $200,000 as of December 31, 2023.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 8 – Investment in Salt Tequila USA, LLC

The Company has a marketing and distribution agreement with SALT in Mexico for the manufacturing of our Tequila product line.

The Company has a 22.5% percentage interest in SALT Tequila USA, LLC (“SALT”), and has the right to increase its ownership to 37.5%. This investment is accounted for at cost.

Note 9 – Lease

We have various operating lease agreements primarily related to real estate and office space. Our real estate leases represent a majority of our lease liability. Our lease payments are mainly fixed. Any variable lease payments, including utilities and common area maintenance are expensed during the period incurred. Variable lease costs were immaterial for the years ended December 31, 2023 and 2022. A majority of our real estate leases include options to extend the lease. We review all options to extend at the inception of the lease and account for these options when they are reasonably certain of being exercised.

Operating lease expense is recognized on a straight-line basis over the lease term and is included in operating expense on our consolidated statement of operations. Operating lease cost was $363,890 and $315,980 during the years ended December 31, 2023 and 2022, respectively.

The following table sets for the maturities of our operating lease liabilities and reconciles the respective undiscounted payments to the operating lease liabilities in the consolidated balance sheet at December 31, 2023:

Schedule of operating lease liabilities  
Undiscounted Future Minimum Lease Payments Operating Lease
   
2024 $286,168 
2025  287,193 
2026  17,857 
Total  591,218 
Amount representing imputed interest  (32,230)
Total operating lease liability  558,988 
Current portion of operating lease liability  (262,860)
Operating lease liability, non-current $296,128 

The table below presents information for lease costs related to our operating leases at December 31, 2023:

Schedule of lease costs    
Operating lease cost:    
Amortization of leased assets $330,728 
Interest of lease liabilities  33,162 
Total operating lease cost $363,890 

The table below presents lease- related terms and discount rates at December 31, 2023:

Schedule of lease- related terms and discount rates
Remaining term on leases30 months
Incremented borrowing rate5.0%


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 10 – Segment Reporting

We have two reportable operating segments: (1) the manufacture and distribution of non-alcoholic and alcoholic beverages, and (2) the retail sale of beverages and groceries online. These operating segments are managed separately and each segment’s major customers have different characteristics. Segment Reporting is evaluated by our chief operating decision maker, which continues to be our chief executive officer.

Schedule of segment reporting information    
Revenue For the Year Ended, December 31,
2023
 For the Year Ended, December 31,
2022
Splash Beverage Group $5,072,479  $4,759,586 
E-Commerce  13,777,673   13,327,900 
         
Total Revenues continuing operations $18,850,152  $18,087,486 
         
Total Revenues discontinuing operations $  $385,174 

Contribution after Marketing expenses 2023 2022
Splash Beverage Group $(1,749,163) $(2,202,790)
E-Commerce  4,824,338   5,314,767 
         
Total Contribution after Marketing expenses continuing operations  3,075,175   3,111,977 
         
 Contracted services  1,402,572   1,505,788 
 Salary and wages  5,003,392   4,179,403 
 Non-cash share-based compensation  1,169,858   7,409,884 
 Other general and administrative  10,786,011   11,411,535 
         
 Loss from continuing operations $(15,286,658) $(21,394,633)

Total Assets December 31, 2023 December 31, 2022
Splash Beverage Group $9,188,213  $14,723,553 
E-Commerce  710,555   2,581,150 
         
Total Assets $9,898,768  $17,304,703 

Splash Beverage Group revenue increased for the year ending December 31, 2023 versus December 31, 2022 by $0.3 million or 7% with the main contribution from the increase in revenue coming from TapouT and Pulpoloco. The contribution after marketing expenses increased by $0.04 million for the year ending December 31, 2023 versus December 31, 2022 due to increased sales partially offset by cost increases.

E-Commerce revenue increased for the year ending December 31, 2023 versus December 31, 2022 by $0.4 million driven by expanded territory coverage, new products being sold and increased cart size when customers checking out. Contribution after Marketing expenses declined by $0.4 million due to increase by cost.

Note 11 – Commitment and Contingencies

We are a party to asserted claims and are subject to regulatory actions in the ordinary course of business. The results of such proceedings cannot be predicted with certainty, but we do not anticipate that the outcome, if any, arising out of any such matter will have a material adverse effect on its business, financial condition or results of operations.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 12 – Registration Statement

Underwriting Agreement

On June 10, 2021, we entered into an underwriting agreement (“Underwriting Agreement”) relating to an unaffiliated investor at $.10/underwritten public offering (the “Offering”) of common stock, (the “Common Stock”) and warrants to purchase one share of Common Stock (the “Warrants”). Pursuant to the Offering, we sold 3,750,000 shares of Common Stock and 4,312,500 Warrants, which include 562,500 Warrants sold upon the partial exercise of the Underwriters’ over-allotment, for total gross proceeds of $35,000.


approximately $15 million. After deducting the underwriting commissions, discounts, and offering expenses, we received net proceeds of approximately $13.2 million.

On February 17, 2022, we entered into an underwriting agreement (“Underwriting Agreement”) relating to an underwritten public offering (the “Offering”) of common stock, (the “Common Stock”) to purchase one share of Common Stock. Pursuant to the Offering, we sold 2,300,000 shares of Common Stock for total gross proceeds of approximately $9.2 million. After deducting the underwriting commissions, discounts, and offering expenses payable by we, we received net proceeds of approximately $7.9 million.

On September 22, 2022, we entered into an underwriting agreement (“Underwriting Agreement”) relating to an underwritten public offering (the “Offering”) of common stock, (the “Common Stock”) to purchase one share of Common Stock. Pursuant to the Offering, we sold 2,296,129 shares of Common Stock for total gross proceeds of approximately $3.6 million. After deducting the underwriting commissions, discounts, and offering expenses, we received net proceeds of approximately $3.1 million.

Representative’s Warrants

On June 15, 2021, pursuant to the Underwriting Agreement, the Company issued Representative’s Warrants to purchase up to an aggregate of 150,000 shares of Common Stock. The Representative’s Warrants may be exercised beginning on December 10, 2021 until June 10, 2026. The initial exercise price of each Representative Warrant is $4.60 per share, which represents 115% of the Offering Price.

Note 13 – Tax Provision

The Company has evaluated subsequent events through the date these financial statements werepositive and negative evidence in assessing the realizability of its deferred tax assets. This assessment included the evaluation of scheduled reversals of deferred tax liabilities, estimates of projected future taxable income and tax planning strategies to determine which deferred tax assets are more likely than not to be realized in the future. Due to uncertainty about the Company’s ability to utilize its deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets.

At December 31, 2023, the Company’s net operating loss carryforward for Federal income tax purposes was $108,922,763, which will be available to offset future taxable income. If not used, these carry forwards will begin to expire in 2032, except for the net operating losses generated January 1, 2018 and after, which amounted to $90,921,071, which can be issuedcarried forward indefinitely.

There was no income tax expense or benefit for the years ended December 31, 2023 and determined that there are no other reportable subsequent events.

2022 due to the full valuation allowance recorded.


Splash Beverage Group, Inc.

Notes to the Consolidated Financial Statements

Note 13 – Tax Provision, continued

The reconciliation of the income tax benefit is computed at the U.S. federal statutory rate as follows:

Schedule of effective income tax rate reconciliation    
  2023 2022
     
Federal Statutory Tax Rate  21.00%  21.00%
Permanent Differences  (0.89)%  (3.80)%
Change in Valuation Allowance  (20.11)%  (17.20)%
Net deferred tax asset      

The tax effects of temporary differences which give rise to the significant portions of deferred tax assets or liabilities at December 31 are as follows:

Schedule of deferred tax assets or liabilities    
  2023 2022
Deferred Tax Assets:        
Net Operating Losses $27,606,474  $22,758,336 
Deferred Rent     380 
Accrued Interest/Interest Expense Limitation  1,518,618   1,263,639 
Total deferred tax assets  29,125,092   24,022,355 
         
Deferred Tax Liabilities:        
Depreciation  (120,502)  (93,476)
Total deferred tax liabilities  (120,502)  (93,476)
         
Less: Valuation allowance  (29,004,590)  (23,928,879)
Total Net Deferred Tax Assets $  $ 

The Company continually evaluates expiring statutes of limitations, audits, proposed settlements, changes in tax law and new authoritative rulings. The open tax years subject to examination with respect to the Company’s operations are 2015 through 2023.

Note 14 – Subsequent Events

In January 2024, the Company entered into a convertible note with an individual in the amount of $250,000. The note has an eighteen-month 18 term, accrues interest at 12% and is convertible into shares of common stock of the Company at $0.50 per share, which also includes 200% warrants at $0.25

In January 2024, the Company entered into a commercial loan in the amount of $500,000. The total cost of the loan is $250,000 and is paid in weekly increments of 6.97% of the current receivable balance.

In February 2024, the Company entered into a convertible note with an individual in the amount of $150,000. The note has an eighteen-month 18 term, accrues interest at 12% and is convertible into shares of common stock of the Company at $0.40 per share, which also includes 250% warrants at $0.25.

In March 2024, the Company received a $109,000 cash advance from our chief executive officer, resulting in a related party payable. This note bears 0% interest.

We have notes that expire in 2024 that we plan to extend or payoff.


F-12


Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.


On September 24, 2013, Ronald R. Chadwick, P.C. ("Chadwick") resigned as the Company's independent registered public accounting firm.  On February 3, 2014, the Company, through and with the approval of its board of directors, engaged Cutler & Co., LLC ("Cutler") as its independent registered public accounting firm.

Cutler subsequently merged its SEC auditing practice with Pritchett, Siler & Hardy, P.C. ("PSH") of Salt Lake City, Utah, and on January 11, 2016, the Company engaged Pritchett, Siler & Hardy, P.C. as its new independent registered public accounting firm.

Since its appointment as our independent registered accounting firm on February 3, 2014, Cutler has completed the audit of our financial statements for the year ended December 31, 2013 and reviewed our financial statements for the quarters ended March 31, 2014, June 30, 2014 and September 30, 2014.  PSH subsequently completed the audits of our December 31, 2014, 2015, and 2016 financial statements, as well as our quarterly reviews for the years ended December 31, 2015 and 2016.

We had no disagreements with either Chadwick or Cutler & Co., LLC with respect to accounting or financial disclosure.

None.

Item 9A. Controls and Procedures.


(a)

(1) Evaluation of Disclosure Controls and Procedures.


OurProcedures

We have adopted and maintain disclosure controls and procedures (as such term is defined in Exchange Act Rules 13a-15(e) and 15d-15(e) under the Exchange Act), that are designed to ensure that information required to be disclosed in our reports under the Exchange Act, is recorded, processed, summarized and reported within the time periods required under the SEC’s rules and forms and that the information is gathered and communicated to our management, including our Chief Executive Officer (Principal Executive Officer) and Chief Financial Officer (Principal Financial Officer), to allow for timely decisions regarding required disclosure.

As required by Exchange Act Rule 13a-15, our Chief Executive Officer and PrincipalChief Financial Officer have evaluatedcarried out an evaluation of the effectiveness of the design and operationsoperation of our disclosure controls and procedures pursuant to Exchange Act Rule 13a-15 as of the end of the period covered by this quarterly report,report. Based on the foregoing evaluation, our Chief Executive Officer and haveChief Financial Officer concluded that due to our limited resources our disclosure controls and procedures are adequate.


(b)not effective in providing material information required to be included in our periodic SEC filings on a timely basis and to ensure that information required to be disclosed in our periodic SEC filings is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure about our internal control over financial reporting discussed below Following the 2022 evaluation by management of the effectiveness of the design and operation of our disclosure controls and procedures we implemented new controls and process in 2023.

(2) Management’s Report on Internal Control over Financial Reporting

Our management is responsible for establishing and maintaining adequate internal control over financial reporting for our company. Our internal control system was designed to, in general, provide reasonable assurance to our management and board regarding the preparation and fair presentation of published financial statements, but because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Our management assessed the effectiveness of our internal control over financial reporting as of December 31, 2023. Based on that assessment, our management has determined that as of December 31, 2023, our internal control over financial reporting was not effective due to material weaknesses related to a limited segregation of duties due to our limited resources and the small number of employees. Management has determined that this control deficiency constitutes a material weakness which could result in material misstatements of significant accounts and disclosures that could result in a material misstatement to our interim or annual financial statements that would not be prevented or detected. In addition, due to limited staffing, we are not always able to detect minor errors or omissions in reporting.

This Annual Report does not include an attestation report of our independent registered public accounting firm regarding management’s assessment of our internal control over financial reporting pursuant to temporary rules of the SEC.

(3) Changes in Internal Control over Financial Reporting.


NoReporting

There has been no change in our internal control over financial reporting (as definedother than items highlighted above, identified in connection with the evaluation required by paragraph (d) of Rules 13a-15(f) and 15d-15(f)13a-15 or 15d-15 under the Securities Exchange Act)Act of 1934 that occurred during the period covered by this reportour most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.


Item 9B. Other Information.

None.

ITEM 9C. DISCLOSURE REGARDING FOREIGN JURISDICTIONS THAT PREVENT INSPECTIONS.

Not applicable.


None.

19

PART III


Item 10. Directors, Executive Officers and Corporate Governance.


Each of

The following table sets forth our directors is elected by the stockholders to a term of one year and serves until his successor is elected and qualified. Each of our officers is elected by the board of directors to a term of one year and serves until his or her successor is duly elected and qualified, or until he or she is removed from office. The board of directors has no committees.


The name, address, age and position of ourexecutive officers and directors, is set forth below:

their ages and position(s) with the Company.

Name and Address Age Position(s)Position
     
Michael J. West
4120 Boardman-Canfield Road
Canfield, OH  44406
Robert Nistico
 6160 President, Chief Executive Officer and Director
     
Stephen H. West
16325 E. Dorado Ave.
Centennial, CO  80045
Stacy McLaughlin
 5942 Chief Financial Officer Secretary and
William Meissner  57 President, Chief Marketing Officer 
Justin Yorke57Director
John Paglia56Director
Bill Caple65Director

The persons named above

Directors are expected toelected annually and hold said offices/positionsoffice until the next annual meeting of our stockholders. These officersthe stockholders of the Company and directorsuntil their successors are our only officers, directors, promoterselected. Officers are elected annually by the Board of Directors (the “Board”) and control persons.


Background Information about Our Officersserve at the discretion of the Board.

Robert Nistico, age 60, on March 31, 2020 became the Chief Executive Officer and Directors


Michael J. West co-founded our Company with his wife in September 1992a member of the Board of the Company. Since 2012, Mr. Nistico has served as the Chief Executive Officer and a member of the Board of Splash Beverage Group, Inc., prior to the Company’s acquisition by CMS. Mr. Nistico also served as the president of Viva Beverages, LLC from 2009 to 2011. Mr. Nistico was the fifth employee at Red Bull North America, Inc. where he worked from 1996 to 2007 and served as Vice-President, SecretaryVice President of Field Marketing and Sr. Vice President/General Manager. Mr. Nistico was instrumental in building the Red Bull brand in North and Central America and the Caribbean from no revenues to $1.45 billion in annual revenues. Earlier, he held the brand position of Regional Portfolio V.P and Division Manager for Diageo (formerly I.D.V. / Heublein), General Sales Manager for Republic National (formerly The Julius Schepps Company) and North Texas State Manager for The E & J Gallo Winery (and a Director until Septembervariety of other management positions for those companies). Mr. Nistico serves as a director of Apollo Brands. Mr. Nistico has more than 27 years of experience in the beverage industry, including direct and indirect sales management, strategic brand management & marketing, finance, operations, production and logistics. Mr. Nistico holds a B.A. from the University of Colorado.

Stacy McLaughlin, age 42, became the Chief Financial Officer on January 24, 2024. Prior to serving as our Chief Financial Officer, Ms. McLaughlin was the Chief Financial Officer of Material Technologies, Corp. from 2022 to 2023. From 2013 to 2021, Ms. McLaughlin was the Vice President and Chief Financial Officer of Willdan Group, Inc. (Willdan), and prior to that, she was their Compliance Manager from 2010 to 2013. During her tenure at Willdan, she was responsible for accounting and finance functions, SEC reporting, investor relations, treasury, and managed a follow-on equity offering. Prior to Willdan, Ms. McLaughlin was, from 2009 to 2010, Senior Associate at Windes & McClaughry Accountancy Corporation and, from 2004 when heto 2009, Senior Audit Associate at the public accounting firm KPMG LLP. Ms. McLaughlin has a Masters in Accounting from the University of Southern California and BS from the University of Arizona. Ms. McLaughlin is a Certified Public Accountant (CPA).

William Meissner, age 57, became the President and sole Director.  He also founded Medical Billing Assistance, Inc. ("Medical Billing")Chief Marketing Officer of the Company in 1994.  Medical Billing was involved in electronic billingMay of medical claims to Medicare.  Medical Billing completed an acquisition of FCID Medical, Inc. in December 2010 and2020. Mr. West resigned from all positionsMeissner is a proven leader with Medical Billing at that time.  Mr. West received a Bachelor's of Arts Degree in Biology from Wittenberg University in 1977.  He plans to continue devoting his full time to our affairs.  We believe that Mr. Michael West's 24more than twenty years of experience serving as either our President or Vice President enables himsuccess in growing consumer brand companies with both large multinational and medium sized entrepreneurial organizations. Meissner has held several other leadership and board director roles. Prior to make valuable contributionsSplash Meissner was a board director and CEO in a beverage vertical organized by a mid-cap PE firm designed to our Board of Directors.


Stephen H. West hasacquire and build emerging brands, where he acquired two legacy tea brands from Nestle, Sweet Leaf Tea and Tradewinds Tea. Meissner served as Secretary, Treasurer, CFOCEO and Board Director or Genesis Today, Inc. a plant based superfood and supplement company, CEO and Board Director of our company since September 2011.  He is the brother of Michael J. West.  He has been involved in the computer data storage market since 1978.  He spent twenty-two years at Storage Technology Corporation where he held positions asa joint venture between Distant Lands Coffee Inc. and Caffitaly Systems s.p.a called Tazza Pronto Inc., CEO and Board Director of Sales for their telecommunications region, ViceJones Soda Inc., President of Talking Rain Beverages, Inc., Chief Marketing Officer of Coca-Cola’s Fuze Beverages, Brand Director of PepsiCo’s SoBe Beverages and GeneralCategory Manager of the Western Region and Vice President of Global Accounts.  He co-founded PeakDataNutritional Beverages for Tetra Pak Inc., a computer data storage company which focuses on sales and integration of enterprise storage solutions for Fortune 1000 companies in March 2001 and served as its Executive Vice president of Sales until January 2009.  Since January 2009, he Meissner has served as Director of Sales of Net Source, a computer storage company. From May 2007 until December 2010 he served as Secretary and a Director of Medical Billing Assistance, Inc. and he continued as a Director until April 2011.  Mr. West graduatedan MBA from the University of CincinnatiPittsburgh’s Katz Graduate School of Business and a Bachelor’s degree from Michigan State University.


Justin Yorke, age 57, became a member of the Board of the Company on March 31, 2020. Since March 31, 2020, Mr. Yorke has also served as the Company’s Secretary. Mr. Yorke has over 25 years of experience in finance. Based in Hong Kong for over 10 years, he managed funds for a private Swiss Bank, Darier Henstch from 1997 to 2000. Prior to that, from 1995 to 1997, Mr. Yorke managed funds for Peregrine Investments and from 1990 to 1995 Unifund, Asia, Ltd, Hong Kong, a high net-worth family office headquartered Geneva, Switzerland. From 2000 to 2004, he was a partner at Asiatic Investment Management, based in San Francisco. Since 2004, Mr. Yorke has been a partner in San Gabriel Advisors, LLC and Arroyo Capital Management, LLC and is the manager of the San Gabriel Fund, JMW Fund and Richland Fund. The funds are highly diversified in focus with investment holdings, public, private equity and debt investments and real estate investments. He has a B.A. degree from UCLA. Mr. Yorke is the principal of WesBev LLC, which prior to the merger between CMS and our Company was the majority shareholder of the Company. He also is an acting director and audit committee chair of Processa Pharmaceuticals, (Nasdaq: PCSA). Mr. Yorke served as non-executive Chairman of Jed Oil and a Director/CEO at JMG Exploration.

Dr. Paglia, age 56, became a member of the Board of the Company as an independent director on February 26, 2024. He is currently an independent director, Audit Committee Chair and a member of the Nominating & Corporate Governance and Compensation Committee of Simulations Plus, Inc., from 2014 to present. Mr. Paglia is also an independent director, Audit Committee Chair and a member of the Nominating & Corporate Governance and Compensation Committee of Aeluma, Inc., from 2021 to present. Additionally, Dr. Paglia is currently on the Advisory Board of multiple companies, including SUM Ventures, Axxes Capital Inc., VitaNav Inc., and DigiLife Fund, among others. Dr. Paglia, a Professor of Finance, currently works at Pepperdine University in various positions, which have included Senior Associate Dean and Executive Director, since 2000-present. Dr. Paglia has a Doctor of Philosophy in Business Administration, from the University of Kentucky, a Master of Business Administration from Gannon University, a Bachelor of Science from Gannon University, and is also a Certified Public Accountant and Charted Financial Analyst.

Bill Caple, age 65, has served as an independent director of the Company since May 3, 2023. Over the past five years, Mr. Caple has primarily served as a consultant on corporate strategies, business development, corporate finance, and M&A. Mr. Caple is currently a board member of Covax Data, Inc. (“Covax”), where he also assists with establishing sales channels and business development for Covax’s cyber security AI blockchain product and assisting the company raise growth capital. Mr. Caple also founded and runs Caple Advisory, an international management consulting practice and investment banking firm, with a BBAconcentration in 1978.  He plansAsia. Previously, Mr. Caple served as a board member and C-suite executive of multiple hi-tech businesses, netting successful exits and public offerings of his companies (e.g. OTG Software NASDAQ: OTGS, now part of Dell EMC and OpenText). The Company believes that Mr. Caple is an asset to devote approximately 5the Company because of his wealth of experience and success in corporate finance strategies, M&A, and business development to 10 hours per monthround out the Board’s top-tier level of expertise in key subjects.

 Family Relationships

There are no family relationships among and between the issuer’s directors, officers, persons nominated or chosen by the issuer to become directors or officers, or beneficial owners of more than ten percent of any class of the issuer’s equity securities.

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act requires that our directors and executive officers and persons who beneficially own more than 10% of our common stock (referred to herein as the “reporting persons”) file with the SEC various reports as to their ownership of and activities relating to our affairs.  Wecommon stock. Such reporting persons are required by the SEC regulations to furnish us with copies of all Section 16(a) reports they file. Based solely on our review of copies of the reports filed with the SEC and the written representations of our directors and executive officers, we believe that Mr. Stephen West's 38 yearsall reporting requirements for fiscal year 2023 were complied with by each person who at any time during the 2023 fiscal year was a director or an executive officer or held more than 10% of salesour common stock, except for the following: Bill Caple, Fatima Dhalla (interim CFO at the time), and Stacy McLaughlin each filed a late Form 3 report at the time of their appointments and on becoming insiders of the Company; Ron Wall filed a late Form 4 report on January 31, 2023 related to the grant of options to purchase our common stock on May 2, 2022; Justin Yorke, Candance Crawford and Peter McDonough each filed a late Form 4 report on May 15, 2023 related to the grant of options to purchase our common stock on April 24, 2023; Bill Caple filed a late Form 4 report on May 19, 2023 related to the grant of options to purchase our common stock on May 1, 2023; and Ron Wall filed a late Form 4 report on August 3, 2023 related to the grant of options to purchase our common stock on May 2, 2023.


Committees of the Board of Directors

Audit Committee

We have separately designated an Audit Committee. The Audit Committee is responsible for, among other things, the appointment, compensation, removal and oversight of the work of the Company’s independent registered public accounting firm, overseeing the accounting and financial reporting process of the Company, and reviewing related person transactions. Our Audit Committee is comprised of John Paglia and Bill Caple. Under NYSE listing standards and applicable SEC rules, all the directors on the audit committee must be independent. Also, as a smaller reporting company, we are only required to maintain an audit committee of two independent directors. Our Board has determined that John Paglia and Bill Caple are independent under NYSE listing standards and applicable SEC rules. John Paglia is the Chairperson of the audit committee. Each member of the audit committee is financially literate and our Board has determined that John Paglia qualifies as an “audit committee financial expert” as defined in applicable SEC rules. The Audit Committee operates under a written charter adopted by the Board of Directors, which can be found on our website at www.splashbeveragegroup.com. During 2023, the Audit Committee held four meetings in person or through conference calls.

Compensation and Management Resources Committee

We have established a Compensation and Management Resources Committee of our Board of Directors. The purpose of the Compensation and Management Resources Committee is to assist the Board in discharging its responsibilities relating to executive experiencecompensation, succession planning for the Company’s executive team, and to review and make recommendations to the Board regarding employee benefit policies and programs, incentive compensation plans and equity-based plans.

The members of our Compensation and Management Resources Committee are Bill Caple, John Paglia and Justin Yorke. Bill Caple is the chairperson of the Compensation and Management Resources Committee.

Under NYSE listing standards, we are required to have at least two members of the compensation committee, all of whom must be independent directors. Our board of directors has determined that each of John Paglia and Bill Caple is independent under NYSE listing standards. The Compensation and Management Resources Committee is responsible for, among other things, (a) reviewing all compensation arrangements for the executive officers of the Company and (b) administering the Company’s stock option plans. The Compensation and Management Resource Committee operates under a written charter adopted by the Board of Directors, which can be found on our website at www.splashbeveragegroup.com within the “Investor Information” section.

The duties and responsibilities of the Compensation and Management Resources Committee in accordance with its charter are to review and discuss with management and the Board the objectives, philosophy, structure, cost and administration of the Company’s executive compensation and employee benefit policies and programs; no less than annually, review and approve, with respect to the Chief Executive Officer and the other executive officers (a) all elements of compensation, (b) incentive targets, (c) any employment agreements, severance agreements and change in control agreements or provisions, in each case as, when and if appropriate, and (d) any special or supplemental benefits; make recommendations to the Board with respect to the Company’s major long-term incentive plans applicable to directors, executives and/or non-executive employees of the Company and approve (a) individual annual or periodic equity-based awards for the Chief Executive Officer and other executive officers and (b) an annual pool of awards for other employees with guidelines for the administration and allocation of such awards; recommend to the Board for its approval a succession plan for the Chief Executive Officer, addressing the policies and principles for selecting a successor to the Chief Executive Officer, both in an emergency situation and in the technology industryordinary course of business; review programs created and his knowledgemaintained by management for the development and succession of other executive officers and any other individuals identified by management or the Compensation and Management Resources Committee; review the establishment, amendment and termination of employee benefits plans, review employee benefit plan operations and administration; and any other duties or responsibilities expressly delegated to the Compensation and Management Resources Committee by the Board from time to time relating to the Committee’s purpose.


The Compensation and Management Resources Committee may request any officer or employee of the Company or the Company’s outside counsel to attend a meeting of the Compensation and Management Resources Committee or to meet with any members of, or consultants to, the Compensation and Management Resources Committee. The Company’s Chief Executive Officer does not attend any portion of a meeting where the Chief Executive Officer’s performance or compensation is discussed, unless specifically invited by the Compensation and Management Resources Committee.

The Compensation and Management Resources Committee has the sole authority to retain and terminate any compensation consultant to be used to assist in the evaluation of director, Chief Executive Officer or other executive officer compensation or employee benefit plans and has sole authority to approve the consultant’s fees and other retention terms. The Compensation and Management Resources Committee also has the authority to obtain advice and assistance from internal or external legal, accounting or other experts, advisors and consultants to assist in carrying out its duties and responsibilities and has the authority to retain and approve the fees and other retention terms for any external experts, advisors or consultants.

During 2023, the Compensation Management Resources Committee held four meetings in person or through conference calls.

Nominating and Corporate Governance Committee

The Nominating and Corporate Governance Committee is responsible for overseeing the appropriate and effective governance of the Company, including, among other things, (a) nominations to the Board of Directors and making recommendations regarding the size and composition of the Board of Directors and (b) the development and recommendation of appropriate corporate governance principles. The Nominating and Corporate Governance Committee consists of John Paglia and Bill Caple, each of whom is an independent director (as defined under Section 803 of the NYSE American LLC Company Guide). The Chairperson of the committee is Bill Caple. The Nominating and Corporate Governance Committee operates under a written charter adopted by the Board of Directors, which can be found on our Company's history qualify himwebsite at www.splashbeveragegroup.com within the “Investor Information” section.

The Nominating and Corporate Governance Committee adheres to servethe Company’s bylaws provisions and Securities and Exchange Commission rules relating to proposals by stockholders when considering director candidates that might be recommended by stockholders, along with the requirements set forth in the committee’s Policy with Regard to Consideration of Candidates Recommended for Election to the Board of Directors, also available on our website. The Nominating and Corporate Governance Committee of the Board of Directors is responsible for identifying and selecting qualified candidates for election to the Board of Directors prior to each annual meeting of the Company’s stockholders. In identifying and evaluating nominees for director, the Committee considers each candidate’s qualities, experience, background and skills, as awell as other factors, such as the individual’s ethics, integrity and values which the candidate may bring to the Board of Directors.

During 2023, the Nominating and Corporate Governance Committee held two meetings in person or through conference calls.

Meetings of the Board of Directors same as above

During 2023, the Board of Directors held five meetings. During 2023, each member of our Board of Directors.

Directors attended at least 75% of the aggregate of all meetings of our Board of Directors and of all meetings of committees of our Board of Directors on which such member served that were held during the period in which such director served.

The Board of Directors also approved certain actions by unanimous written consent.

Director Independence

The NYSE listing standards require that a majority of our Board be independent. Our Board has determined that John Paglia and Bill Caple are “independent directors” as defined in the NYSE listing standards. Our independent directors will have regularly scheduled meetings at which only independent directors are present.



20



Section 16(a) Beneficial Ownership Reporting Compliance

Based solely on

Involvement in Certain Legal Proceedings

Our Directors and Executive Officers have not been involved in any of the following events during the past ten years:

1.any bankruptcy petition filed by or against such person or any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time;
2.any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses);
3.being subject to any order, judgment, or decree, not subsequently reversed, suspended or vacated, of any court of competent jurisdiction, permanently or temporarily enjoining him from or otherwise limiting his involvement in any type of business, securities or banking activities or to be associated with any person practicing in banking or securities activities;
4.being found by a court of competent jurisdiction in a civil action, the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended, or vacated;
5.being subject of, or a party to, any federal or state judicial or administrative order, judgment decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of any federal or state securities or commodities law or regulation, any law or regulation respecting financial institutions or insurance companies, or any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or
6.being subject of or party to any sanction or order, not subsequently reversed, suspended, or vacated, of any self-regulatory organization, any registered entity or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

7.Such person was the subject of, or a party to, any federal or state judicial or administrative order, judgment, decree, or finding, not subsequently reversed, suspended or vacated, relating to an alleged violation of:

i. Any federal or state securities or commodities law or regulation; or

ii. Any law or regulation respecting financial institutions or insurance companies including, but not limited to, a reviewtemporary or permanent injunction, order of Forms 3disgorgement or restitution, civil money penalty or temporary or permanent cease-and-desist order, or removal or prohibition order; or

iii. Any law or regulation prohibiting mail or wire fraud or fraud in connection with any business entity; or

8.Such person was the subject of, or a party to, any sanction or order, not subsequently reversed, suspended or vacated, of any self-regulatory organization (as defined in Section 3(a)(26) of the Exchange Act (15 U.S.C. 78c(a)(26))), any registered entity (as defined in Section 1(a)(29) of the Commodity Exchange Act (7 U.S.C. 1(a)(29))), or any equivalent exchange, association, entity or organization that has disciplinary authority over its members or persons associated with a member.

Board leadership structure and 4role in risk oversight

The Board of Directors oversees our business and amendments thereto furnishedaffairs and monitors the performance of management. In accordance with corporate governance principles, the Board of Directors does not involve itself in day-to-day operations. The directors keep themselves informed through discussions with the Chief Executive Officer and other key executives, visits to the Company duringCompany’s facilities, by reading the fiscal year ended December 31, 2016,reports and certain written representations, no persons who were either a director, executive officerother materials that we send them and by participating in Board and committee meetings. Each director’s term will continue until the election and qualification of his or beneficial owner of more than 10% of the Company's Common Stock, failed to file on a timely basis reports requiredher successor, or his or her earlier death, resignation or removal. The information set forth in Item 1C is incorporated herein by Section 16(a) of the Exchange Act during the fiscal year ended December 31, 2016.

reference.


Code of Ethics


To date, the Company has not

We have adopted a code of business conduct and ethics that applies to itsour directors, officers (including our Chief Executive Officer, Chief Financial Officer and any person performing similar functions) and employees. Our Code of Ethics is available at our website at www.splashbeveragegroup.com.

Clawback Policy

On September 20, 2023, the Board adopted the Splash Beverage Group Clawback Policy (the “Clawback Policy”), effective September 20, 2023, providing for the recovery of certain incentive-based compensation from current and former executive officers because it only has two executive officers who are also board members.


Audit Committee

Theof the Company in the event the Company is not listed for trading yetrequired to restate any of its financial statements filed with the SEC under the Exchange Act in order to correct an error that is material to the previously-issued financial statements, or that would result in a material misstatement if the error were corrected in the current period or left uncorrected in the current period. Adoption of the Clawback Policy was mandated by new Nasdaq listing standards introduced pursuant to Exchange Act Rule 10D-1. The Clawback Policy is in addition to Section 304 of the Sarbanes-Oxley Act of 2002 which permits the SEC to order the disgorgement of bonuses and does not yet have an audit committee.

incentive-based compensation earned by a registrant issuer’s chief executive officer and chief financial officer in the year following the filing of any financial statement that the issuer is required to restate because of misconduct, and the reimbursement of those funds to the issuer. A copy of the Clawback Policy has been filed herewith, and can also be found at www.splashbeveragegroup.com.

Item 11. Executive Compensation.


Compensation

The following table sets forth information for our two most recently completed fiscal years ending December 31, 2023 and December 31, 2022 concerning all of the compensation awarded to, earned by or paid to the executive officers named below.  No other employees earned a salary over $100,000 in the last two completed fiscal years.


Name and Principal PositionYear 
Salary
($)
  
Bonus
($)
  
Stock
Awards($)
  
Option
Awards($)
  
Non-Equity
Incentive Plan
Compensation
($)
  
Nonqualified
Deferred
Compensation
Earnings($)
  
All Other
Compensation
($)
  Total($) 
                          
Michael West2016 $86,750   -   -   -   -   -   -  $86,750 
 2015 $67,750   -   -   -   -   -   -  $67,500 
                                  
Steve West2016 $-   -   -   -   -   -   -  $- 
 2015 $-   -   -   -   -   -   -  $- 

We currently pay our President a salary of approximately $1,300 per week and we intend to continue this during the next twelve months.  Our

Name and Principal Position Year Salary Bonus Other Stock Awards Option   Awards Nonequity Incentive Plan Compensation Nonqualified Deferred Compensation Earnings Total
                   
Robert Nistico, CEO  2023   333,125      14,400               347,525 
   2022   325,000   100,000   14,400               439,000 
                                     
William Meissner, President and CMO  2023   333,125                     333,125 
   2022   325,000   90,000         260,000         415,000 
                                     
Ronald Wall, CFO(1)  2023   249,438                     249,438 
   2022   217,708   60,000   28,429      254,100         560,237 
                                     
Fatima Dhalla, Interim CFO(2)  2023   55,950                     55,950 

(1) On September 26, 2023, Ronald Wall resigned as Chief Financial Officer is not paid a salary.  We doof the Company.

(2) Effective January 19, 2024, Fatima Dhalla, resigned as the Interim Chief Financial Officer of the Company.

Employment Agreements

Except as described below, the Company does not have any employment agreements in place with eitherany of its executive officers. The board of directors reserves the right to increase the salary of our executive officers.

officers, and/or to grant them equity awards, including stock, options or other equity securities, from time to time, as additional compensation or bonuses.


Robert Nistico – CEO and Director


On March 12, 2012, the Company entered into an employment agreement with Robert Nistico, pursuant to which Mr. Nistico serves as Chief Executive Officer of the Company. Pursuant to Mr. Nistico’s employment agreement, the Company pays Mr. Nistico an annual salary of $275,000. Mr. Nistico is also eligible to receive an annual bonus of 50% of his annual salary, and was granted an option to purchase 350,000 shares of common stock. In the event Mr. Nistico terminates his employment with the Company he shall provide the Company a minimum of 45 days of written notice.

On December 9, 2019, the board of directors of the Company extended Mr. Nistico’s employment agreement beginning December 1, 2019, and ending on November 30, 2024. Pursuant to the amendment, the Company increased Mr. Nistico’s base salary from $275,000 to $325,000.

Stacy McLaughlin - CFO

Pursuant to the terms of an employment agreement dated January 22, 2024, the Company employs Ms. Stacy McLaughlin as its Chief Financial Officer on a full-time basis. Effective January 24, 2024, Ms. McLaughlin’s annual salary is $325,000. She is also entitled to an annual performance bonus of up to $162,500, upon achieving certain targets that are to be defined on an annual basis. Ms. McLaughlin is also entitled to participate in all qualified plans, holidays and other employee benefits which the Company, in its sole discretion, may maintain from time to time for the benefit of its employees in general. On March 5, 2024, pursuant to her employment agreement, Ms. McLaughlin was granted 600,000 restricted shares of Common Stock. These shares will vest in tranches of 50,000 per quarter, until exhausted, with the first tranche vesting upon the completion of the first quarter of 2024. Continued vesting of these shares is subject to Ms. McLaughlin’s employment remaining in good standing with the Company. In the event that the company is acquired within the two years of January 24, 2024, the vesting schedule that the shares are subject to will accelerate, contingent on Ms. McLaughlin’s employment being in good standing to the date on which the acquisition closes.

William Meissner – CMO and President

On May 4, 2020, the Company entered into an employment agreement with William Meissner, pursuant to which Mr. Meissner serves as President and Chief Marketing Officer of Company. Pursuant to Mr. Meissner’s employment agreement, the Company pays Mr. Meissner an annual base salary of $325,000 and includes annual increases based on cost of living adjustments and performance at the discretion of the Company’s Chief Executive Officer. Mr. Meissner is also eligible for a discretionary bonus, as determined by the Company’s Chief Executive Officer, of up to 50% of Mr. Meissner’s base salary. Mr. Meissner also received a grant of an option to purchase 666,667 shares of common stock under the Company’s equity incentive plan. The employment agreement with Mr. Meissner’s does not have a fixed termination date and permits the Company to terminate Mr. Meissner upon twenty days prior written notice and grants Mr. Meissner the right to resign upon twenty days prior written notice.

Directors Compensation


Our

During the fiscal year ended December 31, 2023, our directors have not beenwere paid any compensation in cash for serving as Directors of the Company and thereCompany.

Name Year Fees Earned or Paid in Cash All Other Compensation Stock Awards Option Awards Total Compensation
           
Candace Crawford  2023   76,000         125,000   76,000 
                         
Peter McDonough  2023   70,996         125,000   70,996 
                         
Justin Yorke  2023            125,000    
                         
Bill Caple  2023   46,664         125,000    
                         
John Paglia  2023                


Pension, Retirement or Similar Benefit Plans

There are no presentarrangements or plans in which we provide pension, retirement or understandings with respectsimilar benefits for directors or executive officers. We have no material bonus or profit sharing plans pursuant to future compensation.


which cash or non-cash compensation is or may be paid to our directors or executive officers, except that stock options may be granted at the discretion of the Board or a committee thereof.

Indebtedness of Directors, Senior Officers, Executive Officers and Other Management

None of our directors, executive officers or any associate or affiliate of our Company during the last two fiscal years is or has been indebted to our Company by way of guarantee, support agreement, letter of credit or other similar agreement or understanding currently outstanding.

Equity Compensation Plan

On May 21, 2020, the Board adopted the 2020 Long-Term Incentive Compensation Plan (the “2020 Plan”), which provides for the grant of Options, Restricted Stock Awards, Stock Appreciation Rights, Performance Units and Performance Bonuses to consultants and other eligible recipients. The Plan has been in effect since July 1, 2020, for a period of ten years thereafter. The Plan continues to remain in effect until all matters relating to the payment of Awards and administration of the Plan have been settled.

Outstanding Equity Awards at Fiscal Year-End


We did not have any

The following table summarizes the total outstanding equity awards onas of December 31, 2016.


2023, for each Named Executive Officer:

Name Grant
Date
 Number of Securities Underlying Unexercised Options Exercisable Number of Securities Underlying Unexercised Options Un-Exercisable Plan Awards: Number of Securities Underlying Unexercised Unearned Options Option
Exercise
Price
 Option
Expiration
Date
Robert Nistico 2/28/2020  159,008       $1.12  2/21/2025
Robert Nistico 10/16/2020  1,000,000       $1.12  10/15/2025
Robert Nistico 9/16/2021  530,000       $1.12  9/16/2031
William Meissner 10/16/2020  416,667       $1.12  10/16/2025
William Meissner  9/16/2021  66,666    33,334   $1.12  9/16/2031

(1)Unless otherwise noted, the business address of each of the following individuals is 1314 East Las Olas Blvd, Suite 221 Fort Lauderdale, Florida 33301

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.


The following table sets forth certain information with respect to the beneficial ownership of our common stock as of March 27, 2017,29, 2024, for:

each of our current directors and executive officers;
all of our current directors and executive officers as a group; and
each person, or group of affiliated persons, who beneficially owned more than 5% of our common stock.


Except as indicated by (i) each person or entity who is known bythe footnotes below, we believe, based on information furnished to us, that the persons and entities named in the table below have sole voting and sole investment power with respect to own beneficially more than 5% of the outstandingall shares of common stock based on total outstanding shares of 11,277,200, (ii) each of our Directors, (iii)that they beneficially, subject to applicable community property laws. Unless otherwise specified, the address for each of the Executive Officerspersons named in the Summarytable is 1314 E Las Olas Blvd. Suite 221, Fort Lauderdale, Florida 33301.

Our calculation of the percentage of beneficial ownership is based on 45,129,687 shares of common stock outstanding as of March 29, 2024. We have determined beneficial ownership in accordance with the rules of the SEC, and the information is not necessarily indicative of beneficial ownership for any other purpose. Under Rule 13d-3 of the Exchange Act of 1934, as amended (the “Exchange Act”), a beneficial owner of a security includes any person who, directly or indirectly, through any contract, arrangement, understanding, relationship or otherwise has or shares: (i) voting power, which includes the power to vote or to direct the voting of shares; and (ii) investment power, which includes the power to dispose or direct the disposition of shares. Certain shares may be deemed to be beneficially owned by more than one person (if, for example, persons share the power to vote or the power to dispose of the shares). In addition, shares are deemed to be beneficially owned by a person if the person has the right to acquire the shares (for example, upon exercise of an option) within 60 days of the date as of which the information is provided. In computing the percentage ownership of any person or persons, the amount of shares outstanding is deemed to include the amount of shares beneficially owned by such person or persons (and only such person or persons) by reason of these acquisition rights.

Name Shares of Common
Stock
 Percentage of
Common Stock
Executive Officers and Directors    
Robert Nistico  1,410,000   3.1%
         
Justin Yorke(1)  5,486,109   12.2%
         
John Paglia      
         
William Meissner      
         
Stacy McLaughlin      
         
Officers and Directors as a Group (6 individuals)  6,896,109   15.3%
5% or greater owners:        
LK Family Partnership  2,992,014   6.6%
         
Total  9,888,123   21.9%

(1) Of which 3,297,243 shares are held by Richland Fund LLC, 1,398,012 shares are held by JMW Fund LLC and 790,854 shares are held by San Gabriel LLC. All funds are managed by Mr. Yorke.

Securities Authorized for Issuance under our Equity Compensation Table,Plan

The following table gives information as of December 31, 2023, the end of the most recently completed fiscal year, about shares of common stock that have been issued under our Splash Beverage Group, Inc. 2020 Incentive Plan. Under the 2020 Incentive Plan we have 4,259,008 options outstanding as of December 31, 2023. See Note 6. On October 6, 2023, at our 2023 annual meeting of stockholders our stockholders approved an amendment to the 2020 Incentive Plan to: (1) increase the aggregate number of shares of common stock available by 1,500,000 shares to a total of 1,807,415 shares and (iv) all(2) increase the automatic annual increase in the number of our Officers and Directorsshares under the 2020 Incentive Plan from 5% to 7.5% of the total number of shares of common stock outstanding as a Group:

of December 31st of the preceding fiscal year.



21



Name and Address of Beneficial Owner 
Beneficial
Ownership
 
Approximate
Percent Owned
     
Michael J. West
4120 Boardman-Canfield Road
Canfield, OH  44406
 8,344,000 74.0%
     
Stephen H. West
16325 East Dorado Avenue
Centennial, CO  80015
 300,000 2.7%
     
All Officers and Directors as a group
(2 persons)
 8,644,000 76.7%

Plan Category

 No. of Shares to be Issued Upon Exercise or Vesting of Outstanding Stock Options Weighted Average Exercise Price of Outstanding Stock Options Number of Securities Remaining Available for Future Issuance Under Equity Compensation Plans
Equity compensation plan approved by board of directors  4,259,008   1.13   2,846,068 
             
Total  4,259,008   1.13   2,846,068 

Item 13. Certain Relationships and Related Transactions and Director Independence.


None

 The following is a description of the transactions and series of similar transactions, since December 31, 2023, that we were a participant or will be a participant in, which:

the amount involved exceeds the lesser of $120,000 or one percent of the average of the smaller reporting company’s total assets at year-end for the last two completed fiscal years; and

any of our directors, executive officers, holders of more than 5% of our capital stock (which we refer to as “5% stockholders”) or any member of their immediate family had or will have a direct or indirect material interest, other than compensation arrangements with directors and executive officers.

During the normal course of business, we incurred expenses related to services provided by our CEO or Company expenses paid by our CEO, resulting in related party payables. In conjunction with the acquisition of Copa DI Vino®, the Company also entered into a Revenue Loan and Security Agreement (the “Loan and Security Agreement”) by and among the Company, Robert Nistico, additional Guarantor and each of the subsidiary guarantors from time-to-time party thereto (each a “Guarantor”, and, collectively, the “Guarantors”), and Decathlon Alpha IV, L.P. (the “Lender”). The Loan and Security Agreement provided for a revenue-based credit facility of $1,578,237 (the “Gross Amount”) with the Lender (the “Credit Facility”). There was $371,693 outstanding and $989,702 accrued interest under this agreement as of December 31, 2023.

On September 29, 2023, the Company also entered into a Purchase and Sales Future Receivables Agreement (the “Loan and Security Agreement”) by and among the Company, Robert Nistico, additional Guarantor and each of the subsidiary guarantors from time-to-time party thereto (each a “Guarantor”, and, collectively, the “Guarantors”), and Knightsbridge Funding LLC (the “Lender”). The Loan and Security Agreement provided a loan of $165,000, with the gross and interest amount of $241,725 with the Lender (the “Credit Facility”). There was $99,185 outstanding under this agreement as of December 31, 2023.

There were related party advances from our chief executive officer in the amount of $0.4 million outstanding as of December 31, 2023 and a shareholder note payable outstanding in the amount of $200,000 as of December 31, 2023.

Item 14. Principal Accounting Fees and Services.


Approval of Services

Pending establishment of an audit committee, the Board of Directors pre-approves all engagements for audit and non-audit services provided by the Company's former principal accounting firm, Cutler & Co., LLC (2014 and 2015) and current principal accounting firm, Pritchett, Siler & Hardy, P.C. (since January 11, 2016).

Audit Fees

The aggregate fees billed during the fiscal year ended

December 31, 2016 for professional services rendered by our principal accounting firm, Pritchett, Siler & Hardy, P.C., for the audit of our financial statements included in Form 10-K, and for the review of our interim condensed financial statements included in Form 10-Q, were approximately $54,000.  The aggregate fees billed during the fiscal year ended 2023

Audit – Rose, Snyder & Jacobs LLP $40,000 
Audit – Daszkal Bolton, LLP and CohnReznick LLP $10,000 
Audit related   
Tax  29,000 
Total $79,000 


December 31, 2015 for professional services rendered by our former principal accounting firm, Cutler & Co., LLC, for the audit of our financial statements included in Form 10-K, and for the review of our interim condensed financial statements included in Form 10-Q, were approximately $10,000.


Audit Related Fees

The aggregate fees billed during the fiscal years ended December 31, 2016 and 2015 for audit related services rendered by our current principal accounting firm, Pritchett, Siler & Hardy, P.C., and former principal accounting firm, Cutler & Co., LLC, were approximately $0 and $0, respectively.


22



Tax Compliance/Preparation Fees

The aggregate fees billed during the fiscal years ended December 31, 2016 and 2015 for professional services rendered by our current principal accounting firm, Pritchett, Siler & Hardy, P.C., and former principal accounting firm, Cutler & Co., LLC, for tax compliance, tax advice, and tax planning were approximately $0 and $0, respectively. Tax compliance services include the preparation of income tax returns filed with the Internal Revenue Service. Tax advice and planning services included assistance with implementation of tax planning strategies and consultation on other tax matters.

All Other Fees

The aggregate fees billed during the fiscal years ended December 31, 2016 and 2015 for all other professional services rendered by our current principal accounting firm, Pritchett, Siler & Hardy, P.C., and former principal accounting firm, Cutler & Co., LLC, were approximately $0 and $0, respectively. Other services consisted of assistance with the interpretation of new accounting standards and other related services.

Board of Directors Pre-Approval Process, Policies and Procedures

Our principal auditors have performed their audit procedures in accordance with pre-approved policies and procedures established by our Board of Directors. Our principal auditors have informed our Board of Directors of the scope and nature of each service provided. With respect to the provisions of services other than audit, review, or attest services, our principal accountants brought such services to the attention of our Board of Directors prior to commencing such services.


2022

Audit $193,000 
Audit related   
Tax  19,725 
Total $212,725 

PART IV


Item 15. Exhibits and Financial Statement Schedules.


The following documents are filed as part of this Annual Report on Form 10-K:


1. Financial Statements. See the Financial Statements starting on page 18.


F-1, of this Annual Report, which is incorporated into this Item by reference.

2. Exhibits. The exhibits listed in the Exhibit Index, which appears immediately following the signature page and is incorporated herein by reference, and filed as part of this Annual Report on Form 10-K.




23



SIGNATURES


Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.


 
CANFIELD MEDICAL SUPPLY,SPLASH BEVERAGE GROUP, INC.
(Registrant)
   
Date: March 29, 2024By:/s/ Robert Nistico
 
Date:  March 28, 2017Name:
By: /s/ Michael J. West                                          
Robert Nistico
  
Name:  Michael J. West
Title:    PresidentChairman of the Board and CEO (PrincipalChief Executive Officer)
Officer
  
Date:  March 28, 2017
By: /s/ Stephen H. West                                         
Name:  Stephen H. West
Title:    Chief Financial Officer, (Principal Financial and (Principal AccountingExecutive Officer)


Pursuant to the requirements of the Securities Act of 1934 this Annual Report on Form 10-K was signed by the following persons on behalf of the Registrant and in the capacities and on the dates stated:


NameSignature TitleDate
/s/ Robert NisticoChief Executive Officer and DirectorMarch 29, 2024
Robert Nistico(Principle Executive Officer)
/s/ Stacy McLaughlinChief Financial Officer, TreasurerMarch 29, 2024
Stacy McLaughlin(Principal Financial and Accounting Officer)
/s/ Justin YorkeDirector, SecretaryMarch 29, 2024
Justin Yorke
/s/John PagliaDirectorMarch 29, 2024
John Paglia    
    
/s/ Michael J. West              President, CEO (Principal Executive Officer) and DirectorMarch 28, 2017
Michael J. West 
/s/ Bill Caple 
Director  March 29, 2024 
/s/ Stephen H. West             Bill Caple  Chief Financial Officer (Principal Financial and Principal Accounting Officer) and DirectorMarch 28, 2017


EXHIBIT INDEX

Exhibit No.Description of Exhibit
Stephen H. West
1.1


24



EXHIBIT INDEX

Description
1.1 to the Current report on Form 8-K filed with the Securities and Exchange Commission on June 15, 2021)
1.2ArticlesUnderwriting Agreement dated February 14, 2022 between Splash Beverage Group and EF Hutton, division of IncorporationBenchmark Investments, LLC, as representative of the underwriters named therein (incorporated by reference herein to Exhibit 1.1 to the Current report on Form 8-K filed with the Securities and BylawsExchange Commission on February 17, 2022)
3.11.3ArticlesUnderwriting Agreement dated September 23, 2022, between Splash Beverage Group and EF Hutton, division of IncorporationBenchmark Investments, LLC, as representative of the underwriters named therein (incorporated by reference herein to Exhibit 1.1 to the Current report on Form 8-K filed with the Securities and Exchange Commission on September 27, 2022)
2.1Agreement and Plan of Merger dated December 31, 2019 by and among Canfield Medical Supply, Inc., SBG Acquisition, Inc., and Splash Beverage Group, Inc. (incorporated by reference to Exhibit 3.12.1 to the Registrant’s Form 8-K dated January 7, 2020)
2.2Form of Amendment No. 1 to the Agreement and Plan of Merger (incorporated by reference herein to Exhibit 10.1 filed with Form S-18-K filed with the SEC on July 12, 2012)October 7, 2020)
3.23.1Bylaws (incorporated by reference herein to Exhibit 3.2 filed with Form S-18-K1 filed with the SEC on July 12, 2012)November 15, 2021)
31.13.2CertificationArticles of Incorporation filed with the Secretary of State of Nevada (incorporated by CEO (filed herewith electronically)reference herein to Exhibit 3.1 filed with Form8-K filed with the SEC on November 15, 2021)
31.23.3CertificationArticles of Merger filed with the Secretary of State of the State of Nevada (incorporated by CFO (filed herewith electronically)reference herein to Exhibit 2.2 filed with Form8-K filed with the SEC on November 15, 2021)
32.13.4Statement of Merger filed with the Secretary of State of the State of Colorado (incorporated by reference herein to Exhibit 2.3 filed with Form8-K filed with the SEC on November 15, 2021)
3.5Certificate of Amendment to Articles of Incorporation filed with the Secretary of State of Nevada (incorporated by reference herein to Exhibit 3.1 filed with Form 8-K filed with the SEC on December 22, 2022)
4.1Form of Common Stock Certificate (incorporated by reference to exhibit 4.1 filed with the Annual Report on Form 10-K filed with the SEC on March 31, 2022)
4.2Form of Investor Warrant (incorporated by reference to exhibit 4.1 filed with the Current Report on Form 8-K filed with the SEC on June 15, 2021)
4.3Warrant Agent Agreement between Splash Beverage Group Inc. and Equinity Trust Company dated as of June 15, 2001 (incorporated by reference to exhibit 10.1 filed with the Current Report on Form 8-K filed with the SEC on June 15, 2021)
4.4Description of Capital Stock *


10.12020 Long-Term Incentive Compensation Plan (incorporated herein by reference to the Schedule 14C Information Statement filed with the SEC on June 8, 2020)
10.2Form of SBG Warrant (incorporated by reference herein to Exhibit 10.4 filed with Form 8-K filed with the SEC on April 6, 2020)
10.3Form of New Warrant (incorporated by reference herein to Exhibit 10.5 filed with Form 8-K filed with the SEC on April 6, 2020)
10.4Form of Warrant (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on August 18, 2020)
10.5Revenue Loan and Security Agreement dated (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on December 31, 2020)
10.6Asset Purchase Agreement dated (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on December 31, 2020)
10.7Convertible Promissory Note dated (incorporated by reference herein to Exhibit 10.3 filed with Form 8-K filed with the SEC on December 31, 2020)
10.8An Agreement Regarding Other Accounts Payable dated (incorporated by reference herein to Exhibit 10.4 filed with Form 8-K filed with the SEC on December 31, 2020)
10.9Martin Employment Agreement dated (incorporated by reference herein to Exhibit 10.5 filed with Form 8-K filed with the SEC on December 31, 2020)
10.10Non-Competition, Non-Solicitation and Confidential Information Agreement (incorporated by reference herein to Exhibit 10.6 filed with Form 8-K filed with the SEC on December 31, 2020)
10.11Form of Subscription Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on January 21, 2021)
10.12Form of Warrant (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on January 21, 2021)
10.13Form of Subscription Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on February 2, 2021)
10.14Form of Warrant (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on February 2, 2021)
10.15Form of Subscription Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on February 12, 2021)

10.16Form of Warrant (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on February 12, 2021)
10.17Form of Subscription Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on March 2, 2021)
10.18Form of Warrant (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on March 2, 2021)
10.19Securities Purchase Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on January 3, 2023)
10.20Form of Warrant (incorporated by reference herein to Exhibit 4.1 filed with Form 8-K filed with the SEC on January 3, 2023)
10.21Form of Promissory Note (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on January 3, 2023)
10.22Form of Warrant (incorporated by reference herein to Exhibit 4.1 filed with Form 8-K filed with the SEC on August 16, 2023)
10.23Form of Securities Purchase Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on August 16, 2023)
10.24Form of Investor Note (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on August 16, 2023)
10.25Form of Second Investor Note (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on August 16, 2023)
10.26Form of Purchase Agreement (incorporated by reference herein to Exhibit 10.5 filed with Form 8-K filed with the SEC on August 16, 2023)
10.27Form of Investor Note (incorporated by reference herein to Exhibit 10.6 filed with Form 8-K filed with the SEC on August 16. 2023)
10.28Form of Warrant (incorporated by reference herein to Exhibit 4.1 filed with Form 8-K filed with the SEC on October 6, 2023)
10.29Form of Purchase Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on October 6, 2023)
10.30Form of Note (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on October 6, 2023)
10.31Form of Registration Rights Agreement (incorporated by reference herein to Exhibit 10.3 filed with Form 8-K filed with the SEC on October 6, 2023)
10.32Form of Waiver Agreement (incorporated by reference herein to Exhibit 10.1 filed with Form 8-K filed with the SEC on December 18, 2023)
10.33Form of Registration Rights Agreement (incorporated by reference herein to Exhibit 10.2 filed with Form 8-K filed with the SEC on December 18, 2023)
10.34Employment Agreement dated March 12, 2012 with Robert Nistico*


10.35  Employment Agreement dated May 4, 2020 with William Meissner*
10.36Employment Agreement dated January 22, 2024 with Stacy McLaughlin (incorporated herein by reference to Exhibit 10.1 filed with Form 8-K filed with the SEC on January 30, 2024)
21.1  Subsidiaries (incorporated by reference herein to Exhibit 21.1 filed with Form 10-K filed with the SEC on March 8, 2021)
23.1  Consent of Rose, Snyder & Jacobs LLP*
23.2  Consent of Daszkal Bolton LLP*

31.1Rule 13a-14(a)/ 15d-14(a) Certification of Principal Executive Officer*
31.2Rule 13a-14(a)/ 15d-14(a) Certification of Principal Financial Officer*
32.1Certification of CEO pursuant to 18. U.S.C. Section 1350 as adopted, pursuant to Section 906 of Sarbanes-Oxley Act of 2002 (filed herewith electronically)2002**
32.2Certification of CFO pursuant to 18. U.S.C. Section 1350 as adopted, pursuant to Section 906 of Sarbanes-Oxley Act of 20022002**
97.1Clawback Policy of the Company*
*101.INSInline XBRL Instance Document (filed herewith)
*101.SCHInline XBRL Taxonomy Extension Schema (filed herewith)
*101.CALInline XBRL Taxonomy Extension Calculation Linkbase (filed herewith)
*101.LABInline XBRL Taxonomy Extension Label Linkbase (filed herewith)
*101.PREInline XBRL Taxonomy Extension Presentation Linkbase (filed herewith)
*101.DEFInline XBRL Taxonomy Definition Linkbase (filed herewith)
*104Cover Page Interactive Data File (embedded within the Inline XBRL document filed as Exhibit 101)

*Filed herewith electronically)
 
101**XBRLFurnished herewith

42



 


25